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Abstract 
The development of nonviral vectors for safe and efficient gene delivery has 
been gaining considerable attention recently. An ideal nonviral vector must protect 
the gene against degradation by nuclease in the extracellular matrix, internalize the 
plasma membrane, escape from the endosomal compartment, unpackage the gene at 
some point and have no detrimental effects. In comparison to viruses, nonviral 
vectors are relatively easy to synthesize, less immunogenic, low in cost, and have no 
limitation in the size of a gene that can be delivered. Significant progress has been 
made in the basic science and applications of various nonviral gene delivery vectors; 
however, the majority of nonviral approaches are still inefficient and often toxic. To 
this end, two nonviral gene delivery systems using either biodegradable poly(D,L-
lactide-co-glycolide) (PLG) nanoparticles or cell penetrating peptide (CPP) 
complexes have been designed and studied using A549 human lung epithelial cells.   
PLG nanoparticles were optimized for gene delivery by varying particle surface 
chemistry using different coating materials that adsorb to the particle surface during 
formation. A variety of cationic coating materials were studied and compared to more 
conventional surfactants used for PLG nanoparticle fabrication. Nanoparticles (~200 
nm) efficiently encapsulated plasmids encoding for luciferase (80-90%) and slowly 
released the same for two weeks. After a delay, moderate levels of gene expression 
appeared at day 5 for certain positively charged PLG particles and gene expression 
was maintained for at least two weeks. In contrast, gene expression mediated by 
polyethyleneimine (PEI) ended at day 5. PLG particles were also significantly less 
iii 
 
cytotoxic than PEI suggesting the use of these vehicles for localized, sustained gene 
delivery to the pulmonary epithelium.   
On the other hand, a more simple method to synthesize 50-200 nm complexes 
capable of high transfection efficiency or high gene knockdown was also explored. 
Positively charged CPPs were complexed with pDNA or siRNA, which resulted in 
‘loose’ (~1 micron) particles. These were then condensed into small nanoparticles by 
using calcium, which formed "soft" crosslinks by interacting with both phosphates on 
nucleic acids and amines on CPPs. An optimal amount of CaCl2 produced stable, 
~100 nm complexes that exhibited higher transfection efficiency and gene silencing 
than PEI polyplexes. CPPs also displayed negligible cytotoxicity up to 5 mg/mL. 
Biophysical studies of the pDNA structure within complexes suggested that pDNA 
within CPP complexes (condensed with calcium) had similar structure, but enhanced 
thermal stability compared to PEI complexes. Thus, CPP complexes emerged as 
simple, attractive candidates for future studies on nonviral gene delivery in vivo.  
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Chapter 1. Gene Delivery 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1. Introduction 
Gene therapy is a potential application to correct genetic deficiencies or treat 
acquired diseases by altering or manipulating genes. Gene therapy as a modern molecular 
medicine is a relatively young subject that was born in 1989 with the transfer of a drug 
resistance gene marker to a patient's lymphocytes in the first gene transfer clinical trial 1. 
Gene therapies are being developed for cardiovascular 2, neurological 3-5 and infectious 
diseases 6, wound healing 7 and cancer 8-10. They promise a great future and in the 
meantime offer new and distinct challenges ranging from delivery to production. To date, 
nearly 1560 gene therapy clinical trials have been conducted 
(http://www.wiley.com/legacy/wileychi/genmed/clinical/).  
Gene therapies can be categorized on the basis of therapy as gene inhibitors, gene 
vaccines and gene substitutes. Gene inhibitors (i.e. siRNA) are potent therapies that 
silence or alter defective genes 11. Gene vaccines include antigens of specific pathogens 
and often include the genes or RNA that activate cell-mediated and humoral immune 
response 12. Gene substitutes are transcriptionally fully competent genes introduced into 
cells to reimburse deficiency of a specific protein.  
Since its inception the biggest challenge in the field has revolved around the word 
"delivery". Nucleic acids are labile macromolecules that are challenging to deliver 
intracellularly owing to their size and hydrophilic nature, which includes a high density 
of negatively charged phosphate groups. In addition, they are very susceptible to 
degradation by nucleases. Depending on how nucleic acids are introduced, gene therapy 
can be divided into ex vivo and in vivo. In ex vivo gene therapy, cells are removed from 
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the patient, genetically modified and reintroduced into the patient while in vivo gene 
therapy aims to deliver genes directly to the site of action.  
Exogenous genetic materials must be transferred into cells by passing through a 
series of hurdles in gene therapy, for the production of therapeutic proteins 13,14. To 
realize gene therapy, a vehicle that satisfies the requirements for both a high transfection 
efficiency and low toxicity is essential 15.  
 
1.2. Methods of gene delivery 
Gene delivery vehicles can be classified into two categories; viral and nonviral 
vectors. Recombinant viruses have had their genome altered to prevent viral replication 
and allow incorporation of therapeutic transgene. Many viruses have been used for the 
production of viral vectors including retrovirus, adenovirus, adeno-associated virus, 
herpes simplex virus and vaccinia virus. In theory, viral carriers can provide a high 
transfection rate and rapid transcription of the foreign material inserted in the viral 
genome 16,17. However, many clinical trials utilizing viral vectors have been interrupted 
since the application of these vectors induced unexpected adverse effects such 
immunogenicity, pathogenicity and toxicity 18,19. Jesse Gelsinger was the first patient to 
die in a clinical trial for gene therapy in 1999. Gelsinger suffered from ornithine 
transcarbamylase deficiency, an X-linked genetic non-life-threatening disease of the 
liver. After injections of adenovirus carrying the corrected genes, the patient died from a 
massive immune response. Other challenges include limitations in target cell specificity 
and high cost associated with the vector production.  
On the other hand, nonviral vectors are potentially less immunogenic, relatively 
easy to produce, flexible in formulation design and associated with fewer safety concerns 
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20,21. Furthermore, this category of gene delivery may enhance delivery to specific cells 
through incorporation of a targeting ligand 22-27. In general, synthetic nonviral vectors are 
materials that electrostatically bind nucleic acids (i.e., DNA or RNA), condense them into 
particles a few tens to several hundred nanometers in diameter, confer protection from 
degrading factors that exist in the extracellular and intracellular environment and mediate 
cellular internalization. The functionalities of these nonviral systems stem from the 
materials used for the construction of the vectors. Among the many types of materials 
used, lipids and polymers represent the two major classes.    
Gene delivery vectors must be taken up by cells direct the nucleic acids to an 
appropriate intracellular destination (cytoplasm for siRNA and nucleus for pDNA), 
release the nucleic acids to allow their action and exhibit minimal toxicity. Up to now, 
many efforts have addressed these objectives in a serial fashion 28. It is not surprising that 
the efficiency of gene delivery by nonviral vectors has yet to rival viruses as gene 
delivery agents as evidenced by their limited clinical application. A key issue impeding 
the development of nonviral vectors is thus the need to overcome various physiological 
barriers. 
 Compared to viral and nonviral gene delivery, methods employing external energy 
or force offer some advantages for gene transfer. Enhanced gene transfer can be obtained 
with naked pDNA, actively facilitating the passage of the gene across various barriers 
and eliminating some problems associated with the formulation, toxicity and 
immunogenicity. Based on the type of the physical methods employed, these can be 
categorized as direct injection hydrodynamic, electroporation, ultrasound-mediated 
delivery, laser irradiation, magnetic force mediated delivery and electrical field induced 
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molecular vibration 29. Even though these methods are relatively independent of cell type 
and gene size, the efficiency is typically low. The major drawbacks include the small 
amount of cells transfected per treatment, surgical procedures required for transfecting 
internal tissues and high energy (i.e. voltage) that must be applied to tissues which can 
result in irreversible tissue damage. Moreover, most physical techniques are at a 
rudimentary stage of development and much work must be done before reaching human 
clinical trials. 
   
1.3. Barriers to nonviral gene delivery 
Successful gene delivery systems must navigate a series of obstacles, both 
extracellular and intracellular, from the point of administration to the site of action 
(cytoplasm for siRNA and nucleus for pDNA) (Figure 1). Overcoming these barriers is 
the main design goal of nonviral vectors.   
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1.3.1. Extracellular barriers 
The first major barrier to gene delivery is the extracellular milieu, a space which 
surrounds the cells that contains a set of macromolecules, polysaccharides or 
glycosaminoglycans, fibrous proteins, salts and water 30. This space can compromise the 
chemical stability of the nucleic acids as well as the physical stability of the delivery 
vehicle. To reach the plasma membrane of target cells, the nucleic acids must diffuse 
through the extracellular matrix without being degraded by the extracellular nucleases. 
Previous work showed that the delivery of macromolecules such as pDNA to cells is 
affected by the amount of nucleases and by the amount of extracellular environment 
components 31-37. One strategy to increase the diffusion and distribution of pDNA into 
target tissue consists of controlled and partial degradation of extracellular matrix using 
enzymes such as hyaluronidase and collagenase 35,38-45. Results showed that the tissues 
pretreated by these enzymes showed more gene expression than others without enzymatic 
treatment. 
Numerous subtle improvements have been made to overcome nuclease degradation 
within extracellular matrix by either condensing the nucleic acids with a variety of 
polycations or by complexing with polymers that bind to but do not condense nucleic 
acids 46-48. The condensation process is believed to be kinetic 49 and is highly dependent 
on the properties of polycations, the nucleic acids concentration, the order of mixing, and 
the ionic strength of the buffer 49-51. It is important to realize, however, that excessively 
high affinity of nucleic acid with vector components may hinder intracellular release of 
the gene, which is required for its action to take place. Charge-neutral polyelectrolyte 
complexes of nucleic acid with a polycation tend to exhibit rapid aggregation upon 
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exposure to physiological levels of salt. Further, the colloidal stability of positively 
charged nonviral gene vectors may be disrupted in the presence of excess positive charge 
owing to possible interactions with exracellular matrix components that effectively 
compete for binding sites of nucleic acid to the cationic nonviral vehicle 47,52-54. Some 
studies have shown that the aggregate size of positive complexes is time dependent 49. 
Several hydrophilic, nonionic polymers, such as polyethylene glycol (PEG) 55,56, N-(2-
hydroxypropyl) methacrylamide (PHPMA) 56-59, oligosaccharides 56,60, and sugars 61,62, 
have been used to modify the surface of the nonviral vectors in order to decrease 
potential destabilizing particle interactions. PEGylation, for example, has been 
incorporated covalently 55,63-65 and noncovalenty 66,67 into nonviral gene vectors and has 
been found to increase the colloidal stability of formulations. However, this modification 
may minimize the efficiency of gene delivery by reducing internalization or by inhibiting 
endosomal escape of the vector 68.   
One more obstacle to a nonviral gene delivery system in the extracellular milieu is 
the lack of target cell selectivity. The requirement for targeting in gene therapy varies by 
the therapeutic applications. In the case of cancer therapies for example, gene delivery to 
cells of interest might be required for destroying specific cells while maintaining viability 
of healthy tissue. An efficient targeting strategy is thought to depend on factors such as, 
the conjugation chemistry of the ligand to the vehicle, the molecular weight and the size 
of the ligand, the distance between the ligand and its vehicle, the number of targeting 
ligands per vector and the ligand-receptor binding affinity 67,69-71. 
Several strategies have been reported to increase cellular uptake and selectivity. 
Polycations have been shown to essentially increase the cellular association of nucleic 
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acids by mediating the repulsion between the nucleic acid and cell surface through 
electrostatic interaction with cell surface heparin sulfate proteoglycans, a protein core 
with one or more glycosaminoglycans attached, (HSPGs) 72,73. Targeting ligands have 
been incorporated within cationic lipids (Lipoplexes) or polymers (Polyplexes) and, upon 
binding to the receptor on the target cell surface, induce cellular uptake in vitro 74-76 and 
in vivo 48,77-81. Moreover, direct covalent conjugation of targeting ligands to the nucleic 
acid has been investigated 82. 
 
1.3.2. Intracellular barriers 
Nonviral gene delivery systems need to provide mechanisms to overcome 
numerous intracellular obstacles. Cellular internalization, endosomal escape, 
unpackaging of DNA, persistence within the cytoplasm and delivery to the cell nucleus 
are the major barriers for effective nonviral gene delivery. Comprehensive efforts have 
been made to address these perceived barriers.  
Untargeted cationic nonviral vectors bind electrostatically to the surface of cells 
(proteoglycans) 68,73 and are internalized via endocytosis 68,83-86. Clathrin-dependent 
endocytosis has been reported in the internalization of ~ 200 nm cationic nonviral 
complexes 87-90. Phagocytosis and macropinocytosis are other possible pathways of 
internalization that have been reported 84,91,92. Alternatively, delivery systems with 
targeting ligands are often internalized by receptor-mediated endocytosis 74,79,93. 
Following internalization, the vectors are engulfed by membrane vesicles 68,88,94-98 and 
often merge with other vesicles en route to lysosomes filled with degradative enzymes. It 
has been generally assumed that avoidance of lysosomes can give rise to improved gene 
delivery with nonviral systems. Therefore, the escape of gene vector (or the nucleic acid 
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itself) from the endosome has been demonstrated in several studies as one of the 
fundamental hurdles 99-103. 
 Initially the vectors become localized within early endosomes which are divided 
into two types, sorting endosomes from which the internalized material can be 
redistributed and recycling endosomes which are thought to be responsible for returning 
internalized material to the membrane and out of the cell 104. The inability of vectors to 
escape the endosomal compartment and enter the cytoplasm results in trafficking via the 
late endosome to lysosomes where the nucleic acid is eventually degraded.  
Several designs have been applied for engineering endosomal escape in nonviral 
gene delivery. Incorporation of a helper lipid, such as dioleoyl phosphatidylethanolamine 
(DOPE) in the vehicle formulation may promote nucleic acid release by facilitating 
endosomal disruption 105-109. The cationic polymer polyethyleneimine (PEI) is thought to 
facilitate endosomal release by buffering the acidification of the endosomal compartment 
("proton sponge" hypothesis). Accumulation of protons, counterions and water eventually 
leads to osmotic swelling of the endosome and, ultimately, osmotic lysis 13,110-115. In 
addition, fusogenic viral 116-118 or synthetic peptides 76,119-122 have been attached to 
vectors to provide endosomal escape. Some fusogenic liposomes and pH-sensitive 
liposomes have also been designed for destabilizing endosomal compartment 123. 
Transfection efficiency is also potentiated by utilizing nonspecific lysomotropic agents, 
such as chloroquine, polyvinylpyrolidone or sucrose 91,124-126.  
Once released from the endosomes, the vector or freed nucleic acids must traverse 
through the cytoplasm and gain access to the nucleus (e.g., pDNA). The presence of high 
protein concentration, microtubules and many organelles imposes an intensive molecular 
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crowding of the cytoplasm which limits the diffusion of the vehicle or nucleic acid 127. 
The diffusion coefficient of pDNA in the cytoplasm is size dependent with pDNA < 3000 
base pairs in length is less than 1% of the diffusivity in water, and pDNA > 3000 base 
pairs is essentially immobilized 128. To date, no evidence for active transport of pDNA in 
the cytoplasm has been reported. In addition to the physical diffusion barrier, the known 
degradation of pDNA in the cytosol due to the presence of nucleases poses a significant 
barrier to efficient gene delivery as well 129,130. Microinjection of pDNA into the 
cytoplasm resulted in degradation with a half-life of 50-90 min. Some studies have 
provided evidence that pDNA was still partially complexed to cationic polymers (e.g., 
PEI) in the cytoplasm. PEI gene delivery systems are purported to overcome these 
obstacles by actively transporting pDNA along microtubules to the nuclear region which 
resulted in increased gene expression 98,131. The mechanism by which polycations remain 
bound to the nucleic acid in the cytoplasm to facilitate gene expression need to be well 
characterized to improve the design of polymeric vectors.  
The ultimate destination for pDNA delivered inside the cell is the nucleus where 
the gene can be transcribed. Nuclear transport of pDNA alone or complexed to the 
nonviral vector is still not fully clear. There are three possible routes for pDNA to gain 
entry into the nucleus; (i) during mitosis, the nuclear membrane is temporarily disrupted 
which allows pDNA to diffuse into the nucleus, (ii) molecules of < 9 nm can passively 
diffuse through nuclear pores and (iii) particles < 26 nm can be actively transported 
through nuclear pore complexes (NPCs) 132-136. The transfection efficiency of polymer 
and lipid based systems in cells undergoing division was 30 to 500-fold more effective 
than transfection of cells at the beginning of their cell cycle 137. Nuclear localization 
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sequences (NLSs), short cationic peptides that are recognized by importins, have been 
demonstrated to increase nuclear translocation of pDNA 138. Covalently linking NLS to 
pDNA or noncovalent association of NLS to pDNA complexes has been reported to 
enhance nuclear translocation 139. It is quite possible that polycation-based vectors may 
mediate an additional role in the nuclear delivery of pDNA 131,140 but evidence also points 
to poor nuclear transport 141-143.  
 
1.4. Nonviral carriers 
Several nonviral vehicles have been proposed for safe delivery of therapeutic 
nucleic acids. Lipids and polymers can form effective pharmaceutical delivery systems 
for nucleic acids; however, many formulations still suffer from relatively low efficiency 
of gene delivery as well as the toxicity, particularly for in vivo applications. The use of 
cationic lipids and polymers for gene delivery was introduced by Felgner et al. (1987) 
and Wu and Wu (1987), respectively 106,144. Their use has progressed rapidly from the 
transfection of cell cultures to clinical gene therapy applications. Three of the major gene 
delivery systems are described below.  
 
1.4.1. Lipid-based vectors 
Cationic lipids (liposomes, micelles, etc.) are one of the most attractive gene 
delivery vectors. These are amphiphilic molecules composed of a hydrophobic lipid 
anchor group, linker group and a positively charged head group. The nature of each group 
affects the gene delivery efficiency. The positive charge of cationic lipids entraps or 
condenses the nucleic acid to form a complex, commonly known as a lipoplex. The 
ability of this system to mediate transfection was attributed to its spontaneous 
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electrostatic interaction with genes. A net positive charge exhibited by the system can 
promote its association with the negatively charged cell surface and its fusogenic 
properties that can induce fusion and/or destabilization of the plasma membrane 
facilitating the intracellular release of complexed or encapsulated gene.  
The size and the charge of the cationic head group are important for transfection 
145. Different types of cationic head groups have been used such as quaternary 
ammonium, primary, secondary or tertiary amines, guanidinium, heterocyclics, amino 
acids, pyridinium, amidine and peptides 106,146-152. Many cationic lipids showed excellent 
transfection activity in cell culture, but most did not perform well in the presence of 
serum and only a few were active in vivo 153. A large excess of cationic lipids was needed 
to mediate optimal gene delivery.  
A dramatic change in size, surface charge and lipid composition occurs when 
lipoplexes are exposed to the negatively charged and often amphipathic proteins and 
polysaccharides that are present in blood, mucus, epithelial lining fluid and tissue matrix. 
Despite these undesirable characteristics, lipoplexes have been used for in vivo gene 
delivery to lungs by intravenous 154-156 and airway 157-159 administration. In these studies, 
gene expression was detectable but in most cases was very low due to fast clearance of 
lipoplexes. Surface shielding through the use of the hydrophilic and charge neutral 
polymers such as polyethylene glycol (PEG) to reduce excessive charge-charge 
interactions appeared very effective in prolonging the circulation half life of lipoplexes 
160. Unfortunately, inclusion of PEG into lipoplexes caused a concentration-dependent 
inhibition in transfection activity. For this reason, PEGs were made detachable using an 
acid-sensitive linkage through which the PEG moiety can be removed when lipoplexes 
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are inside the endocytic compartment 161,162. Cholesterol and 
dioleoylphosphatidylethanolamine (DOPE) were synergistic with cationic lipids in 
mediating the transfection 47,154,163. In most cases, DOPE lead to reduced charge density 
of lipoplexes, thus lowering toxicity. The fusogenic property of DOPE also facilitated the 
endosomal escape of lipoplexes. The presence of cholesterol was reported to stabilize the 
cationic lipidic membrane structures against the destructive activity of serum components 
and was proposed to provide better activity for in vivo transfection 163.  
Major obstacles for practical use of lipoplex-mediated transfection are acute 
toxicity and short duration of gene expression 154,164,165. Moreover, cationic lipids can 
stimulate potent inflammatory responses in host cells. Rapid production of cytokines 
followed by clearance of transfected cells after administration of uncoated lipoplexes 
compounded these problems. Performance was improved by designing lipids with 
increased biodegradability 166-168 or by shielding lipoplexes using PEG 160,169. In addition, 
cationic lipids that are charged only at mildly acidic but not at neutral pH 170 and those 
whose charge groups can be eliminated after lipoplex formation 166 may provide potential 
solutions  
 
1.4.2. Polymer-based vectors 
Many types of polymers have been used for gene delivery. Among these polymers, 
cationic polymers have garnered attention due to their abilities to form polyelectrolyte 
complexes between nucleic acids and polycations, protect genes from enzymatic 
degradation and facilitate cell uptake and endolysosomal escape 171. Cationic polymers 
are usually classified in two main groups; natural polymers, such as peptides, proteins, or 
polysaccharides and synthetic polymers, such as polyethyleneimine (PEI), biodegradable 
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polymers or dendrimers 172. Natural polymers generally have the advantage of being 
nontoxic even in large doses. In addition, some offer attributes such as good 
mucoadhesion and biodegradability 173. On the other hand, synthetic polymers can 
provide flexibility in formulation design and can be tailored to fit the size and topology of 
the gene.  
 
1.4.2.1. Natural polymers 
Over the years, a significant number of natural polymers, such as chitosan 174, 
cationic proteins (e.g., polylysine, protamine and histones) 175-178 and cationic peptides 
(e.g., arginine-rich and lysine-rich peptides) 179-187 have been explored as carriers for gene 
delivery. In general, natural polymers have been used much less in gene delivery than 
synthetic polymers. Among natural polymers, the cationic polysaccharide chitosan has 
attracted considerable attention as a nonviral gene delivery vector. Although chitosan 
showed effective nucleic acid binding and compaction, the transfection efficiency was 
significantly lower compared to other cationic gene delivery agents. This problem may be 
attributed to retarded endosomal escape of chitosan complexes.  
Gene delivery efficiency when employing chitosan is affected by a lot of factors 
including chitosan molecular weight, salt form, degree of deacetylation and the pH of the 
culture medium 188. The latest strategies to improve its transfection efficiency comprise 
the synthesis of various chitosan derivatives, such as aminoethylchitin (AEC) 189, 
thiolated chitosan 190, chitosan methoxy polyethylene glycol cholesterol (LCP-Ch) 191 and 
low molecular weight alkylated chitosans 192. Incorporation of negatively charged 
compounds such as hyaluronic acid or poly (γ-glutamic acid) with chitosan has been 
reported to increase transfection efficiency significantly 193,194. 
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Peptide-based vectors are advantageous over other nonviral gene delivery systems 
in that they have the potential to protect nucleic acids, target specific cell surface 
receptors, disrupt the endosomal membrane and deliver the gene to the nucleus 195. 
Cationic peptides rich in basic residues such as arginine and/or lysine have been explored 
in recent years as a carrier for gene delivery. They have been used in gene delivery either 
by covalent binding to the vectors 180,185,187 or by simple complexing with the gene 
through electrostatic interactions 181,182,184,186,196. Such peptides were able to efficiently 
condense the gene into particles with a net positive charge that is able to interact with cell 
membranes and facilitate internalization. Cationic peptide complexes were also shown to 
be stable in serum 46,197,198.  
Peptide sequences derived from protein transduction domains (PTD) were 
identified as potentially useful agents for intracellular delivery of nucleic acids 199-203. 
These peptides were able to selectively lyse the endosomal membrane under acidic 
conditions leading to cytoplasmic release of the complex 204,205. Short peptide sequences 
taken from longer viral proteins, such as the TAT peptide from the HIV transactivator 
protein TAT, can provide nuclear localization of condensates once they are in the 
cytoplasm 206-210. Lysine-rich peptides derived from histone H1, H2A and anti-DNA 
antibody can also transfer genes into cells 179,211. The toxicity of the cationic peptides are 
typically low compared to high molecular cationic polymers, however, the gene 
expression levels of their complexes require improvement 212-214. The explanation for the 
poor transfection efficiency may emanate from the fact that the cationic peptides and 
their nucleic acids for the most part remain entrapped in endocytic vesicles 215,216.      
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Poly-L-lysine (PLL) is a polypeptide that offers a natural and biodegradable vector 
for nucleic acids 217. The primary amine groups of lysine in PLL are protonated at neutral 
pH and electrostatically interact with negatively charged phosphate groups of the nucleic 
acid to form nanoparticles. PLL generally has poor transfection efficiency when applied 
alone or without modification 218,219. PLL complexes using high molecular weight of PLL 
showed a relatively high cytotoxicity 220 and a tendency to aggregate and precipitate 
depending on the ionic strength 221. In order to increase the transfection efficiency of 
PLL, histidine residues have been introduced to PLL to facilitate endosomal escape 222. 
Conjugating PLL with chitosan or lipids such as myristic and stearic acids has also been 
reported to modify the transfection efficiency of PLL 223,224. Another useful modification 
was the attachment of polyethylene glycol (PEG) to the PLL to prevent plasma protein 
binding and increase circulation half-life of the complex 225-227. In addition, PLL 
complexes have been targeted to specific cells through conjugation of folate 228, sugars 
134,229,230, antibodies 231 and RGD-displaying peptides 91.   
 
1.4.2.2. Synthetic polymers 
Polyethyleneimine (PEI) is one of the most effective polymer transfection agents 
due to its ability to tightly compact nucleic acids and buffer pH (presumed to facilitate 
endosomal escape). The transfection efficiency of certain formulations has been 
comparable to those of viral vectors 112,232. PEI has primary (25%), secondary (50%) and 
tertiary amines (25%), of which the majority of the amines are not protonated in 
physiological milieu 115,233. The primary amines are mainly responsible for the high 
degree of gene binding, but they also contribute to the toxicity during transfection. The 
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secondary and the tertiary amines provide good buffering capacity to the system 234. The 
buffering property gives PEI an opportunity to escape from endosome 112.  
PEI exists in either branched or linear structures. A study of different cationic 
densities of linear PEI showed that cell cytotoxicity and transfection efficiency were 
dependent not only on cationic density but also on the molecular weight of the polymer 
235. High molecular weight PEI (e.g., 25 kDa) is highly efficient for gene delivery, but 
very toxic to many cell lines; however, PEI of 2 kDa or smaller is essentially nontoxic 
but very ineffective for gene delivery 236,237. The clinical development of PEI has been 
halted due to acute toxicity 232,234.  
PEI has been extensively modified in an effort to reduce toxicity and improve 
transfection efficiency. PEGylation of PEI induced a substantial decrease in cytotoxicity 
and reduced the extent of aggregation of the complexes 65,68,119. Cross-linking of low 
molecular weight PEI with a biodegradable bond such as disulfide or ester bond resulted 
in oligomers that were as active as PEI 25 kDa but significantly less toxic to cells 238,239. 
Conjugation (e.g., sugar, small polymers and antibodies) has yielded PEI derivatives that 
were more efficient in transfection and less toxic 240-243; however, modification or 
elimination of too many amine groups, in general, leads to reduction or loss of the 
transfection activities of PEI.  
Biodegradable polymers were designed to address cytotoxicity and gene delivery 
barriers. Non-degradable polymers are difficult to eliminate and, therefore, they can 
potentially accumulate within tissues or cells to elicit further toxicity. A class of 
biodegradable polymers was reported for gene delivery based on cationic polyesters, 
including poly(α-[4-aminobutyl]-L-glycolic acid) (PAGA) 244, poly(4-hydroxyl-1-proline 
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ester) 245, hyperbranched poly(amino ester) 246 and poly(β-amino esters) 247-249. Generally, 
these polymers showed much less cytotoxicity and higher transfection efficiency 
compared to unmodified PLL, especially in the presence of chloroquine. 
Poly(lactic-co-glycolic acid) (PLGA) is another biocompatible and biodegradable 
polymer that has been investigated as a carrier for controlled release of nucleic acids 250-
252. The release rate could be controlled by the molecular weight and copolymer 
composition of PLGA 253. PLGA has the advantage of lower toxicity compared to 
cationic lipids and cationic polymers, however, its transfection efficiency requires 
significant improvement. Recent efforts have focused on modifying PLGA to yield 
positively charged vectors in order to increase cellular uptake 254,255. PLGA nanoparticles 
that contain a hydrophobic core and a hydrophilic lipid/PEG/folate shell were developed 
for co-delivery of drug and gene to folate receptors 256. Incorporation of PEI or cationic 
polyamines or polysaccharides (e.g., chitosan) into PLGA nanoparticles improved gene 
loading and gene expression 257-262. In addition, dimethyldidodecylammonium bromide 
(DMAB) coated PLGA nanoparticles loaded with GFP reporter plasmid exhibited 
significant improvements in transfection efficiencies with comparison to non-modified 
PLGA nanoparticles 263.    
Several dendrimers such as polyamidoamine (PAMAM) 264, poly(propylene imine) 
(PPI) 265, poly(L-lysine) (PLL) 266 and poly(2,2-bis(hydroxymethyl) propionic acid (bis-
MPA) 267 have been studied as drug delivery systems. Dendrimers with positively 
charged surface groups are used to deliver nucleic acids where their core-shell 
nanostructures enable gene loading by encapsulation, surface adsorption, or chemical 
conjugation 268-271. The biocompatibility (e.g., cytotoxicity and immunogenicity) of the 
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dendrimers is related to their structure, molecular weight and surface charge 272,273. These 
synthetic macromolecules have also been chemically modified to mask the cationic 
groups. PEGylation has increased the gene expression 274,275. The transfection efficiency 
is generally a function of the generation of the dendrimers 276-278. Luteinizing hormone-
releasing hormone (LHRH), galactose, TAT and arginine peptides have been conjugated 
to various dendrimers to improve cell targeting and membrane permeation of 
dendriplexes 279-281. The difficulties encountered with the synthesis of the dendrimers 
have limited their clinical applications.    
   
1.5. Lipid/polymer-based vectors  
Another unique nonviral vector consists of nucleic acid precondensed with 
polycations, then coated with cationic lipids 282,283, anionic lipids 284, or amphiphilic 
polymers with helper lipids 285. Linear poly-L-lysine, protamine, histone and several 
polypeptides have been used as nucleic acid condensation component. Lipid/polymer 
system has been reported to be more efficient in transfection than lipid-based vector in 
vitro 282,283 and is equally active in vivo 286. The cytotoxicity of such vector was reduced 
and the application of receptor-mediated targeting became possible without interference 
of nonspecific charge-charge interaction. In addition, several aspects related to lipid 
composition, the presence of shielding PEG-lipid conjugates and the nature of chemical 
bonding that contributes to the biodegradability of PEG-lipid conjugates in cells have 
been studied 287,288.  
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1.6. Hybrid vectors 
Many ongoing efforts have emphasized new ways of better utilizing the advantages 
of both viral and nonviral vectors for gene delivery. This approach, called a ‘hybrid’ 
system, aims to overcome the limitations of individual vectors by combining them. 
Cationic lipids and polymers may help in improving the transduction efficiency of viral 
vectors by engaging the cell surface and allowing internalization of the viral vectors, 
while possibly reducing immunostimulation. Cationic lipids have been shown to promote 
the delivery of adenovectors into target cells resulting in improved gene expression 289,290. 
Adenovirus protein was reported to enhance the nuclear translocation and increase the 
transfection efficiency of PEI/pDNA complexes 291. Furthermore, polycations and PEG 
have been conjugated to adenoviral vector to prolong circulation half-life, enhance gene 
expression and prevent immune response 292,293.   
 
1.7. Thesis overview 
This thesis work aimed to identify simple, safe and effective gene vectors. 
Biodegradable polyester (poly(D,L-lactide-co-glycolide) (PLG) and short cationic peptides 
(cell penetrating peptides) (CPPs) have been explored as carriers for gene delivery. In 
chapter 2, PLG nanoparticles encapsulating pDNA were coated with different surface 
modifiers and examined for the ability to transfect A549 lung epithelial cells. Cationic 
surface modifiers were confirmed to increase pDNA encapsulation efficiency and 
enhance uptake by A549 cells. PLG nanoparticles exhibited sustained low-level gene 
expression for at least 14 days and negligible cytotoxicity.  
In chapter 3, the addition of CaCl2 to TAT/pDNA complexes yielded a network of 
"soft" crosslinks leading to sustained gene expression levels higher than observed for 
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control branched PEI gene vectors in A549. TAT-Ca complexes were stable, maintaining 
particle size and transfection efficiency in the absence and presence of 10% of fetal 
bovine serum (FBS). In addition, TAT peptide showed no evidence of cytotoxicity and 
A549 cells maintained high viability, while branched PEI induced substantial cytotoxicity 
(IC50 ~ 35 µg/mL). In chapter 4, four representative CPPs were studied as DNA 
complexing agents for gene delivery; Arginine 7 (Arg7), Arginine 9 (Arg9), 
Antennapedia Heptapeptide (Ahp) and Antennapedia Leader Peptide (Alp). A CaCl2 
concentration of 113 mM produced small (100-140 nm) and stable CPP polyplexes with a 
single particle population (polydispersity < 0.23). Cytotoxicity profiles of Arg7, Arg9 
and Ahp peptides revealed no evidence of cytotoxicity and cells maintained high 
viability, while Alp peptide showed moderate cytotoxicity (IC50 ~2144 µg/mL). CPP 
polyplexes showed the highest level of gene expression at 113 mM of added CaCl2 for 
the various N/P ratios when compared to branched PEI, which had excellent transfection 
efficiency only in the absence of CaCl2. A slight decrease in transfection efficiency of 
CPP polyplexes was observed in the presence of serum (10% FBS) and CPP polyplexes 
exerted a similar reduction in gene expression as that observed for PEI polyplexes.  
In chapter 5, pDNA within TAT complexes was characterized with the objective of 
contrasting physical properties with PEI polyplexes. Extrinsic fluorescence studies 
provided evidence of compaction of pDNA, with PEI seemingly inducing tighter 
complexes. Second derivative UV analysis demonstrated that the pDNA maintained the B 
form when complexed with various N/P ratios of TAT and PEI. FTIR and CD 
spectroscopies indicated that the secondary structure of pDNA was stabilized within 
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complexes. TAT complexes including calcium improved the thermal stability of pDNA 
compared to PEI.  
Finally, in chapter 6, TAT and dTAT complexes including different concentrations 
of CaCl2 were tested to see if these carriers could perform as safe, effective siRNA 
vectors. The efficacy of siRNA delivery was studied as a function of CPP/siRNA charge 
ratio and siRNA concentration. We found that 23.1, 34.6, and 69.2 mM CaCl2 produced 
small TAT and dTAT complexes via "soft" crosslinks leading to knockdown efficiencies 
higher than observed for PEI vectors in A549-luc-C8 lung epithelial cells. Only a small 
siRNA dose of 10 nM was necessary to achieve a luciferase knockdown of 80-87%. The 
TAT and dTAT peptide also showed negligible cytotoxicity up to 5 mg/mL. In 
comparison, PEI was very cytotoxic (IC50 22 µg/mL). 
 
 
 
 
 
 
 
 
 
 
 
 
 22
1.8. References 
1. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson 
EM, Lotze MT, Yang JC, Topalian SL 1990. Gene transfer into humans—
immunotherapy of patients with advanced melanoma, using tumor-infiltrating 
lymphocytes modified by retroviral gene transduction. New Eng J Med 323(9):570-578. 
2. Dzau VJ, Beatt K, Pompilio G, Smith K 2003. Current perceptions of 
cardiovascular gene therapy* 1. Am J Cardiol  92(9):18-23. 
3. Alisky JM, Davidson BL 2000. Gene therapy for amyotrophic lateral sclerosis 
and other motor neuron diseases. Hu Gene Ther  11(17):2315-2329. 
4. Burton EA, Glorioso JC, Fink DJ 2003. Gene therapy progress and prospects: 
Parkinson's disease. Gene Ther  10(20):1721-1727. 
5. Tuszynski MH 2002. Growth-factor gene therapy for neurodegenerative 
disorders. Lancet Neurol  1(1):51-57. 
6. Bunnell BA, Morgan RA 1998. Gene therapy for infectious diseases. Clin 
Microbiol Rev  11(1):42. 
7. Cutroneo KR 2003. Gene therapy for tissue regeneration. JCel Biochem  
88(2):418-425. 
8. Kerr D 2003. Clinical development of gene therapy for colorectal cancer. Nat Rev 
Cancer  3(8):615-622. 
9. McNeish IA, Bell SJ, Lemoine NR 2004. Gene therapy progress and prospects: 
cancer gene therapy using tumour suppressor genes. Gene Ther  11(6):497-503. 
10. Vile RG, Russell SJ, Lemoine NR 2000. Cancer gene therapy: hard lessons and 
new courses. Gene Ther  7(1):2. 
 23
11. Leonetti JP, Mechti N, Degols G, Gagnor C, Lebleu B 1991. Intracellular 
distribution of microinjected antisense oligonucleotides. Proc Nat Acad Sci U S A  
88(7):2702. 
12. Srivastava IK, Liu MA 2003. Gene vaccines. Ann Int Med  138(7):550-559. 
13. Pack DW, Hoffman AS, Pun S, Stayton PS 2005. Design and development of 
polymers for gene delivery. Nat Rev Drug Discov  4(7):581-593. 
14. Wiethoff CM, Middaugh CR 2003. Barriers to nonviral gene delivery. J Pharm 
Sci  92(2):203-217. 
15. Hama S, Akita H, Iida S, Mizuguchi H, Harashima H 2007. Quantitative and 
mechanism-based investigation of post-nuclear delivery events between adenovirus and 
lipoplex. Nucleic Acids Res  35(5):1533. 
16. Gardlik R, Palffy R, Hodosy J, Lukacs J, Turna J, Celec P 2005. Vectors and 
delivery systems in gene therapy. Med Sci Monit  11(4):121. 
17. Waehler R, Russell SJ, Curiel DT 2007. Engineering targeted viral vectors for 
gene therapy. Nat Rev Gene  8(8):573-587. 
18. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre 
E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M 2003. A serious adverse event 
after successful gene therapy for X-linked severe combined immunodeficiency. New Eng 
J Med  348(3):255-256. 
19. Marshall E 1999. Gene therapy death prompts review of adenovirus vector. 
Science  286(5448):2244. 
 24
20. Cho CW, Cho YS, Kang BT, Hwang JS, Park SN, Yoon DY 2001. Improvement 
of gene transfer to cervical cancer cell lines using non-viral agents. Cancer Lett  
162(1):75-85. 
21. Nakamura T, Moriguchi R, Kogure K, Minoura A, Masuda T, Akita H, Kato K, 
Hamada H, Ueno M, Futaki S 2006. Delivery of condensed DNA by liposomal non-viral 
gene delivery system into nucleus of dendritic cells. Biolog Pharm Bull  29(6):1290-
1293. 
22. Bruckheimer E, Harvie P, Orthel J, Dutzar B, Furstoss K, Mebel E, Anklesaria P, 
Paul R 2003. In vivo efficacy of folate-targeted lipid–protamine–DNA (LPD-PEG-
Folate) complexes in an immunocompetent syngeneic model for breast adenocarcinoma. 
Can Gene Ther  11(2):128-134. 
23. Hildebrandt IJ, Iyer M, Wagner E, Gambhir SS 2003. Optical imaging of 
transferrin targeted PEI/DNA complexes in living subjects. Gene Ther  10(9):758-764. 
24. Morimoto K, Nishikawa M, Kawakami S, Nakano T, Hattori Y, Fumoto S, 
Yamashita F, Hashida M 2003. Molecular weight-dependent gene transfection activity of 
unmodified and galactosylated polyethyleneimine on hepatoma cells and mouse liver. 
Mol Ther  7(2):254-261. 
25. Nishikawa M, Takemura S, Yamashita F, Takakura Y, Meijer D, Hashida M, 
Swart P 2000. Pharmacokinetics and in vivo gene transfer of plasmid DNA complexed 
with mannosylated poly (L-lysine) in mice. J Drug Targ  8(1):29-38. 
26. Park JW 2002. Liposome-based drug delivery in breast cancer treatment. B 
Cancer Res  4(3):95. 
 25
27. Sato A, Kawakami S, Yamada M, Yamashita F, Hashida M 2001. Enhanced gene 
transfection in macrophages using mannosylated cationic liposome-polyethylenimine-
plasmid DNA complexes. J Drug Targ  9(3):201-207. 
28. Mintzer MA, Simanek EE 2008. Nonviral vectors for gene delivery. Chem Rev  
109(2):259-302. 
29. Gao X, Kim KS, Liu D 2007. Nonviral gene delivery: what we know and what is 
next. AAPS J  9(1):92-104. 
30. Berrier AL, Yamada KM 2007. Cell–matrix adhesion. J Cel Physiol  213(3):565-
573. 
31. Alexandrakis G, Brown EB, Tong RT, McKee TD, Campbell RB, Boucher Y, 
Jain RK 2004. Two-photon fluorescence correlation microscopy reveals the two-phase 
nature of transport in tumors. Nat Med  10(2):203-207. 
32. Bureau MF, Naimi S, Torero Ibad R, Seguin J, Georger C, Arnould E, Maton L, 
Blanche F, Delaere P, Scherman D 2004. Intramuscular plasmid DNA electrotransfer:: 
Biodistribution and degradation. BBA-Gene Str Exp  1676(2):138-148. 
33. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK 2000. Role of 
extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res  
60(9):2497. 
34. Pluen A, Boucher Y, Ramanujan S, McKee TD, Gohongi T, Di Tomaso E, Brown 
EB, Izumi Y, Campbell RB, Berk DA 2001. Role of tumor–host interactions in interstitial 
diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Nat Acad Sci U S A  
98(8):4628. 
 26
35. Vandermeulen G, Staes E, Vanderhaeghen ML, Bureau MF, Scherman D, Préat V 
2007. Optimisation of intradermal DNA electrotransfer for immunisation. J Control 
Release  124(1-2):81-87. 
36. Walther W, Stein U, Fichtner I, Kobelt D, Aumann J, Arlt F, Schlag PM 2005. 
Nonviral jet-injection gene transfer for efficient in vivo cytosine deaminase suicide gene 
therapy of colon carcinoma. Mol Ther 12(6):1176-1184. 
37. Walther W, Stein U, Siegel R, Fichtner I, Schlag PM 2005. Use of the nuclease 
inhibitor aurintricarboxylic acid (ATA) for improved non viral intratumoral in vivo gene 
transfer by jet injection. J Gene Med  7(4):477-485. 
38. Dubensky TW, Campbell BA, Villarreal LP 1984. Direct transfection of viral and 
plasmid DNA into the liver or spleen of mice. Proc Nat Acad Sci U S A  81(23):7529. 
39. Evans V, Foster H, Graham IR, Foster K, Athanasopoulos T, Simons JP, Dickson 
G, Owen JS 2008. Human apolipoprotein E expression from mouse skeletal muscle by 
electrotransfer of nonviral DNA (plasmid) and pseudotyped recombinant adeno-
associated virus (AAV2/7). Hum Gene Ther 19: 569-578 (june 2008)  19(6):569-578. 
40. Favre D, Cherel Y, Provost N, Blouin V, Ferry N, Moullier P, Salvetti A 2000. 
Hyaluronidase enhances recombinant adeno-associated virus (rAAV)-mediated gene 
transfer in the rat skeletal muscle. Gene Ther  7(16):1417-1420. 
41. Kuriyama N, Kuriyama H, Julin CM, Lamborn KR, Israel MA 2001. Protease 
pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment 
of an experimental glioblastoma model. Cancer Res  61(5):1805. 
 27
42. McMahon JM, Signori E, Wells KE, Fazio VM, Wells DJ 2001. Optimisation of 
electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase-
increased expression with reduced muscle damage. Gene Ther  8(16):1264-1270. 
43. Mennuni C, Calvaruso F, Zampaglione I, Rizzuto G, Rinaudo D, Dammassa E, 
Ciliberto G, Fattori E, La Monica N 2002. Hyaluronidase increases electrogene transfer 
efficiency in skeletal muscle. Hu Gene Ther  13(3):355-365. 
44. Molnar MJ, Gilbert R, Lu Y, Liu AB, Guo A, Larochelle N, Orlopp K, 
Lochmuller H, Petrof BJ, Nalbantoglu J 2004. Factors influencing the efficacy, longevity, 
and safety of electroporation-assisted plasmid-based gene transfer into mouse muscles. 
Mol Ther  10(3):447-455. 
45. Schertzer JD, Plant DR, Lynch GS 2006. Optimizing plasmid-based gene transfer 
for investigating skeletal muscle structure and function. Mol Ther  13(4):795-803. 
46. Adami RC, Rice KG 1999. Metabolic stability of glutaraldehyde cross linked 
peptide dna condensates. J Pharm Sci  88(8):739-746. 
47. Li S, Tseng WC, Stolz DB, Wu SP, Watkins SC, Huang L 1999. Dynamic 
changes in the characteristics of cationic lipidic vectors after exposure to mouse serum: 
implications for intravenous lipofection. Gene Ther  6(4):585. 
48. Yang Y, Park Y, Man S, Liu Y, Rice KG 2001. Cross linked low molecular 
weight glycopeptide mediated gene delivery: Relationship between DNA metabolic 
stability and the level of transient gene expression in vivo. J Pharm Sci  90(12):2010-
2022. 
49. Lai E, van Zanten JH 2001. Monitoring DNA/poly-L-lysine polyplex formation 
with time-resolved multiangle laser light scattering. Biophys J  80(2):864-873. 
 28
50. Bloomfield VA 1997. DNA condensation by multivalent cations. Biopolymers  
44(3):269-282. 
51. Kabanov AV, Astafyeva IV, Chikindas ML, Rosenblat GF, Kiselev VI, Severin 
ES, Kabanov VA 1991. DNA interpolyelectrolyte complexes as a tool for efficient cell 
transformation. Biopolymers  31(12):1437-1443. 
52. Oupick D, Konلk C, Dash PR, Seymour LW, Ulbrich K 1999. Effect of albumin 
and polyanion on the structure of DNA complexes with polycation containing 
hydrophilic nonionic block. Bioconjug Chem  10(5):764-772. 
53. Ruponen M, Ylن-Herttuala S, Urtti A 1999. Interactions of polymeric and 
liposomal gene delivery systems with extracellular glycosaminoglycans: physicochemical 
and transfection studies. BBA-Biomembranes  1415(2):331-341. 
54. Wiethoff CM, Smith JG, Koe GS, Middaugh CR 2001. The potential role of 
proteoglycans in cationic lipid-mediated gene delivery. J Biolog Chem  276(35):32806. 
55. Ogris M, Brunner S, Schüller S, Kircheis R, Wagner E 1999. PEGylated 
DNA/transferrin-PEI complexes: reduced interaction with blood components, extended 
circulation in blood and potential for systemic gene delivery. Gene Ther  6(4):595. 
56. Toncheva V, Wolfert MA, Dash PR, Oupicky D, Ulbrich K, Seymour LW, 
Schacht EH 1998. Novel vectors for gene delivery formed by self-assembly of DNA with 
poly (-lysine) grafted with hydrophilic polymers. BBA-Genl Sub  1380(3):354-368. 
57. Dash PR, Read ML, Fisher KD, Howard KA, Wolfert M, Oupicky D, Subr V, 
Strohalm J, Ulbrich K, Seymour LW 2000. Decreased binding to proteins and cells of 
polymeric gene delivery vectors surface modified with a multivalent hydrophilic polymer 
and retargeting through attachment of transferrin. J Biolog Chem  275(6):3793. 
 29
58. Howard KA, Dash PR, Read ML, Ward K, Tomkins LM, Nazarova O, Ulbrich K, 
Seymour LW 2000. Influence of hydrophilicity of cationic polymers on the biophysical 
properties of polyelectrolyte complexes formed by self-assembly with DNA. BBA-Gen 
Sub 1475(3):245-255. 
59. Oupick D, Howard KA, Konلk C, Dash PR, Ulbrich K, Seymour LW 2000. 
Steric stabilization of poly-L-Lysine/DNA complexes by the covalent attachment of 
semitelechelic poly [N-(2-hydroxypropyl) methacrylamide]. Bioconjug Chem  11(4):492-
501. 
60. Wang W, Tetley L, Uchegbu IF 2001. The level of hydrophobic substitution and 
the molecular weight of amphiphilic poly--lysine-based polymers strongly affects their 
assembly into polymeric bilayer vesicles. J Col Int Sci  237(2):200-207. 
61. Erbacher P, Bousser MT, Raimond J, Monsigny M, Midoux P, Roche AC 1996. 
Gene transfer by DNA/glycosylated polylysine complexes into human blood monocyte-
derived macrophages. Hu Gene Ther  7(6):721-729. 
62. Nishikawa M, Takemura S, Takakura Y, Hashida M 1998. Targeted delivery of 
plasmid DNA to hepatocytes in vivo: optimization of the pharmacokinetics of plasmid 
DNA/galactosylated poly (L-lysine) complexes by controlling their physicochemical 
properties. J Pharmacol Exp Ther  287(1):408. 
63. Kursa M, Walker GF, Roessler V, Ogris M, Roedl W, Kircheis R, Wagner E 
2003. Novel shielded transferrin-polyethylene glycol-polyethylenimine/DNA complexes 
for systemic tumor-targeted gene transfer. Bioconjug Chem  14(1):222-231. 
64. Kwok KY, McKenzie DL, Evers DL, Rice KG 1999. Formulation of highly 
soluble poly (ethylene glycol) peptide DNA condensates. J Pharm Sci  88(10):996-1003. 
 30
65. Petersen H, Fechner PM, Martin AL, Kunath K, Stolnik S, Roberts CJ, Fischer D, 
Davies MC, Kissel T 2002. Polyethylenimine-graft-poly (ethylene glycol) copolymers: 
influence of copolymer block structure on DNA complexation and biological activities as 
gene delivery system. Bioconjug Chem  13(4):845-854. 
66. Pun SH, Bellocq NC, Liu A, Jensen G, Machemer T, Quijano E, Schluep T, Wen 
S, Engler H, Heidel J 2004. Cyclodextrin-modified polyethylenimine polymers for gene 
delivery. Bioconjug Chem  15(4):831-840. 
67. Pun SH, Davis ME 2002. Development of a nonviral gene delivery vehicle for 
systemic application. Bioconjug Chem  13(3):630-639. 
68. Mishra S, Webster P, Davis ME 2004. PEGylation significantly affects cellular 
uptake and intracellular trafficking of non-viral gene delivery particles. Eur J Cell Biolog  
83(3):97-111. 
69. Kunath K, von Harpe A, Fischer D, Kissel T 2003. Galactose-PEI-DNA 
complexes for targeted gene delivery: degree of substitution affects complex size and 
transfection efficiency. J Control Release  88(1):159-172. 
70. Olivier V, Meisen I, Meckelein B, Hirst TR, Peter-Katalinic J, Schmidt MA, Frey 
A 2003. Influence of targeting ligand flexibility on receptor binding of particulate drug 
delivery systems. Bioconjug Chemistry  14(6):1203-1208. 
71. Zhang Y, Bryant J, Charles A, Boado RJ, Pardridge WM 2004. Intravenous RNA 
interference gene therapy targeting the human epidermal growth factor receptor prolongs 
survival in intracranial brain cancer. Clin Cancer Res  10(11):3667. 
 31
72. Belting M, Petersson P 1999. Protective role for proteoglycans against cationic 
lipid cytotoxicity allowing optimal transfection efficiency in vitro. Biochem J  342(Pt 
2):281. 
73. Mislick KA, Baldeschwieler JD 1996. Evidence for the role of proteoglycans in 
cation-mediated gene transfer. Proc Nat Acad Sci U S A  93(22):12349. 
74. Gottschalk S, Cristiano RJ, Smith LC, Woo SL 1994. Folate receptor mediated 
DNA delivery into tumor cells: potosomal disruption results in enhanced gene 
expression. Gene Ther  1(3):185. 
75. Lim DW, Yeom YI, Park TG 2000. Poly (DMAEMA-NVP)-b-PEG-galactose as 
gene delivery vector for hepatocytes. Bioconjug Chem  11(5):688-695. 
76. Mahato RI, Monera OD, Smith LC, Rolland A 1999. Peptide-based gene delivery. 
Curr Opin Mol Ther  1(2):226. 
77. Chowdhury NR, Wu CH, Wu GY, Yerneni PC, Bommineni VR, Chowdhury JR 
1993. Fate of DNA targeted to the liver by asialoglycoprotein receptor-mediated 
endocytosis in vivo. Prolonged persistence in cytoplasmic vesicles after partial 
hepatectomy. J Biolog Chem  268(15):11265. 
78. Collard WT, Yang Y, Kwok KY, Park Y, Rice KG 2000. Biodistribution, 
metabolism, and in vivo gene expression of low molecular weight glycopeptide 
polyethylene glycol peptide DNA co condensates. J Pharm Sci  89(4):499-512. 
79. Hofland HE, Masson C, Iginla S, Osetinsky I, Reddy JA, Leamon CP, Scherman 
D, Bessodes M, Wils P 2002. Folate-targeted gene transfer in vivo. Mol Ther  5(6):739-
744. 
 32
80. Wu GY, Wilson JM, Shalaby F, Grossman M, Shafritz DA, Wu CH 1991. 
Receptor-mediated gene delivery in vivo. Partial correction of genetic analbuminemia in 
Nagase rats. J Biolog Chem  266(22):14338. 
81. Wu GY, Wu CH 1998. Receptor-mediated delivery of foreign genes to 
hepatocytes. Adv Drug Deliv Rev  29(3):243-248. 
82. Neves C, Byk G, Scherman D, Wils P 1999. Coupling of a targeting peptide to 
plasmid DNA by covalent triple helix formation. FEBS Lett  453(1-2):41-45. 
83. Ghinea N, Hasu M 1986. Charge effect on binding, uptake and transport of 
ferritin through fenestrated endothelium. J Submicro Cytolog  18(4):647. 
84. Labat-Moleur F, Steffan AM, Brisson C, Perron H, Feugeas O, Furstenberger P, 
Oberling F, Brambilla E, Behr JP 1996. An electron microscopy study into the 
mechanism of gene transfer with lipopolyamines. Gene Ther  3(11):1010. 
85. Pratten MK, Cable HC, Ringsdorf H, Lloyd JB 1982. Adsorptive pinocytosis of 
polycationic copolymers of vinylpyrrolidone with vinylamine by rat yolk sac and rat 
peritoneal macrophage. BBA-Gen Sub  719(3):424-430. 
86. Stenseth K, Hedin U, Thyberg J 1983. Endocytosis, intracellular transport, and 
turnover of anionic and cationic proteins in cultured mouse peritoneal macrophages. Eur 
J Cell Biol  31(1):15. 
87. Friend DS, Papahadjopoulos D, Debs RJ 1996. Endocytosis and intracellular 
processing accompanying transfection mediated by cationic liposomes. BBA-
Biomembranes  1278(1):41-50. 
88. Goncalves C, Mennesson E, Fuchs R, Gorvel JP, Midoux P, Pichon C 2004. 
Macropinocytosis of  polyplexes and recycling of plasmid via the clathrin-dependent 
 33
pathway impair the transfection efficiency of human hepatocarcinoma cells&ast. Mol 
Ther  10(2):373-385. 
89. Rejman J, Oberle V, Zuhorn IS, Hoekstra D 2004. Size-dependent internalization 
of particles via the pathways of clathrin-and caveolae-mediated endocytosis. Biochem J  
377(Pt 1):159. 
90. Zuhorn IS, Kalicharan R, Hoekstra D 2002. Lipoplex-mediated transfection of 
mammalian cells occurs through the cholesterol-dependent clathrin-mediated pathway of 
endocytosis. J Biol Chem  277(20):18021. 
91. Harbottle RP, Cooper RG, Hart SL, Ladhoff A, McKay T, Knight AM, Wagner E, 
Miller AD, Coutelle C 1998. An RGD-oligolysine peptide: a prototype construct for 
integrin-mediated gene delivery. Hu Gene Ther  9(7):1037-1047. 
92. Matsui H, Johnson LG, Randell SH, Boucher RC 1997. Loss of binding and entry 
of liposome-DNA complexes decreases transfection efficiency in differentiated airway 
epithelial cells. J Biol Chem  272(2):1117. 
93. Turk MJ, Reddy JA, Chmielewski JA, Low PS 2002. Characterization of a novel 
pH-sensitive peptide that enhances drug release from folate-targeted liposomes at 
endosomal pHs. BBA-Biomembranes  1559(1):56-68. 
94. Fajac I, Allo JC, Souil E, Merten M, Pichon C, Figarella C, Monsigny M, Briand 
P, Midoux P 2000. Histidylated polylysine as a synthetic vector for gene transfer into 
immortalized cystic fibrosis airway surface and airway gland serous cells. J Gene Med  
2(5):368-378. 
 34
95. Grosse S, Tremeau-Bravard A, Aron Y, Briand P, Fajac I 2002. Intracellular rate-
limiting steps of gene transfer using glycosylated polylysines in cystic fibrosis airway 
epithelial cells. Gene Ther  9(15):1000-1007. 
96. Itaka K, Harada A, Yamasaki Y, Nakamura K, Kawaguchi H, Kataoka K 2004. In 
situ single cell observation by fluorescence resonance energy transfer reveals fast intra 
cytoplasmic delivery and easy release of plasmid DNA complexed with linear 
polyethylenimine. J Gene Med  6(1):76-84. 
97. Rosenkranz AA, Yachmenev SV, Jans DA, Serebryakova NV, Murav'ev VI, 
Peters R, Sobolev AS 1992. Receptor-mediated endocytosis and nuclear transport of a 
transfecting DNA construct. Exp Cell Res 199(2):323-329. 
98. Suh J, Wirtz D, Hanes J 2003. Efficient active transport of gene nanocarriers to 
the cell nucleus. Proc Nat Acad Sci U S A 100(7):3878. 
99. Erbacher P, Roche AC, Monsigny M, Midoux P 1996. Putative role of 
chloroquine in gene transfer into a human hepatoma cell line by DNA/lactosylated 
polylysine complexes. Exp Cell Ces  225(1):186-194. 
100. Gonzalez H, Hwang SJ, Davis ME 1999. New class of polymers for the delivery 
of macromolecular therapeutics. Bioconjug Chem  10(6):1068-1074. 
101. Midoux P, Mendes C, Legrand A, Raimond J, Mayer R, Monsigny M, Roche AC 
1993. Specific gene transfer mediated by lactosylated poly-L-lysine into hepatoma cells. 
Nucleic Acids Res  21(4):871. 
102. Oupick D, Carlisle RC, Seymour LW 2001. Triggered intracellular activation of 
disulfide crosslinked polyelectrolyte gene delivery complexes with extended systemic 
circulation in vivo. Gene ther  8(9):713. 
 35
103. Zhang X, Sawyer GJ, Dong X, Qiu Y, Collins L, Fabre JW 2003. The in vivo use 
of chloroquine to promote non viral gene delivery to the liver via the portal vein and bile 
duct. Journal Gene Med  5(3):209-218. 
104. Clague MJ, Urbe S 2001. The interface of receptor trafficking and signalling. J 
Cell Sci  114(Pt 17):3075. 
105. Farhood H, Serbina N, Huang L 1995. The role of dioleoyl 
phosphatidylethanolamine in cationic liposome mediated gene transfer. BBA-
Biomembranes  1235(2):289-295. 
106. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, 
Ringold GM, Danielsen M 1987. Lipofection: a highly efficient, lipid-mediated DNA-
transfection procedure. Proc Nat Acad Sci U S A  84(21):7413. 
107. Hui SW, Langner M, Zhao YL, Ross P, Hurley E, Chan K 1996. The role of 
helper lipids in cationic liposome-mediated gene transfer. Biophys J  71(2):590-599. 
108. Im Hafez NM, Cullis PR 2001. On the mechanism whereby cationic lipids 
promote intracellular delivery of polynucleic acids. Gene Ther  8(15):1188-1196. 
109. Xu Y, Szoka Jr FC 1996. Mechanism of DNA release from cationic 
liposome/DNA complexes used in cell transfection. Biochemistry  35(18):5616-5623. 
110. Akinc A, Thomas M, Klibanov AM, Langer R 2005. Exploring polyethylenimine 
mediated DNA transfection and the proton sponge hypothesis. J Gene Med  7(5):657-
663. 
111. Behr JP 1997. The proton sponge: a trick to enter cells the viruses did not exploit. 
CHIMIA Int J Chem, 51  1(2):34-36. 
 36
112. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, 
Behr JP 1995. A versatile vector for gene and oligonucleotide transfer into cells in culture 
and in vivo: polyethylenimine. Proc Nat Acad Sci U S A  92(16):7297. 
113. Grabe M, Oster G 2001. Regulation of organelle acidity. J Gen Physiol  
117(4):329. 
114. Mellman I, Fuchs R, Helenius A 1986. Acidification of the endocytic and 
exocytic pathways. Ann Rev Biochem  55(1):663-700. 
115. Suh J, Paik HJ, Hwang BK 1994. Ionization of poly (ethylenimine) and poly 
(allylamine) at various pH's. Bioorg Chem  22(3):318-327. 
116. Plank C, Oberhauser B, Mechtler K, Koch C, Wagner E 1994. The influence of 
endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer 
systems. J Biol Chem  269(17):12918. 
117. Plank C, Zatloukal K, Cotten M, Mechtler K, Wagner E 1992. Gene transfer into 
hepatocytes using asialoglycoprotein receptor mediated endocytosis of DNA complexed 
with an artificial tetra-antennary galactose ligand. Bioconjug Chem  3(6):533-539. 
118. Wagner E, Plank C, Zatloukal K, Cotten M, Birnstiel ML 1992. Influenza virus 
hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-
polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle. Proc Nat 
Acad Sci U S A  89(17):7934. 
119. Lee H, Jeong JH, Park TG 2001. A new gene delivery formulation of 
polyethylenimine/DNA complexes coated with PEG conjugated fusogenic peptide. J 
Control Release  76(1-2):183-192. 
 
 37
120. Vaysse L, Burgelin I, Merlio JP, Arveiler B 2000. Improved transfection using 
epithelial cell line-selected ligands and fusogenic peptides. BBA-Gen Subjects  
1475(3):369-376. 
121. Wagner E 1998. Effects of membrane-active agents in gene delivery. J Control 
Release  53(1-3):155-158. 
122. Wyman TB, Nicol F, Zelphati O, Scaria PV, Plank C, Szoka Jr FC 1997. Design, 
synthesis, and characterization of a cationic peptide that binds to nucleic acids and 
permeabilizes bilayers. Biochemistry  36(10):3008-3017. 
123. Legendre JY, Szoka Jr FC 1992. Delivery of plasmid DNA into mammalian cell 
lines using pH-sensitive liposomes: comparison with cationic liposomes. Pharm Res  
9(10):1235-1242. 
124. Ciftci K, Levy RJ 2001. Enhanced plasmid DNA transfection with 
lysosomotropic agents in cultured fibroblasts. Int J Pharm 218(1-2):81-92. 
125. Luthman H, Magnusson G 1983. High efficiency polyoma DNA transfection of 
chloroquine treated cells. Nucleic Acids Res  11(5):1295. 
126. Niidome T, Ohmori N, Ichinose A, Wada A, Mihara H, Hirayama T, Aoyagi H 
1997. Binding of cationic -helical peptides to plasmid DNA and their gene transfer 
abilities into cells. J Biol Chem  272(24):15307. 
127. Lechardeur D, Lukacs GL 2002. Intracellular barriers to non-viral gene transfer. 
Curr Gene Ther  2(2):183-194. 
 
128. Lukacs GL, Haggie P, Seksek O, Lechardeur D, Freedman N, Verkman AS 2000. 
Size-dependent DNA mobility in cytoplasm and nucleus. J Biol Chem  275(3):1625. 
 38
129. Lechardeur D, Sohn KJ, Haardt M, Joshi PB, Monck M, Graham RW, Beatty B, 
Squire J, O'Brodovich H, Lukacs GL 1999. Metabolic instability of plasmid DNA in the 
cytosol: a potential barrier to gene transfer. Gene Ther 6(4):482. 
130. Pollard H, Toumaniantz G, Amos JL, Avet Loiseau H, Guihard G, Behr JP, 
Escande D 2001. Ca2+ sensitive cytosolic nucleases prevent efficient delivery to the 
nucleus of injected plasmids. J Gene Med  3(2):153-164. 
131. Pollard H, Remy JS, Loussouarn G, Demolombe S, Behr JP, Escande D 1998. 
Polyethylenimine but not cationic lipids promotes transgene delivery to the nucleus in 
mammalian cells. J Biol Chem  273(13):7507. 
132. Dean DA 1997. Import of plasmid DNA into the nucleus is sequence specific* 1. 
Exp Cell Res  230(2):293-302. 
133. Mattaj IW, Englmeier L 1998. Nucleocytoplasmic transport: the soluble phase. 
Ann Rev Biochem  67:265. 
134. Perales JC, Ferkol T, Beegen H, Ratnoff OD, Hanson RW 1994. Gene transfer in 
vivo: sustained expression and regulation of genes introduced into the liver by receptor-
targeted uptake. Proc Nat Acad Sci U S A  91(9):4086. 
135. Ryan KJ, Wente SR 2000. The nuclear pore complex: a protein machine bridging 
the nucleus and cytoplasm. Curr Opin Cell Biol 12(3):361-371. 
136. Whittaker GR, Kann M, Helenius A 2000. Viral entry into the nucleus. Annu Rev 
Cell Devel Biol  16(1):627-651. 
137. Brunner S, Sauer T, Carotta S, Cotten M, Saltik M, Wagner E 2000. Cell cycle 
dependence of gene transfer by lipoplex, polyplex and recombinant adenovirus. Gene 
Ther  7(5):401. 
 39
138. Zanta MA, Belguise-Valladier P, Behr JP 1999. Gene delivery: a single nuclear 
localization signal peptide is sufficient to carry DNA to the cell nucleus. Proc Nat Acad 
Sci U S A  96(1):91. 
139. Brandén LJ, Mohamed AJ, Smith CIE 1999. A peptide nucleic acid-nuclear 
localization signal fusion that mediates nuclear transport of DNA. Nat Biotechnol  
17:784-787. 
140. Zabner J, Fasbender AJ, Moninger T, Poellinger KA, Welsh MJ 1995. Cellular 
and molecular barriers to gene transfer by a cationic lipid. J Biol Chem  270(32):18997. 
141. Bremner KH, Seymour LW, Logan A, Read ML 2004. Factors influencing the 
ability of nuclear localization sequence peptides to enhance nonviral gene delivery. 
Bioconjug Chem  15(1):152-161. 
142. Chan CK, Jans DA 1999. Enhancement of polylysine-mediated transferrinfection 
by nuclear localization sequences: polylysine does not function as a nuclear localization 
sequence. Hu Gene Ther  10(10):1695-1702. 
143. Chan CK, Senden T, Jans DA 2000. Supramolecular structure and nuclear 
targeting efficiency determine the enhancement of transfection by modified polylysines. 
Gene Ther  7(19):1690. 
144. Wu GY, Wu CH 1987. Receptor-mediated in vitro gene transformation by a 
soluble DNA carrier system. J Biol Chem  262(10):4429. 
145. Horobin RW, Weissig V 2005. A QSAR modeling perspective on cationic 
transfection lipids. 1. Predicting efficiency and understanding mechanisms. J Gene Med  
7(8):1023-1034. 
 40
146. El Ouahabi A, Thiry M, Pector V, Fuks R, Ruysschaert JM, Vandenbranden M 
1997. The role of endosome destabilizing activity in the gene transfer process mediated 
by cationic lipids. FEBS Lett  414(2):187-192. 
147. Gao X, Huang L 1991. A novel cationic liposome reagent for efficient 
transfection of mammalian cells. Biochem Biophys Res Commun  179(1):280-285. 
148. Hirko A, Tang F, Hughes JA 2003. Cationic lipid vectors for plasmid DNA 
delivery. Curr Med Chem  10(14):1185-1193. 
149. Van Der Woude I, Wagenaar A, Meekel AAP, Ter Beest M, Ruiters MHJ, 
Engberts JBFN, Hoekstra D 1997. Novel pyridinium surfactants for efficient, nontoxic in 
vitro gene delivery. Proc Nat Acad Sci U S A  94(4):1160. 
150. Vigneron JP, Oudrhiri N, Fauquet M, Vergely L, Bradley JC, Basseville M, Lehn 
P, Lehn JM 1996. Guanidinium-cholesterol cationic lipids: efficient vectors for the 
transfection of eukaryotic cells. Proc Nat Acad Sci U S A  93(18):9682. 
151. Zhang G, Gurtu V, Smith TH, Nelson P, Kain SR 1997. A cationic lipid for rapid 
and efficient delivery of plasmid DNA into mammalian cells. Biochem  Biophys Res 
Commun  236(1):126-129. 
152. Zhu L, Lu Y, Miller DD, Mahato RI 2008. Structural and formulation factors 
influencing pyridinium lipid-based gene transfer. Bioconjug Chem  19(12):2499-2512. 
153. Liu D, Ren T, Gao X 2003. Cationic transfection lipids. Curr Med Chem  
10(14):1307-1315. 
154. Song YK, Liu F, Chu S, Liu D 1997. Characterization of cationic liposome-
mediated gene transfer in vivo by intravenous administration. Hu Gene Ther  8(13):1585-
1594. 
 41
155. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN 
1997. Improved DNA: liposome complexes for increased systemic delivery and gene 
expression. Nat Biotechnol  15(7):647-652. 
156. Thierry AR, Lunardi-Iskandar Y, Bryant JL, Rabinovich P, Gallo RC, Mahan LC 
1995. Systemic gene therapy: biodistribution and long-term expression of a transgene in 
mice. Proc Nat Acad Sci U S A  92(21):9742. 
157. Bragonzi A, Dina G, Villa A, Calori G, Biffi A, Bordignon C, Assael BM, Conese 
M 2000. Biodistribution and transgene expression with nonviral cationic vector/DNA 
complexes in the lungs. Gene Ther  7(20):1753-1760. 
158. Hyde SC, Southern KW, Gileadi U, Fitzjohn EM, Mofford KA, Waddell BE, 
Gooi HC, Goddard CA, Hannavy K, Smyth SE 2000. Repeat administration of 
DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther  
7(13):1156-1165. 
159. Noone PG, Hohneker KW, Zhou Z, Johnson LG, Foy C, Gipson C, Jones K, 
Noah TL, Leigh MW, Schwartzbach C 2000. Safety and Biological Efficacy of a Lipid–
CFTR Complex for Gene Transfer in the Nasal Epithelium of Adult Patients with Cystic 
Fibrosis&ast. Mol Ther 1(1):105-114. 
160. Harvie P, Wong FMP, Bally MB 2000. Use of poly (ethylene glycol)–lipid 
conjugates to regulate the surface attributes and transfection activity of lipid–DNA 
particles. J Pharm Sci  89(5):652-663. 
161. Ambegia E, Ansell S, Cullis P, Heyes J, Palmer L, MacLachlan I 2005. Stabilized 
plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation 
lifetimes and tumor selective gene expression. BBA-Biomembranes  1669(2):155-163. 
 42
162. Guo X, Szoka Jr FC 2001. Steric stabilization of fusogenic liposomes by a low-
pH sensitive PEG-diortho ester-lipid conjugate. Bioconjug Chem  12(2):291-300. 
163. Li S, Rizzo MA, Bhattacharya S, Huang L 1998. Characterization of cationic 
lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther  
5(7):930. 
164. Ruiz FE, Clancy JP, Perricone MA, Bebok Z, Hong JS, Cheng SH, Meeker DP, 
Young KR, Schoumacher RA, Weatherly MR 2001. A clinical inflammatory syndrome 
attributable to aerosolized lipid-DNA administration in cystic fibrosis. Hu Gene Ther  
12(7):751-761. 
165. Scheule RK, George JAS, Bagley RG, Marshall J, Kaplan JM, Akita GY, Wang 
KX, Lee ER, Harris DJ, Jiang C 1997. Basis of pulmonary toxicity associated with 
cationic lipid-mediated gene transfer to the mammalian lung. Hu Gene Ther  8(6):689-
707. 
166. Huang Z, Li W, MacKay JA, Szoka FC 2005. Thiocholesterol-based lipids for 
ordered assembly of bioresponsive gene carriers. Mol Ther  11(3):409-417. 
167. Tang F, Hughes JA 1999. Use of dithiodiglycolic acid as a tether for cationic 
lipids decreases the cytotoxicity and increases transgene expression of plasmid DNA in 
vitro. Bioconjug Chem  10(5):791-796. 
168. Wetzer B, Byk G, Frederic M, Airiau M, Blanche F, Pitard B, Scherman D 2001. 
Reducible cationic lipids for gene transfer. Biochem J  356(Pt 3):747. 
169. Blume G, Cevc G 1990. Liposomes for the sustained drug release in vivo. BBA-
Biomembranes  1029(1):91-97. 
 43
170. Singh RS, Gonçalves C, Sandrin P, Pichon C, Midoux P, Chaudhuri A 2004. On 
the Gene Delivery Efficacies of pH-Sensitive Cationic Lipids via Endosomal 
Protonation:: A Chemical Biology Investigation. Chem biol  11(5):713-723. 
171. Park MR, Han KO, Han IK, Cho MH, Nah JW, Choi YJ, Cho CS 2005. 
Degradable polyethylenimine-alt-poly (ethylene glycol) copolymers as novel gene 
carriers. J Control Release  105(3):367-380. 
172. Park TG, Jeong JH, Kim SW 2006. Current status of polymeric gene delivery 
systems. Adv Drug Deliv Rev  58(4):467-486. 
173. Ratner BD, Bryant SJ 2004. Biomaterials: where we have been and where we are 
going. Annu Rev Biomed Eng  6:41-75. 
174. Weecharangsan W, Opanasopit P, Ngawhirunpat T, Apirakaramwong A, 
Rojanarata T, Ruktanonchai U, Lee RJ 2008. Evaluation of chitosan salts as non-viral 
gene vectors in CHO-K1 cells. International Journal of Pharmaceutics  348(1-2):161-168. 
175. Balicki D, Beutler E 1997. Histone H2A significantly enhances in vitro DNA 
transfection. Mol Med  3(11):782. 
176. Farrell LL, Pepin J, Kucharski C, Lin X, Xu Z, Uludag H 2007. A comparison of 
the effectiveness of cationic polymers poly-L-lysine (PLL) and polyethylenimine (PEI) 
for non-viral delivery of plasmid DNA to bone marrow stromal cells (BMSC). European 
J Pharma Biopharma  65(3):388-397. 
177. Mannisto M, Vanderkerken S, Toncheva V, Elomaa M, Ruponen M, Schacht E, 
Urtti A 2002. Structure-activity relationships of poly (-lysines): effects of pegylation and 
molecular shape on physicochemical and biological properties in gene delivery. J Control 
Release  83(1):169-182. 
 44
178. Maruyama K, Iwasaki F, Takizawa T, Yanagie H, Niidome T, Yamada E, Ito T, 
Koyama Y 2004. Novel receptor-mediated gene delivery system comprising 
plasmid/protamine/sugar-containing polyanion ternary complex. Biomaterials  
25(16):3267-3273. 
179. Balicki D, Putnam CD, Scaria PV, Beutler E 2002. Structure and function 
correlation in histone H2A peptide-mediated gene transfer. Proc Nat Acad Sci U S A  
99(11):7467. 
180. Eguchi A, Akuta T, Okuyama H, Senda T, Yokoi H, Inokuchi H, Fujita S, 
Hayakawa T, Takeda K, Hasegawa M 2001. Protein transduction domain of HIV-1 Tat 
protein promotes efficient delivery of DNA into mammalian cells. J Biol Chem  
276(28):26204. 
181. Futaki S, Ohashi W, Suzuki T, Niwa M, Tanaka S, Ueda K, Harashima H, 
Sugiura Y 2001. Stearylated arginine-rich peptides: a new class of transfection systems. 
Bioconjug Chem  12(6):1005-1011. 
182. Ignatovich IA, Dizhe EB, Pavlotskaya AV, Akifiev BN, Burov SV, Orlov SV, 
Perevozchikov AP 2003. Complexes of plasmid DNA with basic domain 47-57 of the 
HIV-1 Tat protein are transferred to mammalian cells by endocytosis-mediated pathways. 
J Biol Chem  278(43):42625. 
183. Rudolph C, Plank C, Lausier J, Schillinger U, Müller RH, Rosenecker J 2003. 
Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of 
transferring plasmid DNA into cells. J Biol Chem  278(13):11411. 
184. Sandgren S, Cheng F, Belting M 2002. Nuclear targeting of macromolecular 
polyanions by an HIV-Tat derived peptide. J Biol Chem  277(41):38877. 
 45
 
185. Torchilin VP, Rammohan R, Weissig V, Levchenko TS 2001. TAT peptide on the 
surface of liposomes affords their efficient intracellular delivery even at low temperature 
and in the presence of metabolic inhibitors. Proc Nat Acad Sci U S A  98(15):8786. 
186. Tung CH, Mueller S, Weissleder R 2002. Novel branching membrane 
translocational peptide as gene delivery vector. Bioorg Med Chem  10(11):3609-3614. 
187. Tung CH, Stein S 2000. Preparation and applications of peptide-oligonucleotide 
conjugates. Bioconjug Chem  11(5):605-618. 
188. Kim TH, Jiang HL, Jere D, Park IK, Cho MH, Nah JW, Choi YJ, Akaike T, Cho 
CS 2007. Chemical modification of chitosan as a gene carrier in vitro and in vivo. Prog  
Poly Sci 32(7):726-753. 
189. Je JY, Cho YS, Kim SK 2006. Characterization of (aminoethyl) chitin/DNA 
nanoparticle for gene delivery. Biomacromolecules  7(12):3448-3451. 
190. Lee D, Zhang W, Shirley SA, Kong X, Hellermann GR, Lockey RF, Mohapatra 
SS 2007. Thiolated chitosan/DNA nanocomplexes exhibit enhanced and sustained gene 
delivery. Pharm Res  24(1):157-167. 
191. Choi C, Kim DG, Jang MJ, Kim TH, Jang MK, Nah JW 2006. DNA delivery 
using low molecular water soluble chitosan nanocomplex as a biomedical device. J App 
Poly Sci  102(4):3545-3551. 
192. Ercelen S, Zhang X, Duportail G, Grandfils C, Desbrières J, Karaeva S, Tikhonov 
V, Mély Y, Babak V 2006. Physicochemical properties of low molecular weight 
alkylated chitosans: A new class of potential nonviral vectors for gene delivery. Col Sur 
B: Biointerfaces  51(2):140-148. 
 46
193. Duceppe N, Tabrizian M 2009. Factors influencing the transfection efficiency of 
ultra low molecular weight chitosan/hyaluronic acid nanoparticles. Biomaterials  
30(13):2625-2631. 
194. Peng SF, Yang MJ, Su CJ, Chen HL, Lee PW, Wei MC, Sung HW 2009. Effects 
of incorporation of poly ([gamma]-glutamic acid) in chitosan/DNA complex 
nanoparticles on cellular uptake and transfection efficiency. Biomaterials  30(9):1797-
1808. 
195. Mahato RI 1999. Non-viral peptide-based approaches to gene delivery. J Drug 
Targ  7(4):249-268. 
196. Bloomfield VA 1996. DNA condensation. Curr Opin Str Biol  6(3):334-341. 
197. McKenzie DL, Kwok KY, Rice KG 2000. A potent new class of reductively 
activated peptide gene delivery agents. J Biol Chem 275(14):9970. 
198. Wadhwa MS, Collard WT, Adami RC, McKenzie DL, Rice KG 1997. Peptide-
mediated gene delivery: influence of peptide structure on gene expression. Bioconjug 
Chem  8(1):81-88. 
199. Cao G, Pei W, Ge H, Liang Q, Luo Y, Sharp FR, Lu A, Ran R, Graham SH, Chen 
J 2002. In vivo delivery of a Bcl-xL fusion protein containing the TAT protein 
transduction domain protects against ischemic brain injury and neuronal apoptosis. J 
Neurosci  22(13):5423. 
200. Dietz GPH 2004. Delivery of bioactive molecules into the cell: the Trojan horse 
approach* 1. Mol Cel Neurosci  27(2):85-131. 
201. Gupta B, Torchilin VP 2006. Transactivating transcriptional activator-mediated 
drug delivery. 
 47
202. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF 1999. In vivo protein 
transduction: delivery of a biologically active protein into the mouse. Science  
285(5433):1569. 
203. Tung CH, Weissleder R 2003. Arginine containing peptides as delivery vectors. 
Adv Drug Deliv Rev  55(2):281-294. 
204. Deshayes S, Morris MC, Divita G, Heitz F 2005. Cell-penetrating peptides: tools 
for intracellular delivery of therapeutics. Cel Mol Life Sci  62(16):1839-1849. 
205. Gupta B, Levchenko TS, Torchilin VP 2005. Intracellular delivery of large 
molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv 
Rev  57(4):637-651. 
206. Bremner KH, Seymour LW, Pouton CW 2001. Harnessing nuclear localization 
pathways for transgene delivery. Curr Opin Mol Ther  3(2):170. 
207. El-Sayed A, Futaki S, Harashima H 2009. Delivery of macromolecules using 
arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. AAPS 
J  11(1):13-22. 
208. Gorlich D, Mattaj IW 1996. Nucleocytoplasmic transport. Science  
271(5255):1513. 
209. Vivès E, Brodin P, Lebleu B 1997. A truncated HIV-1 Tat protein basic domain 
rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J 
Biol Chem  272(25):16010. 
210. Wadia JS, Dowdy SF 2005. Transmembrane delivery of protein and peptide drugs 
by TAT-mediated transduction in the treatment of cancer. Adv Drug Delive Rev  
57(4):579-596. 
 48
211. Avrameas A, Ternynck T, Nato F, Buttin G, Avrameas S 1998. Polyreactive anti-
DNA monoclonal antibodies and a derived peptide as vectors for the intracytoplasmic 
and intranuclear translocation of macromolecules. Proc Nat Acad Sci Uni S A  
95(10):5601. 
212. Putnam D, Gentry CA, Pack DW, Langer R 2001. Polymer-based gene delivery 
with low cytotoxicity by a unique balance of side-chain termini. Proc Nat Acad Sci U S 
A 98(3):1200. 
213. Reineke TM, Davis ME 2003. Structural effects of carbohydrate-containing 
polycations on gene delivery. 2. Charge center type. Bioconjug Chem  14(1):255-261. 
214. Reineke TM, Davis ME 2003. Structural effects of carbohydrate-containing 
polycations on gene delivery. 1. Carbohydrate size and its distance from charge centers. 
Bioconjug Chem  14(1):247-254. 
215. Brissault B, Kichler A, Guis C, Leborgne C, Danos O, Cheradame H 2003. 
Synthesis of linear polyethylenimine derivatives for DNA transfection. Bioconjug Chem  
14(3):581-587. 
216. Meade BR, Dowdy SF 2008. Enhancing the cellular uptake of siRNA duplexes 
following noncovalent packaging with protein transduction domain peptides. Adv Drug 
Deliv Rev  60(4-5):530-536. 
217. Zauner W, Ogris M, Wagner E 1998. Polylysine-based transfection systems 
utilizing receptor-mediated delivery. Adv Drug Deliv Rev  30(1-3):97-113. 
218. Park S, Healy KE 2003. Nanoparticulate DNA packaging using terpolymers of 
poly (lysine-g-(lactide-b-ethylene glycol)). Bioconjug Chem 14(2):311-319. 
 49
219. Winblade ND, Nikolic ID, Hoffman AS, Hubbell JA 2000. Blocking Adhesion to 
Cell and Tissue Surfaces by the Chemisorption of a Poly-l-lysine-g raft-(poly (ethylene 
glycol); phenylboronic acid) Copolymer. Biomacromolecules  1(4):523-533. 
220. Choi YH, Liu F, Kim JS, Choi YK 1998. Polyethylene glycol-grafted poly--lysine 
as polymeric gene carrier. J Control Release  54(1):39-48. 
221. Liu G, Molas M, Grossmann GA, Pasumarthy M, Perales JC, Cooper MJ, Hanson 
RW 2001. Biological properties of poly-L-lysine-DNA complexes generated by 
cooperative binding of the polycation. J Biol Chem  276(37):34379. 
222. Midoux P, Monsigny M 1999. Efficient gene transfer by histidylated 
polylysine/pDNA complexes. Bioconjug Chem  10(3):406-411. 
223. Abbasi M, Uludag H, Incani V, Yu Ming Hsu C, Jeffery A 2008. Further 
investigation of lipid-substituted poly (L-lysine) polymers for transfection of human skin 
fibroblasts. Biomacromolecules  9(6):1618-1630. 
224. Yu H, Chen X, Lu T, Sun J, Tian H, Hu J, Wang Y, Zhang P, Jing X 2007. Poly 
(L-lysine)-graft-chitosan copolymers: synthesis, characterization, and gene transfection 
effect. Biomacromolecules  8(5):1425-1435. 
225. El-Aneed A 2004. An overview of current delivery systems in cancer gene 
therapy. J Control Release  94(1):1-14. 
226. Tang MX, Szoka FC 1997. The influence of polymer structure on the interactions 
of cationic polymers with DNA and morphology of the resulting complexes. Gene Ther  
4(8):823. 
227. Tiera MJ, Winnik FM, Fernandes JC 2006. Synthetic and natural polycations for 
gene therapy: state of the art and new perspectives. Curr Gene Ther  6(1):59-71. 
 50
228. Leamon CP, Weigl D, Hendren RW 1999. Folate copolymer-mediated 
transfection of cultured cells. Bioconjug Chem  10(6):947-957. 
229. Ferkol T, Perales JC, Mularo F, Hanson RW 1996. Receptor-mediated gene 
transfer into macrophages. Proc Nat Acad Sci U S A  93(1):101. 
230. Hashida M, Takemura S, Nishikawa M, Takakura Y 1998. Targeted delivery of 
plasmid DNA complexed with galactosylated poly (-lysine). J Control Release  53(1-
3):301-310. 
231. Suh W, Chung JK, Park SH, Kim SW 2001. Anti-JL1 antibody-conjugated poly 
(L-lysine) for targeted gene delivery to leukemia T cells. J Control Release  72(1-3):171-
178. 
232. Godbey WT, Wu KK, Mikos AG 1999. Poly (ethylenimine) and its role in gene 
delivery. J Control Release  60(2-3):149-160. 
233. Garnett MC 1999. Gene-delivery systems using cationic polymers. Cri Rev Ther 
Drug Carr Sys 16(2):147. 
234. Mansoor A 2004. Polymeric gene delivery: Principles & Applications. 
235. Jeong JH, Song SH, Lim DW, Lee H, Park TG 2001. DNA transfection using 
linear poly (ethylenimine) prepared by controlled acid hydrolysis of poly (2-ethyl-2-
oxazoline). J Control Release  73(2-3):391-399. 
236. Fischer D, Bieber T, Li Y, Elsنsser HP, Kissel T 1999. A novel non-viral vector 
for DNA delivery based on low molecular weight, branched polyethylenimine: effect of 
molecular weight on transfection efficiency and cytotoxicity. Pharm Res  16(8):1273-
1279. 
 51
237. Fischer D, Li Y, Ahlemeyer B, Krieglstein J, Kissel T 2003. In vitro cytotoxicity 
testing of polycations: influence of polymer structure on cell viability and hemolysis. 
Biomaterials  24(7):1121-1131. 
238. Forrest ML, Koerber JT, Daniel W 2003. A degradable polyethylenimine 
derivative with low toxicity for highly efficient gene delivery. Bioconjug Chem  
14(5):934-940. 
239. Gosselin MA, Guo W, Lee RJ 2001. Efficient gene transfer using reversibly 
cross-linked low molecular weight polyethylenimine. Bioconjug Chem  12(6):989-994. 
240. Benns JM, Maheshwari A, Furgeson DY, Mahato RI, Kim SW 2001. Folate-PEG-
folate-graft-polyethylenimine-based gene delivery. J Drug Targ  9(2):123-139. 
241. Chiu SJ, Ueno NT, Lee RJ 2004. Tumor-targeted gene delivery via anti-HER2 
antibody (trastuzumab, Herceptin®) conjugated polyethylenimine. J Control Release  
97(2):357-369. 
242. Kichler A 2004. Gene transfer with modified polyethylenimines. J Gene Med  
6(S1):S3-S10. 
243. Merdan T, Callahan J, Petersen H, Kunath K, Bakowsky U, Kopec kovل P, Kissel 
T, Kopec ek J 2003. Pegylated polyethylenimine-Fab'antibody fragment conjugates for 
targeted gene delivery to human ovarian carcinoma cells. Bioconjug Chem  14(5):989-
996. 
244. Lim YB, Han SO, Kong HU, Lee Y, Park JS, Jeong B, Kim SW 2000. 
Biodegradable polyester, poly [ -(4-aminobutyl)-L-glycolic acid], as a non-toxic gene 
carrier. Pharm Res  17(7):811-816. 
 52
245. Lim Y, Choi YH, Park J 1999. A self-destroying polycationic polymer: 
Biodegradable poly (4-hydroxy-L-proline ester). J Am Chem Soc  121(24):5633-5639. 
246. Lim Y, Kim SM, Lee Y, Lee W, Yang T, Lee M, Suh H, Park J 2001. Cationic 
hyperbranched poly (amino ester): a novel class of DNA condensing molecule with 
cationic surface, biodegradable three-dimensional structure, and tertiary amine groups in 
the interior. J Am Chem Soc  123(10):2460-2461. 
247. Lynn DM, Amiji MM, Langer R 2001. pH Responsive Polymer Microspheres: 
Rapid Release of Encapsulated Material within the Range of Intracellular pH. Ang 
Chemie  113(9):1757-1760. 
248. Lynn DM, Anderson DG, Putnam D, Langer R 2001. Accelerated discovery of 
synthetic transfection vectors: parallel synthesis and screening of a degradable polymer 
library. J Am Chem Soc 123(33):8155-8156. 
249. Lynn DM, Langer R 2000. Degradable poly ( -amino esters): synthesis, 
characterization, and self-assembly with plasmid DNA. J Am Chem Soc  122(44):10761-
10768. 
250. Kumar MNVR, Sameti M, Mohapatra SS, Kong X, Lockey RF, Bakowsky U, 
Lindenblatt G, Schmidt CH, Lehr CM 2004. Cationic silica nanoparticles as gene 
carriers: synthesis, characterization and transfection efficiency in vitro and in vivo. J 
Nanosci Nanotechnol  4(7):876-881. 
251. Yi F, Wu H, Jia GL 2006. Formulation and characterization of poly (d, l lactide 
co glycolide) nanoparticle containing vascular endothelial growth factor for gene 
delivery. J Clin Pharm Ther  31(1):43-48. 
 53
252. Ziegler A, Seelig J 2007. High affinity of the cell-penetrating peptide HIV-1 Tat-
PTD for DNA. Biochemistry  46(27):8138-8145. 
253. Holland SJ, Tighe BJ, Gould PL 1986. Polymers for biodegradable medical 
devices. 1. The potential of polyesters as controlled macromolecular release systems. J 
Control Release  4(3):155-180. 
254. Katas H, Chen S, Osamuyimen AA, Cevher E, Oya Alpar H 2008. Effect of 
preparative variables on small interfering RNA loaded Poly (D, L-lactide-co-glycolide)-
chitosan submicron particles prepared by emulsification diffusion method. J Microencap  
25(8):541-548. 
255. Nafee N, Taetz S, Schneider M, Schaefer UF, Lehr CM 2007. Chitosan-coated 
PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on 
complexation and transfection of antisense oligonucleotides. Nanomed: Nanotechnol, 
Biol Med 3(3):173-183. 
256. Wang H, Zhao P, Su W, Wang S, Liao Z, Niu R, Chang J 2010. PLGA/polymeric 
liposome for targeted drug and gene co-delivery. Biomaterials. 
257. Katas H, Cevher E, Alpar HO 2009. Preparation of polyethyleneimine 
incorporated poly (d, l-lactide-co-glycolide) nanoparticles by spontaneous emulsion 
diffusion method for small interfering RNA delivery. Int J Pharm  369(1-2):144-154. 
258. Patil Y, Panyam J 2009. Polymeric nanoparticles for siRNA delivery and gene 
silencing. Int J Pharm  367(1-2):195-203. 
259. Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, Saltzman WM 
2009. Intravaginal gene silencing using biodegradable polymer nanoparticles densely 
loaded with small-interfering RNA. Nat Mat  8(6):526-533. 
 54
260. Kim JH, Park JS, Yang HN, Woo DG, Jeon SY, Do HJ, Lim HY, Kim JM, Park 
KH 2010. The use of biodegradable PLGA nanoparticles to mediate SOX9 gene delivery 
in human mesenchymal stem cells (hMSCs) and induce chondrogenesis. Biomaterials. 
261. Andersen MØ, Lichawska A, Arpanaei A, Rask Jensen SM, Kaur H, Oupicky D, 
Besenbacher F, Kingshott P, Kjems J, Howard KA 2010. Surface functionalisation of 
PLGA nanoparticles for gene silencing. Biomaterials  31(21):5671-5677. 
262. Tahara K, Yamamoto H, Hirashima N, Kawashima Y 2010. Chitosan-modified 
poly (d, l-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-
silencing effects. Eur J Pharm Biopharm  74(3):421-426. 
263. Fay F, Quinn DJ, Gilmore BF, McCarron PA, Scott CJ 2010. Gene delivery using 
dimethyldidodecylammonium bromide-coated PLGA nanoparticles. Biomaterials  
31(14):4214-4222. 
264. Tomalia DA, Baker H, Dewald J, Hall M, Kallos G, Martin S, Roeck J, Ryder J, 
Smith P 1985. A new class of polymers: starburst-dendritic macromolecules. Polymer J 
17(1):117-132. 
265. Buhleier E, Wehner W, Vögtle F 1978. Cascade and nonskid-chain-like synthesis 
of molecular cavity topologies. Synthesis  2:155-158. 
266. Denkewalter RG, Kolc J, Lukasavage WJ. 1981. Macromolecular highly 
branched homogeneous compound based on lysine units. ed.: Google Patents. 
267. Ihre H, Hult A, Söderlind E 1996. Synthesis, characterization, and 1H NMR self-
diffusion studies of dendritic aliphatic polyesters based on 2, 2-bis (hydroxymethyl) 
propionic acid and 1, 1, 1-tris (hydroxyphenyl) ethane. J Am Chem Soc  118(27):6388-
6395. 
 55
268. Bielinska AU, Chen C, Johnson J, Baker Jr JR 1999. DNA complexing with 
polyamidoamine dendrimers: implications for transfection. Bioconjug Chem  10(5):843-
850. 
269. Lee RJ, Wang S, Low PS 1996. Measurement of endosome pH following folate 
receptor-mediated endocytosis. BBA-Mol Cell Res  1312(3):237-242. 
270. Shah DS, Sakthivel T, Toth I, Florence AT, Wilderspin AF 2000. DNA 
transfection and transfected cell viability using amphipathic asymmetric dendrimers. Int J 
Pharm  208(1-2):41-48. 
271. Toth I, Sakthivel T, Wilderspin AF, Bayele H, O'Donnell M, Perry DJ, Pasi KJ, 
Lee CA, Florence AT 1999. Novel cationic lipidic peptide dendrimer vectors in vitro 
gene delivery. STP pharma Sci 9(1):93-99. 
272. Svenson S 2009. Dendrimers as versatile platform in drug delivery applications. 
Eur J Pharm Biopharm  71(3):445-462. 
273. Jevprasesphant R, Penny J, Jalal R, Attwood D, McKeown N, D'emanuele A 
2003. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. 
Int J Pharm  252(1-2):263-266. 
274. Yang H, Morris JJ, Lopina ST 2004. Polyethylene glycol-polyamidoamine 
dendritic micelle as solubility enhancer and the effect of the length of polyethylene glycol 
arms on the solubility of pyrene in water. J Col Inter Sci  273(1):148-154. 
275. Kobayashi H, Kawamoto S, Saga T, Sato N, Hiraga A, Ishimori T, Haque T, 
Konishi J, Togashi K, Brechbiel M 2001. Positive effects of polyethylene glycol 
conjugation to generation-4 polyamidoamine dendrimers employed as macromolecular 
MR contrast agents. Magn Reson Med  46:781-788. 
 56
276. Haensler J, Szoka Jr FC 1993. Polyamidoamine cascade polymers mediate 
efficient transfection of cells in culture. Bioconjug Chem  4(5):372-379. 
277. Kabanov V, Sergeyev V, Pyshkina O, Zinchenko A, Zezin A, Joosten J, 
Brackman J, Yoshikawa K 2000. Interpolyelectrolyte complexes formed by DNA and 
astramol poly (propylene imine) dendrimers. Macromolecules  33(26):9587-9593. 
278. Zinselmeyer BH, Mackay SP, Schatzlein AG, Uchegbu IF 2002. The lower-
generation polypropylenimine dendrimers are effective gene-transfer agents. Pharm Res  
19(7):960-967. 
279. Patil ML, Zhang M, Taratula O, Garbuzenko OB, He H, Minko T 2009. Internally 
cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: effect of the 
degree of quaternization and cancer targeting. Biomacromolecules  10(2):258-266. 
280. Choi JS, Nam K, Park J, Kim JB, Lee JK 2004. Enhanced transfection efficiency 
of PAMAM dendrimer by surface modification with L-arginine. J Control Release  
99(3):445-456. 
281. Kim KS, Lei Y, Stolz DB, Liu D 2007. Bifunctional compounds for targeted 
hepatic gene delivery. Gene Ther  14(8):704-708. 
282. Gao X, Huang L 1996. Potentiation of cationic liposome-mediated gene delivery 
by polycations. Biochemistry  35(3):1027-1036. 
283. Sorgi FL, Bhattacharya S, Huang L 1997. Protamine sulfate enhances lipid-
mediated gene transfer. Gene Ther  4(9):961. 
284. Lee RJ, Huang L 1996. Folate-targeted, anionic liposome-entrapped polylysine-
condensed DNA for tumor cell-specific gene transfer. J Biol Chem 271(14):8481. 
 57
285. Lee LK, Williams CL, Devore D, Roth CM 2006. Poly (propylacrylic acid) 
enhances cationic lipid-mediated delivery of antisense oligonucleotides. 
Biomacromolecules  7(5):1502-1508. 
286. Li S, Huang L 1997. In vivo gene transfer via intravenous administration of 
cationic lipid-protamine-DNA (LPD) complexes. Gene Ther  4(9):891. 
287. Longmuir KJ, Haynes SM, Dickinson ME, Murphy JC, Willson RC, Waring AJ 
2001. Optimization of a peptide/non-cationic lipid gene delivery system for effective 
microinjection into chicken embryo in vivo. Mol Ther  4(1):66-74. 
288. Murphy EA, Waring AJ, Murphy JC, Willson RC, Longmuir KJ 2001. 
Development of an effective gene delivery system: a study of complexes composed of a 
peptide-based amphiphilic DNA compaction agent and phospholipid. Nucleic Acids Res  
29(17):3694. 
289. Price AR, Limberis MP, Wilson JM, Diamond SL 2007. Pulmonary delivery of 
adenovirus vector formulated with dexamethasone–spermine facilitates homologous 
vector re-administration. Gene Ther  14(22):1594-1604. 
290. Yotnda P, Chen DH, Chiu W, Piedra PA, Davis A, Templeton NS, Brenner MK 
2002. Bilamellar cationic liposomes protect adenovectors from preexisting humoral 
immune responses. Mol Ther  5(3):233-241. 
291. Carlisle RC, Bettinger T, Ogris M, Hale S, Mautner V, Seymour LW 2001. 
Adenovirus hexon protein enhances nuclear delivery and increases transgene expression 
of polyethylenimine/plasmid DNA vectors. Mol Ther  4(5):473-483. 
 58
292. Croyle MA, Le HT, Linse KD, Cerullo V, Toietta G, Beaudet A, Pastore L 2005. 
PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an 
enhanced safety profile. Gene Ther 12(7):579-587. 
293. Subr V, Kostka L, Selby-Milic T, Fisher K, Ulbrich K, Seymour LW, Carlisle RC 
2009. Coating of adenovirus type 5 with polymers containing quaternary amines prevents 
binding to blood components. J Control Release  135(2):152-158. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 59
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2. 
 
Cationic Surface Modification of PLG Nanoparticles Offers Sustained Gene 
Delivery to Pulmonary Epithelial Cells 
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2.1. Introduction 
Biodegradable nanoparticles have received considerable attention in recent years as 
a possible means of delivering drugs and genes through multiple routes of administration. 
Various biodegradable polyesters have been used in drug delivery, such as poly(D,L-
lactide-co-glycolide) (PLG) and poly(lactic acid) (PLA) 1,2 as they may control drug 
release and thus increase the therapeutic benefit, while minimizing side-effects 3-6. Many 
techniques are available for producing nanoparticles from these or other materials 
including double-emulsion solvent evaporation, interfacial polymerization, solvent 
diffusion, nanoprecipitation, and salting-out emulsification methods 7; however, PLG 
may be of special interest since it is FDA approved. 
Pharmaceutical nanoparticles generally range in size from 10 to 1000 nm and the 
drug is encapsulated or attached to the nanoparticle matrix 8. The nanometer size-ranges 
of such systems offer certain distinct advantages for drug delivery. Due to their size, 
nanoparticles can penetrate into tissues through fine capillaries, cross the fenestrations 
present in the endothelial lining (e.g., liver), and are generally taken up efficiently by 
many types of cells 9. Also, by modulating polymer chemistry or molecular weight, one 
can control the release of a therapeutic agent from nanoparticles to achieve a desired drug 
level in the target tissue for a required duration to optimize therapeutic efficacy. Further, 
nanoparticles may be delivered to target sites either by localized delivery using a 
catheter-based approach with a minimally invasive procedure 10 or by conjugating a bio-
specific ligand, which could direct them to the target tissue or organ 11. 
Indeed, biodegradable PLG nanoparticles are extensively investigated for drug 
delivery 12-15 and, to a limited extent, gene delivery 16,17. Robust and scalable methods are 
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still needed to overcome the difficulties in formulation reproducibility, particle size, and 
surface chemistry.  The size and surface chemistry of nanoparticles have been identified 
as the most significant factors in determining pharmacokinetics and biodistribution 9,18,19. 
The particle size and charge of nanoparticles depend upon some preparative variables 
such as the type and concentration of stabilizer or coating material, biodegradable 
polymer used, time and mechanism of shear (e.g., stirring, sonication or 
homogenization), diffusion rate of organic solvent, ratio between aqueous and organic 
phases, etc. 7,20. Creating the proper particle size is a key to effective drug delivery. For 
example, it has been shown that the efficiency of cellular uptake of 100-200 nm size 
particles was 15-250 fold greater in various cells than larger sized microparticles 21,22.   
Apart from the size of nanoparticles, surface modification of particles is desired 
since the surface charge and relative hydrophobicity determine the amount of adsorbed 
components, mainly proteins, which qualifies the in vivo fate of nanoparticles 23,24. This 
modification has been achieved by two methods; (1) reactions to coat the particle surface 
or (2) adsorption of surfactants or other coating materials 6. Some of the widely used 
surface coating materials possess a hydrophilic segment such as poly(ethylene glycol) 
(PEG) 25-30.  Block co-polymers such as poloxamine and poloxamer 31-36 have been used 
as well with fewer examples of coatings such as polyethyleneimine (PEI) 37-40. Previous 
reports show that the type of coating material has important effects on drug loading into 
nanoparticles 41 and on the cellular uptake of nanoparticles 42,43. Hydrophilic coating 
materials such as PEG have been effective for increasing the circulation half-life of 
nanoparticles delivered by IV administration; however, this study is primarily interested 
in the potential of direct application of nanoparticles to the pulmonary epithelium. 
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Controlling particle size and surface chemistry dramatically affect endocytic uptake and 
intracellular distribution of the vehicles, which in turn will affect the delivery of 
therapeutics such as DNA.  
In this study, PLG nanoparticles (~200 nm) encapsulating pDNA encoding for 
firefly luciferase were prepared via the solvent diffusion method in the presence of 
selected coating materials. Surface modifications using a variety of cationic materials 
were compared to more conventional surfactants for the ability to transfect cells. Certain 
cationic PLG nanoparticles enhanced gene expression for at least 14 days in A549 cells 
(Type II pneumocytes), which serve as a model of the alveolar epithelium. Perhaps most 
interestingly, PLG particles did not exhibit detectable gene expression until day 5 
whereas gene expression achieved using PEI ended on the same day. Reports in the field 
of gene typically assay for gene expression at short times (24-48 hours), which has led to 
the potential of PLG for gene delivery going largely unnoticed. Here, the features of 
sustained, low-level gene expression and negligible toxicity suggest potential value for 
localized, PLG-based gene delivery to the pulmonary epithelium. 
 
2.2. Materials and methods 
 
2.2.1. Materials 
Poly(D,L-lactide-co-glycolide) (PLG) 50:50 with molecular weight of 20 kDa was 
purchased from LACTEL Absorbable Polymers. 2,2,2-trifluoroethanol and 
dimethyldioctadecylammonium bromide (DODAB) were obtained from Fisher Scientific 
(Pittsburgh, PA). 3β-[N-(Dimethylaminoethane)carbamoyl]cholesterol (DC-Chol), 
hexadecyl trimethyl ammonium bromide (Cetrimide), chitosan, and protamine, were 
purchased from Sigma-Aldrich (St. Louis, MO). Pluronic F-127 was obtained from 
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Invitrogen (Carlsbad, CA). Poly(vinyl alcohol) (PVA) and Coumarin 6, laser grade, were 
obtained from Polysciences, Inc (Warrington, PA). The plasmid DNA encoding firefly 
luciferase (pGL3, 4.8 kbp) was obtained from Promega (San Luis Obispo, CA) and 
transformed into Escherichia coli DH5α™ (Invitrogen). A single transformed colony 
picked from an agar plate was cultured in LB Broth Base (Invitrogen) liquid for plasmid 
DNA preparation. Plasmid DNA was purified with Plasmid Giga Kit 5 (Qiagen, 
Valencia, CA) following the manufacturer's instructions. All pDNA had purity levels of 
1.8 or greater by UV/Vis (A260/A280). A549 cells were obtained from the American Type 
Culture Collection (ATCC, Manassa, VA). The cell culture medium (Ham’s F-12 
Nutrient Mixture, Kaighn’s modified with L-glutamine) was purchased through Fisher 
Scientic. Fetal bovine serum (FBS) was purchased from Hyclone (Waltham, MA). 
Penicillin-streptomycin was purchased from MB Biomedical, LLC (Solon, OH). Trypsin-
EDTA was purchased through Gibco® Invitrogen. MTS reagent [tetrazolium compound; 
3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt] was purchased from Promega. 
 
2.2.2. Encapsulation of pDNA in PLG nanoparticles 
 
PLG nanoparticles were prepared using the solvent diffusion method. In brief, 
aqueous solution (0.2 mL) containing pGL3 (100-200 µg) in Tris-EDTA (TE) buffer (pH 
8) was mixed with 1 mL of PLG (50:50 lactide to glycolide ratio, 20 kDa) solution (15 
mg/mL) in 2,2,2-trifluoroethanol (TFE)44. The resultant mixture was added dropwise 
through a syringe pump (17.5 mL/h) to an aqueous solution (10 mL) containing various 
coating materials stirring at 100-250 rpm at room temperature. The formed nanoparticles 
were dialyzed using a 1,000,000 Da MWCO Dialysis Cassette (Spectrum Laboratories, 
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Inc., Rancho Oominguez, CA) for 6-16 h against distilled deionized water (DI) to remove 
excess coating materials and unentrapped pGL3. The mean particle size and zeta 
potential of the PLG nanoparticles encapsulating pGL3 were measured using a ZetaPALS 
dynamic light scattering instrument (Brookhaven Instruments Corporation, Holtsville, 
NY).  Zeta potential was determined in 1 mM KCl solution.      
 
2.2.3. Plasmid DNA analysis 
 
 The integrity of pGL3 extracted from PLG nanoparticles was studied. Plasmid 
DNA was extracted from lyophilized particles using a 2,2,2-trifluoroethanol and Tris-
EDTA buffer (TFE-TE) extraction method. Briefly, PLG nanoparticles (20 mg) were 
dissolved in 150 µL TFE into which 850 µL of TE buffer were added and the tube was 
rotated for 1 h at room temperature. The aqueous layer was removed after centrifugation 
at 10,000 rpm for 10 minutes. The pGL3 from the extraction was analyzed for its 
integrity using UV spectrophotometry and agarose gel electrophoresis.    
 
2.2.4. Release and stability studies of PLG nanoparticles 
 
To study the pGL3 release and the change in particle size and zeta potential of 
incubated nanoparticles over a period of time, some preparations of PLG nanoparticles of 
different coating materials; PVAm, chitosan, cetrimide, PVA and Pluronic F-127 were 
used. Each batch was suspended in 7 mL of PBS and the suspension was split into 7 
tubes. The tubes were maintained in a shaker incubator (150 rpm) at 37°C. At 
predetermined time points, the tubes were centrifuged at 12,000 rpm for 8 minutes and 
the nanoparticles were then washed twice with double-distilled water and resuspended in 
water. Study of the size stability of PLG nanoparticles in cell culture media in the 
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absence and presence of 10% FBS was achieved by suspending 200 µL of fresh sample 
in 800 µL media and the suspension was incubated at 37°C for 5 h and 12 h. The particles 
size and zeta potential of each sample were measured using the ZetaPALS dynamic light 
scattering system. On the other hand, for the release study the tubes were centrifuged and 
then the supernatant was collected into a new tube after a period of time and the 
nanoparticles were resuspended in fresh PBS and placed back in the incubator. Plasmid 
DNA concentration was measured in the supernatant using UV spectrophotometry.  
 
2.2.5. Determination of pDNA loading and encapsulation efficiency 
 
An accurately weighed amount of nanoparticles (20 mg), freeze-dried without 
lyoprotectant, was dissolved in 150 µL TFE into which 850 µL of TE buffer were added 
and the tube was rotated for 1-2 h at room temperature. The amount of DNA extracted 
was assayed using UV spectroscopy at 260 nm. The DNA loading and the encapsulation 
efficiency were calculated in the following manner. 
100  
particles ofweight 
 particlesin pDNA  ofamount 
    loadingpDNA ×=  
 
100  
loadingpDNA  ltheoretica
 loadingpDNA  
      efficiencyion Encapsulat ×=  
The pDNA loading studies were performed in triplicate.  
 
 
2.2.6. Cell culture 
 
Culturing of human epithelial lung cell line A549 was performed according to the 
protocol given by the American Type Culture Collection. A549 cells were grown in F-
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12K supplemented with 10% (v/v) FBS and 1% (v/v) Penicillin-streptomycin at 37º C in 
a humidified air atmosphere containing 5% CO2. 
 
2.2.7. In vitro cell transfection studies 
 
A549 cells were trypsinized, counted and diluted to a concentration of 
approximately 80,000 cells/ mL. Then 0.1 mL of that dilution was added to each well of a 
96-well plate and the cells were incubated in a humid 5% CO2 incubator at 37°C for 24h. 
Immediately before transfection, the cells were washed once with PBS and a 100 µL 
sample (15% of fresh PLG nanoparticles (1.5 mg/mL, 273 ng of DNA) to 85% of serum 
free cell culture media) was added to each well. Cells were incubated with the PLG 
nanoparticles for 5 h. The media containing nanoparticles was then removed and 100 µL 
of fresh serum media was added followed by further incubation. A luciferase expression 
assay was performed using the Luciferase Assay System from Promega following the 
manufacturer’s recommended protocol. The light units were normalized against protein 
concentration in the same cells extracts, which were measured using Coomassie Plus™ 
Protein Assay (Thermo Scientific, Waltham, MA). The transfection results were 
expressed as Relative Light Units (RLU) per mg of cellular protein.  
 
2.2.8. Assessment of cytotoxicity (MTS Assay) 
 
Cytotoxicity of lyophilized PLG nanoparticles with 5% w/v mannitol was 
determined by the CellTiter 96® Aqueous Cell Proliferation Assay. A549 cells were 
grown as described in the transfection experiments. Cells were treated with the samples 
for 24 h. The media were then removed and replaced with a mixture of 100 µL fresh 
culture medium and 20 µL MTS reagent solution. The cells were incubated for 3 h at 
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37°C in a 5% CO2 incubator. The absorbance of each well was then measured at 490 nm 
using a microtiter plate reader (SpectraMax, M25, Molecular Devices Corp., CA) to 
determine cell viability. 
 
2.2.9. Cell uptake studies  
 
A549 cells were seeded and incubated for 1 h with PLG nanoparticles 
encapsulating coumarin 6 (Polysciences, Inc., Warrington, PA), using a solvent diffusion 
method, in 96-well plates as described above for transfection studies. Cells were then 
washed thrice with ice-cold PBS and solubilized (80 µL/well) with 0.5% Triton X-100 in 
0.2 M NaOH for 30 minutes. Cell-associated nanoparticles were quantified by analyzing 
the cell lysate using a fluorescence plate reader (SpectraMax, M25, Molecular Devices 
Corp., CA, λex 458 nm, λem 505 nm). The fluorescent intensity was normalized against 
protein concentration in the same cells lysate, which were measured using a BCA protein 
assay kit (Pierce Biotechnology). 
 
2.2.10. Statistical analysis  
 
Statistical evaluation of data was performed using an analysis of variance (one-way 
ANOVA). Newman–Keuls was used as a post-hoc test to assess the significance of 
differences. To compare the significance of the difference between the means of two 
groups, a t-test was performed; in all cases, a value of p < 0.05 was accepted as 
significant. 
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2.3. Results 
 
2.3.1. Preparation and characterization of PLG nanoparticles 
 
Different coating materials were used for the preparation of PLG/DNA 
nanoparticles by the solvent diffusion method. Transmission electron micrographs of 
PLG nanoparticles showed that the nanoparticles were spherical and discrete particles 
without agglomeration and that they were smooth in surface morphology (Figure 1). The 
average particle size of the PLG nanospheres encapsulating DNA was ~200 nm with 
relatively narrow polydispersity regardless of coating material. A variety of zeta 
potentials were observed with the different types of coating materials. The values ranged 
from 32 to 40 mV for cationic surface modifiers and from -11 to -24 mV for weakly 
anionic surfactants (Table 1).  
 
 
 
Table 1. Characteristics of PLG nanoparticles coated with cationic and anionic materials. 
 
 
 
 
 
 
 
 
* Weight/ volume percent (the concentration of the coating materials).  
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Figure 1. Transmission electron micrograph (TEM) of PLG nanoparticles. 
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2.3.2. Stability and encapsulation efficiency of DNA  
 
Maximum extraction of pGL3 from the PLG/TFE phase into the aqueous phase 
was achieved within 60 min. The plasmid DNA structure was determined by agarose gel 
electrophoresis. The distinct bands present on the gel showed that the encapsulated DNA 
retained its structural integrity regardless of coating material when compared with the 
original DNA (Figure 2A). Aqueous extracts from various nanoparticles were analyzed 
by UV spectrophotometry to determine DNA loading. The efficiency of pGL3 
encapsulation in the PLG nanoparticles did not significantly depend on the type of 
cationic coating materials. Various cationic coating materials exhibited encapsulation 
efficiencies as high as ~88% (Table 1). Nanoparticles made using weakly anionic coating 
materials showed lower efficiencies for the encapsulation of DNA, reaching only ~79 %. 
These results suggested that the presence of cationic coating materials could improve the 
entrapment of the anionic DNA molecule within the PLG nanoparticles. 
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Figure 2. (A) Gel electrophoresis of plasmid DNA extracted from PLG nanoparticles, (1) 
marker, (2) naked pDNA, (3) PLG-PVA, (4) PLG-PluronicF-127, (5) PLG-PVAm, (6) 
PLG-Chitosan, (7) PLG-DC-Chol, (8) PLG-Cetrimide, (9) PLG-Protamine, and (10) 
PLG-DODAB nanoparticles. (B) Release profile of pDNA from PLG nanoparticles in 
PBS at 37°C. 
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2.3.3. In vitro release and stability studies of PLG nanoparticles 
In vitro profiles of plasmid DNA release were compared for five different PLG 
coating materials, PVAm, chitosan, cetrimide, PVA and Pluronic F-127 in PBS at 37°C. 
Irrespective of the type of coating material, the DNA was released in a sustained manner 
for 14 days (Figure 2B). Using cationic coating materials significantly decreased the 
initial burst release of the DNA from the nanoparticles. At the end of the experiment, 
more than 84% of the total DNA encapsulated in the cationic PLG nanoparticles was 
released.  
Apart from the release study, the stability of the size and the zeta potential of 
PVAm, DC-Chol, cetrimide, DODAB, PVA and Pluronic F-127 coated PLG 
nanoparticles was investigated as a function of time. Zeta potential and size of gene 
delivery vehicles have been reported to be important factors in facilitating gene transfer 
in cells 46,47. The endocytotic uptake of particles is clearly affected by their size and tends 
to increase with decreasing diameters and increasing zeta potential 48,49. The PLG 
nanoparticles remained stable in PBS over a period of 3 days and retained their size and 
surface charge. Exemplary data are shown (Figures 3A and B). The initial change in the 
particle size and the zeta potential over the first five hours of this study may be 
attributable to a reduction in agglomeration as the resuspended nanoparticle/mannitol 
powders slowly hydrated and dispersed.  
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Figure 3. (A) Size of PLG nanoparticles coated with various materials as a function of 
time. (B) Zeta potential of PLG nanoparticles coated with various materials as a function 
of time. Data are presented as mean ± SD (n = 3).        
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On the other hand, PLG nanoparticles coated with PVA and Pluronic F-127 showed 
good stability in serum-free culture media over a period of 5 and 12 h. PLG nanoparticles 
with cationic coating materials showed some agglomeration. In the presence of 10% FBS, 
only PLG-PVA nanoparticles retained their size (Figures 4A and B). Precipitation was 
not noted in any of the samples over the course of 5 h, which was an analogous time to 
the transfection experiments. The colloidal stability of the PLG particles over this time 
suggested that any differences in gene transfection were not attributable to particles 
precipitating onto the cell monolayers. 
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Figure 4. Stability of PLG nanoparticles coated with various materials over time in (A) 
the absence and (B) presence of 10%FBS. Data are presented as mean ± SD (n = 3).        
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2.3.4. Effect of PLG nanoparticles on cell viability 
 
The effect of the PLG nanoparticles on the viability of A549 cells was studied by 
incubating the cells up to 5 mg/mL of lyophilized PLG/DNA nanoparticles with 5% w/v 
mannitol. Minimal cytotoxic effects were evident and cells maintained a high viability 
(Figure 5) even for cationic coating materials (IC50 ~1190-2450 µg/mL). In contrast, 
branched PEI complexes showed significant cytotoxicity at low concentration (IC50 ~35 
µg/mL).  
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Figure 5. Cell viability of PLG nanoparticles in A549 cells in comparison with branched 
PEI (25k). Data are presented as mean ± SD (n = 3).        
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2.3.5. Nanoparticle uptake by A549 cells 
 
PLG nanoparticles coated with different materials were used to study cellular 
uptake by A549 lung epithelial cells. In these studies, PLG nanoparticles were stained 
with the fluorescent dye, coumarin 6. All coating materials showed uptake of 
nanoparticles within 1 h of incubation but with different magnitudes (Figure 6). The 
nanoparticles formulated from PLG with cationic coatings, especially chitosan, showed 
high levels of nanoparticle uptake compared to weakly anionic coatings as expected. No 
correlation of the magnitude of zeta potential and nanoparticle uptake was observed. 
These results support previous research indicating that the nanoparticle surface can be 
modified to provide enhanced uptake by cells 25. To exclude the possibility of non-
specific staining of cells by coumarin 6, control experiments were performed. PLG-
coumarin 6 nanoparticles were shaken in serum free cell culture media for 3 h and 
centrifuged. The supernatant was incubated with A549 cells to check for any leakage of 
dye from nanoparticles, which might stain cells. No fluorescence was detected in the 
cells. 
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Figure 6. Cellular uptake of PLG nanoparticles coated with various materials. Cationic 
coating materials enhanced the level of nanoparticle uptake compared to anionic coatings. 
Data are presented as mean ± SD (n = 3).  
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2.3.6. In vitro transfection efficiency of PLG nanoparticles 
 
To assess the feasibility of PLG nanoparticles for gene delivery, in vitro 
transfection was performed using the human lung carcinoma cell line A549. The 
luciferase-encoding plasmid pGL3 was used as a reporter. On day 2 after transfection, 
PLG nanoparticles did not show gene expression. In comparison, branched PEI showed 
excellent transfection efficiency on day 2 (Figure 7). Gene expression mediated by 
certain cationic PLG nanoparticles suddenly appeared on day 5, whereas the gene 
expression of branched PEI showed a marked decrease during the same time frame. The 
enhanced gene expression from certain cationic PLG nanoparticles was sustained for at 
least 14 days. The transfection efficiency of PLG with PVAm, DC-Chol, cetrimide and 
DODAB coatings was almost similar to the transfection efficiency of branched PEI at 
day 5, but tended to increase at day 7 and 14. On the other hand, no expression was 
observed for PLG nanoparticles coated with chitosan, protamine and Pluronic F-127 
despite the fact that these coating materials showed relatively efficient cellular uptake. 
These results support the findings reported in the literature that nanoparticle uptake is not 
indicative of gene expression 50. Importantly, however, transfection performance may be 
the result of the fact that the type of coating materials can ultimately affect uptake 
pathways and nanoparticle fate within the cell, which remains to be investigated.   
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Figure 7. Transfection efficiency of PLG nanoparticles in A549 cells varied with 
different coating materials. Most PLG nanoparticles exhibited long-term expression that 
tended to increase over time. PEI complexes N/P 10 showed higher gene expression that 
dropped to negligible levels by day 5. Expression of day 14 was significantly higher than 
day 7 in A549 cells. Data are presented as mean ± SD (n = 3), * p < 0.001 when 
compared to day 5 for the same sample.   
 
 
 
 
 
 
 
 
 81
2.4. Discussion 
 
Nanoparticles of PLG have been widely studied for their use in drug delivery 51. 
Among non-viral vehicles, these particulates may offer a non-toxic and efficient carrier 
for sustained intracellular delivery of genes. However, PLG nanoparticles encapsulating 
DNA need to be carefully designed to achieve efficient gene delivery. In the present 
study, PLG/DNA nanoparticles were fabricated using a solvent diffusion method. The 
protocol was developed to avoid shear and centrifugation. These processes may not only 
affect the integrity of DNA encapsulated in nanoparticles but may also diminish DNA 
encapsulation efficiency. In addition, the nanoparticle stability may be compromised by 
centrifugation procedures, which can lead to irreversible agglomeration. The methods 
reported here resulted in high encapsulation efficiencies (~88%) and retention of DNA 
structure as indicated by gel electrophoresis of the pDNA extracted from various PLG 
nanoparticles.  
Positively charged nanoparticles have been shown to bind to the negatively charged 
cell surface, and thereby facilitate their uptake 52. Higher levels of cellular uptake of PLG 
nanoparticles were achieved using cationic coating materials compared to the weakly 
anionic PVA and Pluronic F-127 coatings. Unlike PEI, PLG nanoparticles degrade by 
hydrolysis, and were expected to sustain delivery of DNA; however, a cationic coating 
material was desired to improve cellular uptake of the particles. In the present study, the 
release of DNA from PLG nanoparticles was sustained for approximately 14 days and 
release was found to be more constant for nanoparticles with cationic coatings. After 
observing the slow release of DNA, gene transfection levels were studied for 2 weeks in 
A549 cells.  
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The level of gene expression in the A549 lung epithelial cells was higher in the 
branched PEI/DNA complexes than in the PLG nanoparticles for the initial 4 days, but 
the trend was reversed after day five. This was perhaps a result of the sustained DNA 
release from the PLG nanoparticles. Thus, modified PLG/DNA nanoparticles appeared to 
be superior to PEI/DNA complexes for the long-term expression of DNA. Typical gene 
transfection studies reported in the literature assess gene expression at 24 or 48 h, which 
may explain the low level of previous reports on PLG nanoparticles for gene delivery. At 
this point, it is difficult to speculate if the differences in gene expression observed for 
different cationic PLG nanoparticles were caused by endosomal escape, differences in the 
release of DNA within cells, or other factors. Perhaps most importantly, modified PLG 
nanoparticles showed little to no cytotoxicity after 24 h incubation with A549 cells 
compared to branched PEI complexes. 
 
2.5. Conclusion 
 
In this study, PLG nanoparticles coated with different surface modifiers were 
examined for the ability to transfect A549 lung epithelial cells. A series of 
physicochemical studies demonstrated that the PLG nanoparticles coated with cationic 
materials increased DNA encapsulation efficiency and enhanced uptake by A549 lung 
epithelial cells. PLG nanoparticles exhibited excellent particle size and surface charge 
stability during three days incubation in PBS at 37°C, however, some increase in particle 
size was noted in media with serum at longer incubation times (>5 h). Gene expression 
was sustained for at least 14 days for several PLG nanoparticle formulations and gene 
expression levels tended to increase over the duration of the study. Conversely, gene 
expression levels for branched PEI/DNA complexes showed high initial gene expression 
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that dropped to negligible levels by day 5. In vitro cytotoxicity studies showed that 
cationic PLG nanoparticles exhibited much lower cytotoxicity than branched PEI (25 
kDa). Taken cumulatively, these data suggest that cationic PLG nanoparticles may be an 
effective vehicle for delivering DNA to the pulmonary epithelium.   
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Chapter 3. 
 
"Soft" Calcium Crosslinks Enable Highly Efficient Gene Transfection Using TAT 
Peptide 
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3.1. Introduction 
Intensive effort has been devoted to develop gene therapy systems capable of 
overcoming a variety of limitations including low gene transfection efficiency, toxicity, 
and in vivo instability 1-7. Nonviral vectors have been given considerable attention as 
gene delivery vehicles because of their presumed safety, ease of synthesis, relatively 
unrestricted vector size, low cost, and low degree of immunogenicity in comparison to 
viral vectors 8. Plasmid DNA complexed with cationic lipids (lipoplexes) and polymers 
(polyplexes) are the most commonly employed nonviral gene delivery vehicles 9-17. 
Because naked plasmid DNA does not easily penetrate cellular membranes 18, nonviral 
gene delivery systems may include agents to improve intracellular delivery in an effort to 
promote transfection. Finally, gene delivery vehicles are subject to dilution, degradation 
and elimination in vivo, which amplify the need for safe and efficient gene delivery at 
high doses of DNA. 
New strategies have been put forward to enhance cellular uptake of gene delivery 
vehicles, among which peptides enhancing cell adhesion and internalization have reached 
a prominent position 19. Peptide sequences, also designated as protein transduction 
domains (PTD) or membrane translocalization signals (MTS), were identified as 
potentially useful labels for intracellular delivery of peptides, proteins, oligonucleotides, 
and plasmid DNA 20-24. By modifying the surface of gene delivery vectors with cell 
penetrating peptides (CPPs), vectors have been shown to traverse the membranes of 
biological cells within seconds to minutes 25. Polycationic CPPs have even been reported 
to enhance cell permeability and facilitate the intracellular delivery of nanoparticles 26.  
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The mechanism of cell entry of CPPs alone or with their cargoes still remains 
somewhat of an enigma. Some reports indicating that cellular translocation of CPPs is 
energy as well as endocytosis independent and that there is direct transfer of the peptides 
through the lipid bilayer by inverted micelle formation 27-32. Another report, however, 
proposed an energy dependent mechanism of cell entry of CPPs 33, which may also 
involve extracellular heparan sulfate and various endocytosis and macropinocytosis 
pathways 34-41. It was also suggested that classical and nonclassical endocytosis pathways 
may be associated simultaneously with CPP translocation depending upon the 
biophysical properties of CPPs and their cargo 32,42,43.  
One particular CPP of interest is the HIV-1 TAT peptide. This peptide, which 
represents a protein transduction domain 44,45 and a nuclear localization sequence (NLS) 
46, has been reported to show unusual translocation abilities by directly crossing 
biological membranes independent of receptors and temperature 47. In addition, the NLS 
function of TAT peptide could facilitate nuclear localization of a therapeutic agent due to 
interaction with the endogenous cytoplasmic nuclear transport machinery. The cationic 
nature of the TAT sequence arising from several arginine residues has already been 
utilized in gene delivery either by covalent coupling of this CPP to the gene delivery 
vehicle 48-50 or by simple mixing of plasmid DNA with TAT to form TAT/pDNA 
complexes via noncovalent electrostatic interactions 51-54. However, the transfection 
efficiency of such complexes remains quite low and requires improvement.   
Obviously, a strong affinity between TAT peptide and plasmid DNA is required to 
stabilize the resulting polyplex and to achieve an optimized transfection yield. On the 
other hand, a sufficiently low affinity between TAT peptide and plasmid DNA is desired 
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to facilitate the release of the cargo after cellular uptake. Thus, the critical balance 
between the TAT/pDNA binding affinities has important consequences for enhancing the 
transfection efficiency. Our objective was to design a more efficient and less toxic means 
of gene delivery using TAT/pDNA complexes containing "soft" crosslinks. Calcium was 
found to control the delicate balance between binding affinities within TAT/pDNA 
polyplexes. The addition of CaCl2 to TAT/pDNA complexes directly affected particle 
size and transfection efficiency in a concentration-dependent manner. The optimum 
calcium concentration (113 mM final CaCl2 concentration) resulted in a 1000-fold 
enhancement in TAT/pDNA polyplex transfection efficiency and showed no detectable 
cytotoxicity. Gene transfection levels were as high as that observed for PEI polyplexes 
suggesting the possible translation of the TAT-Ca/pDNA complexes.  
 
3.2. Materials and methods 
3.2.1. Materials 
 Plasmid DNA encoding firefly luciferase (pGL3, 4.8 kbp) was obtained from 
Promega (Madison, WI, USA) and transformed into Escherichia coli DH5ά (Invitrogen, 
Carlsbad, CA). A single transformed colony picked from an agar plate was cultured in 
LB Broth Base (Invitrogen) liquid for plasmid DNA preparation. Plasmid DNA was 
purified with Plasmid Giga Kit 5 (Qiagen, Germantown, MD) following the 
manufacturer's instructions. All pDNA had purity levels of 1.8 or greater as determined 
by UV/Vis inspection (A260/A280). TAT peptide (RKKRRQRRR; Mw = 1338.85 Da, 
TFA salt = 2632.9 Da) was synthesized in house. Branched polyethyleneimine (PEI, 25 
kDa) was obtained from Aldrich (Milwaukee, WI). Calcium chloride (CaCl2. 2H2O) and 
agarose medium were purchased from Fisher Scientific (Pittsburgh, PA). A549 cells were 
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obtained from the American Type Culture Collection (ATCC, Rockville, MD). The cell 
culture medium (Ham’s F-12 Nutrient Mixture, Kaighn’s modified with L-glutamine) 
was purchased through Fisher Scientic. Fetal bovine serum (FBS) was purchased from 
Hyclone. Penicillin-streptomycin was purchased from MB Biomedical, LLC. Trypsin-
EDTA was purchased through Gibco. MTS reagent [tetrazolium compound; 3-(4, 5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, 
inner salt] was purchased from Promega. Heparin sodium was obtained from Spectrum 
(Gardena, CA). 
                                                                                                                                
3.2.2. Preparation of TAT-Ca/pDNA complexes 
     
TAT/pDNA complexes were synthesized by rapidly adding 10 µL (0.1 µg/µL) of 
pDNA to 15 µL (N/P ratio of 25) TAT solution while pipetting. To this solution, 15 µL 
of known molarity (e.g. 113 mM final CaCl2 concentration) CaCl2 was added and mixed 
by vigorous pipetting followed by 20 min incubation at 4º C prior to use.  
 
3.2.3. Formation of PEI/pDNA complexes  
 
PEI-DNA complexes were prepared by adding 10 µl (0.1 µg/µL) of pDNA solution 
to 15 µL (N/P ratio of 5 or 10) PEI solution dropwise while stirring. Complexes were 
incubated at 4º C for 20 min before dilution 1.7 times (15 µL) with the appropriate buffer 
(e.g. nuclease-free water or CaCl2 solution). Complexes were freshly prepared before 
each individual experiment. 
 
3.2.4. Size and Zeta potential measurement  
 
Suspensions containing complexes with TAT or PEI were prepared as described 
earlier using a DNA concentration of 0.1 µg/µL. All samples intended for light scattering 
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analyses were prepared using 10 mM Tris buffer, pH 7.4, which was prefiltered with a 
0.22 µm filter to remove any trace particulates. Particle sizes were measured by dynamic 
light scattering (DLS) using a Brookhaven (Holtsville, NY) instrument equipped with a 
9000AT autocorrelator, a 50 mW HeNe laser operating at 532 nm (JDS Uniphase), an 
EMI 9863 photomultiplier tube, and a BI 200M goniometer. The light scattered at 90º 
from the incident light was fit to an autocorrelation function using the method of 
cumulants. Zeta potential measurements were obtained by phase analysis light scattering 
using a Brookhaven Zeta PALS instrument. The electrophoretic mobility of the samples 
was determined from the average of 10 cycles of an applied electric field. The zeta 
potential was determined from the electrophoretic mobility from the Smoluchowski 
approximation. Zeta potential was determined in 1 mM KCl solution.      
 
3.2.5. Agarose gel electrophoresis assays 
 
The pDNA binding ability of the TAT, TAT-Ca, CaCl2 and PEI complexes was 
analyzed by agarose gel electrophoresis. The TAT-Ca/pDNA and PEI/DNA complexes 
containing 1 µg luciferase reporter gene were prepared as described at various N/P ratios. 
The N/P ratio refers to the molar ratio of amine groups in the cationic polymer, which 
represent the positive charges, to phosphate groups in the plasmid DNA, which represent 
the negative charges. The DNA complex suspensions (i.e. 25 µL) at various N/P ratios 
were diluted by adding 4 µL of 10X Tris-acetate-EDTA (TAE) gel running buffer 
(Promega) and 4 µL of 100X SYBR Green (Invitrogen) solutions. The DNA loading 
buffer (7 µL of 6X) was added to the complex suspensions. The mixtures were allowed to 
incubate at room temperature for 40 min to ensure labeling of the DNA with the SYBR 
Green dye. Thereafter, the complexes were loaded into individual wells of 1% agarose/ 
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1X TAE gel buffer, and subjected to electrophoresis at 110 V for 30 min. Uncomplexed 
DNA diluted with an identical volume of solution was used as a control. The resulting 
DNA migration patterns were revealed using an AlphaImager® Imaging System (Alpha 
Innotech, San Leandro, CA).  
 
3.2.6. Cell culture 
  
Culturing of human epithelial lung cell line A549 was performed according to the 
protocol provided by the American Type Culture Collection. A549 cells were grown in F-
12K supplemented with 10% (v/v) FBS and 1% (v/v) Penicillin/streptomycin at 37º C in 
a humidified air atmosphere containing 5% CO2. 
 
3.2.7. In vitro cell transfection studies 
 
A549 cells were trypsinized, counted and diluted to a concentration of 
approximately 80,000 cells/ mL. Then 0.1 mL of that dilution was added to each well of a 
96-well plate and the cells were incubated in a humidified atmosphere at 5% CO2 and 
37°C for 24 h. Immediately before transfection, the cells were washed once with PBS and 
100 µl sample (20% of complex to 80% of serum free cell culture medium) was added to 
each well. Cells were incubated with the complexes for 5 h. The transfection agent was 
then removed by aspiration and 100 µL of fresh serum medium was added followed by 
further incubation. The Luciferase Assay System from Promega was used to determine 
gene expression following the manufacturer’s recommended protocol. The light units 
were normalized against protein concentration in the cells extracts, which were measured 
using the Coomassie Plus™ Protein Assay (Thermo Scientific). The transfection results 
were expressed as Relative Light Units (RLU) per mg of cellular protein.  
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3.2.8. Assessment of cytotoxicity (MTS Assay) 
 
Cytotoxicity of polymers was determined by the CellTiter 96® Aqueous Cell 
Proliferation Assay. A549 cells were grown as described in the transfection experiments. 
Cells were treated with the samples for ~24 h. The media were then removed and 
replaced with a mixture of 100 µL fresh culture media and 20 µL MTS reagent solution. 
The cells were incubated for 3 h at 37°C in the 5% CO2 incubator. The absorbance of 
each well was then measured at 490 nm using a microtiter plate reader (SpectraMax, 
M25, Molecular Devices Corp., CA) to determine cell viability. 
 
3.2.9. SYBR Green assay of TAT and PEI complexes 
 
The degree of pDNA accessibility following complexation with TAT or PEI was 
assessed by the double-stranded-DNA-binding reagent SYBR Green (Invitrogen). 
Briefly, 10 μL (0.1 mg/mL) of pDNA was mixed with 15 μL of TAT or PEI solution, 
then 15 μL deionized water or metal solution was added. Complexes were allowed to 
form for 30 min at room temperature prior to use. After incubation, 120 μL deionized 
water and 160 μL 10X SYBR Green solutions were added. And then 80 μL of sample 
was added to three wells of a 96-well cell culture plate. The fluorescence was measured 
using a fluorescence plate reader (SpectraMax M5; Ex., 497 nm; Em, 520 nm). 
 
3.2.10. TNBS assay of TAT and PEI complexes  
 
The accessibility of free amine groups of TAT or PEI following complexation with 
pDNA was measured using a colorimetric assay with 2,4,6-trinitro-benzenesulphonic 
acid (TNBS) as an assay reagent (Pierce). Briefly, 10 μL of complex solution was added 
to 190 μL deionized water and then 200 μL of 0.02 % TNBS solution in 0.1 M sodium 
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bicarbonate buffer (pH 8.5) was added. The solution was rapidly mixed. After incubation 
at 37 °C for 2 hours, 80 μL of sample was added to three wells of a 96-well cell culture 
plate. The absorption at 335 nm was determined using a plate reader.   
 
3.2.11. The effect of heparin on the stability of TAT and PEI complexes 
 
The effect of heparin on the stability of complexes was evaluated by the means of 
the change in fluorescence intensity obtained with the fluorescent probe SYBR Green. 
TAT and PEI complexes were freshly prepared in absence and the presence of CaCl2 (113 
mM) as above described. 120 μL of heparin solution was added to these various 
complexes to yield final diverse heparin concentrations up to 50 µg/µL, incubated for 30 
min at room temperature and then 160 μL 10X SYBR Green was added. In triplicate, 80 
μL of each sample was added to the well of 96-well plate and the fluorescence was 
measured as indicated in SYBR Green assay.    
 
3.2.12. Statistical analysis 
 
Statistical evaluation of data was performed using an analysis of variance (one-way 
ANOVA). Newman–Keuls was used as a post-hoc test to assess the significance of 
differences. To compare the significance of the difference between the means of two 
groups, a t-test was performed; in all cases, a value of p < 0.05 was accepted as 
significant. 
 
3.3. Results 
 
3.3.1. Formation of TAT-Ca/pDNA and PEI/pDNA complexes 
 
TAT and PEI complexes were prepared by mixing pDNA with each polycation at 
various N/P ratios as described. In order to demonstrate complex formation, a gel 
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electrophoresis assay was performed using 1% agarose gel. Uncomplexed pDNA was 
used as a control. Gel electrophoresis indicated that pDNA complexed with polycations 
could be retained in the loading wells. Above a certain N/P ratio no bands were observed 
during electrophoresis indicating that TAT and PEI completely complexed the pDNA. 
Under these conditions, CaCl2 showed negligible ability to complex the plasmid DNA 
even at high concentration (375 mM) (Figure 1). 
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Figure 1. Gel electrophoresis study of (A) CaCl2/pDNA complexes; 1 = 38mM, 2 = 
75mM, 3 = 113mM, 4 = 150mM, 5 = 188mM, 6 = 225mM, 7 = 263mM, 8 = 300mM, 9 = 
338mM, 10 = 375mM, 11 = 1.13M, 12 = 1.9M and 13 = 2.63M of CaCl2. (B) 
TAT/pDNA complexes. (C) TAT-Ca/pDNA (N/P 25) complexes; 1 = 0mM, 2 = 23mM, 
3 = 47mM, 4 = 94mM, 5 = 113mM, 6 = 131mM, 7 = 150mM, 8 = 188mM, 9 = 375mM 
and 10 = 750mM of CaCl2. (D) TAT/pDNA complexes with 113mM CaCl2. (E) 
Branched PEI/pDNA complexes. (F) Linear PEI/pDNA complexes. 
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3.3.2. Morphological and physical characterization of TAT-Ca/pDNA and 
PEI/pDNA complexes 
 
The effect of calcium chloride concentration on the particle size and surface charge 
of TAT/pDNA and PEI/pDNA complexes was investigated. Over a certain concentration 
range, calcium addition to TAT/pDNA complexes induced a substantial decrease in the 
particle size. In comparison, PEI/pDNA complexes showed an increase in particle size 
(Figure 2A). The added CaCl2 concentration range of 113-188 mM (final CaCl2 
concentration) produced small (50-100 nm) and stable TAT/pDNA complexes with 
relatively narrow polydispersity (< 0.15). In general, the zeta potential of TAT and PEI 
complexes increased significantly from 11 to 27 mV with increasing concentration of 
CaCl2 (Figure 2B).  
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Figure 2. The effect of CaCl2 concentration on (A) particle size and (B) charge of TAT-
Ca/pDNA (N/P 25) complexes and PEI/pDNA complexes (N/P 5 and 10). Data are 
presented as mean ± SD (n = 3).        
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A transmission electron microscope (FEI field emission transmission electron 
microscope, Tecnai G2 at 200 kV) equipped with an energy-dispersive analytical X-ray 
(EDAX) was used to image the morphology of the TAT/pDNA and TAT-Ca/pDNA 
complexes and to characterize elements in these complexes, respectively. TEM samples 
were prepared by depositing a drop of the complex suspension on a copper carbon grid 
and allowing it to dry in a dessicater overnight. Transmission electron micrographs of 
TAT/pDNA complexes revealed an asymmetric morphology. The darker areas in TAT-
Ca/pDNA seemed to suggest calcium trapped inside the particles (Figure 3A and B).  
 
 
A                                                B 
 
 
 
 
 
 
 
 
 
 
Figure 3. Transmission electron micrograph (TEM) of (A) TAT/pDNA and (B) TAT-
Ca/pDNA complexes.    
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Samples were imaged using scanning transmission electron microscopy and 
analyzed using EDAX spectroscopy to detect the location of calcium. EDAX spectrum 
for two labeled areas in the scanning transmission electron micrograph (on the particles 
and substrate) revealed significantly higher calcium concentration in the particles 
compared to free calcium that would have dried on the substrate (Figure 4A, B and C).  
 
          A 
 
 
 
 
 
 
 
               
B                                               C 
 
 
 
 
 
Figure 4. (A) Scanning transmission electron micrograph and EDAX spectrum of TAT-
Ca/pDNA. The characterized areas (B) on particles and (C) on substrate are indicated in 
the scanning transmission electron micrograph. EDAX spectra showed the elemental 
composition of particles and substrate (Cu peaks result from the copper grid).    
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The stability of TAT and PEI complexes was investigated as a function of time in 
the absence and presence of 113 mM CaCl2 and 10% FBS (Figure 5A and B). 
TAT/pDNA complexes including 113 mM CaCl2 remained stable in the absence and 
presence of 10% FBS over a period of 8 days. Conversely, PEI/pDNA complexes showed 
a marked increase in size.  
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Figure 5. The stability of TAT-Ca/pDNA and PEI/pDNA complexes over time in (A) the 
absence and (B) presence of 10%FBS. Results are presented as mean ± SD (n = 3).        
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3.3.3. Cytotoxicity of TAT and PEI complexes 
 
Low cytotoxicity together with high transfection efficiency are extremely important 
attributes for nonviral gene vectors. The cytotoxicity of free TAT, PEI, and CaCl2 was 
studied by incubating A549 cells with up to 5 mg/mL of TAT or PEI and with up to 5 M 
CaCl2 (Figure 6A and B). TAT peptide revealed no evidence of cytotoxicity and cells 
maintained high viability. Branched PEI induced significant cytotoxicity (IC50 ~35 
µg/mL). CaCl2 alone showed modest cytotoxicity (IC50 ~210 mM).  
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Figure 6. Cytotoxicity profiles of (A) TAT, PEI and (B) CaCl2 in A549 cells. Viability is 
expressed as a function of polymer concentration. Results are presented as mean ± SD (n 
= 3).       
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3.3.4. In vitro transfection efficiency of TAT-Ca/pDNA and PEI/pDNA complexes 
 
The in vitro transfection efficiency of these complexes was studied using the 
human lung carcinoma cell line A549. Luciferase gene expression was evaluated on day 
1 of transfection using the TAT or PEI polyplexes including different concentrations of 
CaCl2 during the complex formation. TAT complexes showed a higher level of gene 
expression at 113 mM CaCl2 when compared to PEI, which had excellent transfection 
efficiency in the absence of CaCl2 (Figure 7). It was interesting that the optimized level 
of gene expression of TAT-Ca/pDNA complexes was similar to the transfection 
efficiency of branched PEI and increased over the first four days. Conversely, the gene 
expression of PEI/pDNA complexes showed a marked decrease during the same time 
frame. The gene expression was sustained for at least 10 days and TAT-Ca/pDNA 
complexes appeared to be superior to PEI/DNA complexes at day 8 and 10 (Figure 8). 
Strikingly, no expression was observed for TAT/pDNA complexes without CaCl2. In 
addition, PEI-Ca/pDNA complexes exhibited lower levels of gene expression compared 
to PEI/pDNA complexes. It is important to note that the optimum gene transfection for 
TAT-Ca/pDNA complexes occurred when 113 mM of CaCl2 was used, well below the 
CaCl2 IC50 value of 210 mM.      
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Figure 7. The transfection efficiency of TAT-Ca/pDNA and PEI/pDNA complexes with 
different concentration of CaCl2. Results are presented as mean ± SD (n = 3).        
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Figure 8. The transfection efficiency of TAT-Ca/pDNA (N/P 25) and PEI/pDNA 
polyplexes with and without 113 mM CaCl2. Results are presented as mean ± SD (n = 3). 
*** p< 0.001.  
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3.3.5. The effect of serum on transfection efficiency and particle size  
 
It has been previously reported that the presence of serum may have a significant 
influence on the transfection efficiency of nonviral gene delivery vehicles 55-57. To 
determine the effect of serum on gene expression, A549 cells were transfected with 
optimized TAT-Ca/pDNA (113 mM CaCl2) or PEI/pDNA complexes in the absence and 
presence of 10% FBS. Results indicated that serum did not significantly inhibit the 
transfection efficiency mediated by TAT-Ca/pDNA complexes. In contrast, PEI 
complexes showed slightly decreased transfection efficiency in the presence of 10% FBS 
(Figure 9). The effect of serum on transfection efficiency should be considered in light of 
the stability of the size of TAT and PEI complexes which were investigated as a function 
of time. TAT/pDNA complexes without CaCl2 exhibited some agglomeration behavior in 
the absence and presence of 10% of FBS after 8 days (Figure 5A and B). However, TAT-
Ca/pDNA complexes showed good stability in serum-free and supplemented culture 
media during the same time frame. On the other hand, PEI/pDNA complexes remained 
stable in the absence of serum and CaCl2 over a period of 8 days and retained their size, 
whereas the particle size of PEI-Ca/pDNA showed a marked decrease during the same 
time frame in the presence of serum.  
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Figure 9. Transfection efficiency of TAT-Ca/pDNA (N/P 25) and PEI/pDNA (N/P 10) 
complexes in A549 cells in the absence or presence of 10% FBS. Results are presented as 
mean ± SD (n = 3).        
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3.3.6. SYBR Green assay  
 
Dye displacement assays provide a simple, nondestructive, and high throughput 
method for investigating the pDNA accessibility within complexes. Various 
concentrations of CaCl2 were examined to identify the effect on pDNA packaging. SYBR 
green, which binds double-stranded DNA, was used for the assay 58. TAT/pDNA 
complexes showed weak fluorescence intensity. The addition of different CaCl2 
concentrations up to 113 mM likely condensed the TAT complexes, which resulted in 
lowering the accessibility of pDNA (Figure 10A). The fluorescence intensity transitioned 
into a gradual increase with increasing concentration of CaCl2. In contrast, PEI/pDNA 
complexes exhibited a negligible fluorescence for all concentrations of CaCl2 except at 0 
and 750 mM CaCl2 where slight fluorescence intensities were observed. 
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3.3.7. TNBS assay  
 
A TNBS assay was also used to determine the accessibility of the primary amine 
groups within the TAT/pDNA or PEI/pDNA complexes. The TNBS assay revealed that 
the free TAT had more primary amine groups than PEI, which decreased to negligible 
levels when adding the designated volume of 113 mM CaCl2 to them (Figure 10B). 
Control studies indicated that adding 23 mM CaCl2 decreased the absorption intensity of 
TNBS by less than 10%. Increasing CaCl2 concentration did not affect the absorption 
intensity further. These results supported the hypothesis that the efficiency of DNA 
compaction was increased by the introduction of CaCl2. Therefore, calcium interaction 
with amines also facilitated the observed stabilization and decrease in particle size for 
TAT/pDNA complexes. PEI complexes including CaCl2 showed low binding of the dye 
as well, but this may result from particle agglomeration or precipitation as suggested by 
the particle size studies.  
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Figure 10. (A) Effect of CaCl2 concentration on the TAT/pDNA and PEI/pDNA 
complexes by using the SYBR Green assay to assess DNA accessibility and (B) 
condensation of TAT and PEI complexes assessed using the TNBS assay as a probe for 
amine accessibility. Results are presented as mean ± SD (n = 3).       
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3.3.8. Stability of complexes exposed to heparin 
 
The stability of TAT and PEI complexes when exposed to the biological polyanion 
heparin was studied by determining changes in the SYBR Green-pDNA fluorescence. 
Exposing the complexes to heparin yielded an increase in the fluorescence signal as the 
heparin concentration increased (Figure 11). TAT and PEI complexes including 113 mM 
CaCl2 showed release of the plasmid DNA from the complexes at lower heparin 
concentrations than without calcium. These results indicated that calcium may control the 
delicate balance between binding affinities within polycations and pDNA complexes.  
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Figure 11. Unpackaging of TAT and PEI complexes by heparin displacement of DNA. 
Results are presented as mean ± SD (n = 3).        
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3.4. Discussion 
Improvement in the field of gene therapy is currently hindered by the lack of 
translatable gene delivery vectors. Synthetic, nonviral, vehicles based on polycations are 
promising vectors for gene delivery 59-64. The toxicity of these materials may be reduced 
or eliminated by reducing polycation molecular weight. However, the levels of gene 
expression mediated by low molecular weight polycations are typically low compared to 
higher molecular weight polycations (e.g. 25 kDa PEI) 65,66. As a result, many researchers 
have aimed to improve upon the deficiency of either system.     
Among nonviral vehicles, cell penetrating peptides (CPPs) have been used to 
deliver a variety of therapeutics. For example, experimental anti-cancer cargo including 
small molecules, proteins and nucleic acids, were delivered  into cells in vitro using CPPs 
and have been explored to treat pre-clinical tumor models in vivo 67,68. Complexes of 
plasmid DNA with TAT peptides have been used in gene delivery either by covalent 
coupling of the peptide to the vectors, or by simple mixing of the plasmid DNA with the 
TAT peptide to form TAT/pDNA complexes via electrostatic interactions. However, the 
transfection efficiency for these complexes was quite low in comparison to PEI.  
In our studies, TAT/pDNA complexes alone also exhibited no gene expression. The 
size of these complexes was quite large (~1000 nm) for gene delivery.  Therefore, 
calcium was explored as a condensing agent to reduce the size of TAT/pDNA complexes 
and to improve transfection efficiency. Calcium was found to form tight and compact 
complexes (~60 nm) through "soft" crosslinks that could be competitively disrupted in 
order to increase transfection efficiency. The precise balance between binding affinities 
within TAT/pDNA polyplexes was adjusted by controlling CaCl2 concentration as a 
 120
means to optimize transfection efficiency. Previous studies have shown that both small 
and larges particles may provide efficient levels of gene expression 69-72. However, the 
condensed size of TAT-Ca/pDNA complexes in this study appeared to correlate with 
enhanced transfection efficiency.  
The ability of calcium to condense TAT/pDNA complexes occurred as a result of 
calcium interactions with both amines (polycations) and phosphates (DNA). The binding 
affinity of calcium to double-stranded DNA was observed as indicated by gel 
electrophoresis of the TAT-Ca/pDNA complexes. A specific CaCl2 concentration range 
was necessary to achieve small particles. Dye displacement studies provided some 
indication of the extent of compaction of DNA when bound to TAT or PEI. Nearly 
complete exclusion of TNBS from both TAT/pDNA and PEI/pDNA complexes was 
achieved when 113 mM calcium was added to the polyplexes suggesting that the primary 
amine groups within these complexes were blocked. Moreover, pDNA was mostly 
inaccessible to SYBR green when TAT/pDNA complexes were formulated with up to 
113 mM CaCl2 suggesting that pDNA was also extensively condensed within the 
complexes. The accessibility of pDNA increased at higher concentrations of CaCl2 which 
demonstrated that calcium may also competitively inhibit the amine/phosphate 
interaction.  
The stability of TAT and PEI complexes upon exposure to the polyanion heparin 
revealed that complex dissociation depended on the inclusion of calcium as well. Heparin 
and heparan sulfate have been previously reported to bind to PEI and release pDNA from 
complexes 73,74. Complex stability is significant because sufficiently low affinity between 
polycation and plasmid DNA may be desirable to facilitate the release of the DNA after 
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cellular uptake. The inclusion of calcium in the formulation of TAT and PEI complexes 
facilitated the dissociation of these complexes by heparin. Therefore, the release of 
pDNA from the complexes suggested that a critical concentration of calcium can 
condense the complexes into small particles yet facilitate the release of DNA.  
A successful gene delivery system should be able to deliver DNA to the cell 
without negatively affecting the viability of the host cell. A cytotoxicity study in A549 
human lung carcinoma cells indicated that TAT peptide provided substantially higher cell 
viability than PEI. Further studies will be necessary to determine if this gene vector is 
benign in primary human cells.  
 
3.5. Conclusion 
 
Drug delivery strategies using CPPs such as TAT have been widely explored to 
improve the intracellular delivery of a large number of cargo molecules. Electrostatic 
complexation of pDNA using TAT has been less explored due to the relatively low levels 
of gene expression observed when using such low molecular weight polycations as DNA 
condensing agents. We have found that the binding affinity of calcium for TAT peptide 
and pDNA can be used to effectively mediate the charge balance within these complexes. 
In this study, it was shown that 113 mM CaCl2 produced small and stable TAT/pDNA 
complexes via "soft" crosslinks leading to gene expression levels higher than observed 
for control PEI gene vectors in A549 lung epithelial cells. TAT-Ca/pDNA complexes 
were stable, maintaining particle size in the absence and presence of 10% of FBS over a 
period of 8 days. Gene expression of TAT-Ca/pDNA complexes was sustained for at 
least 10 days and tended to increase over the first four days of the study. Conversely, 
gene expression levels for PEI/pDNA complexes showed high initial gene expression that 
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dropped to low levels after day 4. Moreover, the transfection efficiency of TAT-
Ca/pDNA complexes was not significantly influenced by the presence of serum. The 
TAT peptide also showed negligible cytotoxicity up to 5 mg/mL. In comparison, PEI was 
very cytotoxic (IC50 ~35 µg/mL). Thus, these data suggest that TAT-Ca complexes are a 
novel and effective vehicle offering some potential for translatable gene delivery. 
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Chapter 4. 
 
Calcium Condensation of DNA Complexed with Cell Penetrating Peptides Offers 
Efficient, Noncytotoxic Gene Delivery   
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4.1. Introduction 
Nucleic acid therapeutics continue to offer promise for the treatment of both 
acquired and inherited diseases. One major obstacle impeding the successful application 
of nucleic acid drugs is the difficulty to develop a simple, safe, and efficacious delivery 
system 1-3. Gene delivery vectors must compact genetic material into nanoparticles that 
are colloidally stable, protect nucleic acids from enzymatic degradation, effectively 
transit nucleic acids to target cells, and achieve a significant transfection yield. Viral 
vectors remain the most effective method of gene delivery even though problems such as 
immunogenicity remain a concern.   
Polymer-mediated gene delivery has emerged as a viable alternative to viral 
transfection due to potential attributes such as low immunogenicity, low toxicity, ease of 
synthesis and low cost 4-6. Many studies have shown that DNA complexes 
electrostatically with polycations to form "polyplexes" that are endocytosed by many cell 
types and deliver DNA with varying degrees of efficiency and toxicity 7-16. Frequently, 
the most effective polyplexes are also the most toxic, thus hampering clinical translation 
1-6. As a primary example, polyethyleneimine (PEI) exhibits efficient gene delivery but is 
also very cytotoxic 17,18. Cell penetrating peptides (CPPs) offer a potential alternative to 
PEI. These short polycations achieve intracellular access by crossing the plasma 
membrane directly or by endocytosis 19-25 while typically exhibiting low cytotoxicity 26,27. 
Covalently conjugating CPPs to gene vectors (e.g. liposomes, polymer nanoparticle, etc.) 
has shown some promise, but polyplexes of CPPs and DNA have proven to be relatively 
inefficient and require improvement 28,29.  
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To provide a simple method for improving the gene delivery of CPP polyplexes, 
calcium was used to condense large and inefficient CPP polyplexes. The resulting 
nanoparticles transfected human lung carcinoma cell line A549 more efficiently than PEI 
and exhibited very low cytotoxicity. Four representative CPPs were studied; Arginine 7 
(Arg7), Arginine 9 (Arg9), Antennapedia Heptapeptide (Ahp) and Antennapedia Leader 
Peptide (Alp) (Table 1). Plasmid DNA encoding firefly luciferase (pGL3, 4.8 kbp) was 
used as a reporter.  
 
Table 1. Structure of CPPs, Arginine 7 (Arg7), Arginine 9 (Arg9), Antennapedia        
Heptapeptide (Ahp) and Antennapedia Leader Peptide (Alp). 
 
 
CPP Sequence Molecular weight (Da) 
Arg7 RRRRRRR 1,111.3 
Arg9 RRRRRRRRR 1,423.3 
Ahp RRMKWKK 1,032.6 
Alp KKWKMRRNQFWVKVQRG 2,276.2 
 
4.2. Experimental Section 
4.2.1. Materials 
Plasmid DNA encoding firefly luciferase (pGL3, 4.8 kbp) was obtained from 
Promega (Madison, WI). Cell penetrating peptides (CPPs) were purchased from Pi 
Proteomics (Huntsville, AL). Branched polyethyleneimine (PEI, 25 kDa) was obtained 
from Aldrich (Milwaukee, WI). Calcium chloride (CaCl2. 2H2O) was purchased from 
Fisher Scientific (Pittsburgh, PA). A549 cells were obtained from the American Type 
Culture Collection (ATCC, Rockville, MD). The cell culture medium (Ham’s F-12 
Nutrient Mixture, Kaighn’s modified with L-glutamine) was purchased through Fisher 
Scientic. Fetal bovine serum (FBS) was purchased from Hyclone (Logan, UT). Penicillin-
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streptomycin was purchased from MB Biomedical, LLC (Solon, OH). Trypsin-EDTA 
was purchased through Gibco. MTS reagent [tetrazolium compound; 3-(4, 5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, 
inner salt] was purchased from Promega (Madison, WI). 
 
4.2.2. Preparation of CPP/pGL3 complexes 
 
CPP/pGL3 complexes were prepared by adding 10 µL (0.1 µg/µL) of pGL3 to 15 
µL CPP solution while pipetting. To this solution, 15 µL of known molarity (e.g. 113 
mM) CaCl2 was added and mixed by vigorous pipetting. Before performing experiments, 
the complexes were allowed to equilibrate for 20 min at 4º C.  
 
4.2.3. Preparation of PEI/pGL3 complexes 
PEI/pGL3 complexes were prepared by adding 10 µl (0.1 µg/µL) of pGL3 solution 
to 15 µL (N/P ratio 10) PEI solution while pipetting followed by 20 min incubation at 4º 
C. Complexes were freshly prepared before each individual experiment. 
 
4.2.4. Characterization of CPPs and PEI complexes 
The size and zeta potential of the different complexes were measured by using 
ZetaPALS dynamic light scattering (DLS) (Brookhaven, Holtsville, NY). 
 
4.2.5. Cell culture 
Culturing of human epithelial lung cell line A549 was performed according to the 
protocol provided by the American Type Culture Collection. A549 cells were grown in F-
12K supplemented with 10% (v/v) FBS and 1% (v/v) Penicillin/streptomycin at 37º C in 
a humidified air atmosphere containing 5% CO2. 
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4.2.6. In vitro cell transfection studies 
 
A549 cells were trypsinized, counted and diluted to a concentration of 
approximately 80,000 cells/ mL. Then 0.1 mL of that dilution was added to each well of a 
96-well plate and the cells were incubated in a humidified atmosphere at 5% CO2 and 
37°C for 24 h. Immediately before transfection, the cells were washed once with PBS and 
100 µl sample (20% of complex to 80% of serum free cell culture medium) was added to 
each well. Cells were incubated with the complexes for 5 h. The transfection agent was 
then removed by aspiration and 100 µL of fresh serum medium was added followed by 
further incubation. The Luciferase Assay System from Promega was used to determine 
gene expression following the manufacturer’s recommended protocol. The light units 
were normalized against protein concentration in the cells extracts, which were measured 
using the BCA™ Protein Assay (Thermo Scientific, Rockford, IL). The transfection 
results were expressed as Relative Light Units (RLU) per mg of cellular protein.  
 
4.2.7. Assessment of cytotoxicity (MTS Assay) 
 
Cytotoxicity of polymers was determined by the CellTiter 96® Aqueous Cell 
Proliferation Assay. A549 cells were grown as described in the transfection experiments. 
Cells were treated with the samples for ~24 h. The media were then removed and 
replaced with a mixture of 100 µL fresh culture media and 20 µL MTS reagent solution. 
The cells were incubated for 3 h at 37°C in the 5% CO2 incubator. The absorbance of 
each well was then measured at 490 nm using a microtiter plate reader (SpectraMax, 
M25, Molecular Devices Corp., CA) to determine cell viability. 
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4.3. Results and Discussion 
Peptides offer a highly attractive feature of incorporating various biological 
activities required for biomedical applications 30-34. Cell penetrating peptides, a group of 
short peptides with the potent ability to translocate across the plasma membrane of the 
cells, have been reported to mediate plasmid DNA delivery into cells 35-37; however, 
improving the transfection efficiency of their DNA complexes remains a major challenge. 
The relatively low transfection level of certain complexes may be due to inadequate 
escape from endosomes or the inefficient release of DNA from the complexes 38. 
Previous studies demonstrated that the HIV-1 TAT peptide could only provide a high 
level of gene expression when chloroquine (an endosomolytic agent) was added, which is 
not feasible for gene delivery in vivo 28,39-41. One approach for overcoming this limitation 
was to link the CPPs to produce high molecular weight polypeptides 42-44 or to directly 
conjugate the CPPs using histidine or cysteine residues38,45. Others have tried a low 
molecular weight PEI with covalently linked TAT to overcome the poor transfection 
efficiency of the CPP alone 39. Targeting studies have also been explored. For example, 
the YIGSR pentapeptide, known to target cell surface laminin receptors, or the LK15 
peptide was conjugated to TAT.  In each case, the transfection efficiency improved, but 
gene expression levels were still low compared to PEI 46-48.  
In studies reported here, CPP/pGL3 complexes were synthesized by rapidly adding 
pGL3 to CPP.  These complexes were thoroughly mixed by pipetting and then CaCl2 was 
added to decrease the large size of these complexes. Calcium was previously reported to 
interact with both amines (e.g. on CPPs) and pDNA within polyplexes to form compact 
complexes through "soft" crosslinks. Here, the reduction in the size of CPP/pGL3 
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complexes likely led to some of the noted increase in transfection. A CaCl2 concentration 
of 113 mM consistently produced small (100-140 nm) and stable CPP polyplexes with a 
single particle population (polydispersity < 0.23). In general, the zeta potential of CPP 
polyplexes increased significantly from 8 to 26 mV with increasing concentration of 
CaCl2 (Figure 1). The CPP polyplexes synthesized with CaCl2 remained stable in the 
absence and presence of 10% FBS at 37º C for 1 hr. Conversely, CPP polyplexes without 
added calcium remained large (Figure 2).  
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Figure 1. The effect of CaCl2 (113 mM) on the charge of CPPs and PEI complexes. 
Results are presented as mean ± SD (n = 3).       
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        A 
 
 
 
 
 
 
 
 
 
 
 B 
 
 
 
 
 
 
 
 
 
Figure 2. The diameter of CPPs-Ca/pGL3 and PEI complexes (without and with 113 mM 
CaCl2) in (A) the absence and (B) presence of 10% FBS. Results are presented as mean ± 
SD (n = 3).   
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A successful gene delivery vector should be able to deliver gene to the cell without 
negatively affecting the viability of the host cell. To investigate whether the CPPs 
affected the viability of A549 human lung carcinoma cells, an MTS cytotoxicity assay of 
free CPP or branched PEI (25 kDa) was conducted. A549 cells were incubated with up to 
5 mg/mL of CPPs or PEI for ~24 hrs. Cytotoxicity profiles of Arg7, Arg9 and Ahp 
peptides revealed no evidence of cytotoxicity and cells maintained high viability (Figure 
3), while Alp peptide showed moderate cytotoxicity (IC50 ~2144 µg/mL). Branched PEI 
induced substantial cytotoxicity (IC50 ~35 µg/mL).  
 
0
20
40
60
80
100
120
0.1 1 10 100 1000 10000
Concentration (µg/ml)
%
 V
ia
bi
lit
y 
PEI Arg7
Arg9 Alp
Ahp
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Cytotoxicity profiles of CPPs and PEI in A549 cells.  Viability is expressed as a 
function of polymer concentration. Results are presented as mean ± SD (n = 3).       
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Luciferase gene expression was measured 24 h after transfection in order to study 
the ability of CPP polyplexes to transfect A549 cells.  Different N/P ratios of the CPP or 
branched PEI (N/P 10) polyplexes were studied using different concentrations of CaCl2; 
0, 28.3, 56.5, and 113 mM as a condensing agent after complex formation. Most CPP 
polyplexes showed the highest level of gene expression at 113 mM of added CaCl2 for 
the various N/P ratios when compared to branched PEI, which had excellent transfection 
efficiency only in the absence of CaCl2 (Figure 4). Arg7, Arg9, Ahp and Alp revealed the 
greatest transfection efficiency with 113 mM CaCl2 at N/P ratios of 36, 35, 29 and 15 
respectively. It is important to note that gene expression was not detectable for 
CPPs/pDNA complexes without CaCl2.  
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Figure 4. The transfection efficiency of CPP and PEI complexes using (A) Arg7, (B) 
Arg9, (C) Ahp or (D) Alp with different concentrations of added CaCl2. Results are 
presented as mean ± SD (n = 3).   
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To gain insight into the potential of utilizing calcium condensed CPP polyplexes as 
delivery vectors in vivo, A549 cells were transfected in the presence of serum (Figure 5). 
A slight decrease in transfection efficiency was observed and CPP polyplexes exerted a 
similar reduction in gene expression as that observed for PEI polyplexes. PEI polyplexes 
have shown effective gene transfection in vivo, but is dose limited due to toxicity.   
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Figure 5. The transfection efficiency of CPP and PEI polyplexes in the absence and 
presence of 10% FBS. Results are presented as mean ± SD (n = 3).   
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4.4. Conclusion 
     
The delivery of therapeutic nucleic acids by CPP polyplexes condensed with 
calcium may offer a simple and effective gene delivery method with potential for clinical 
translation. Adding CaCl2 to CPP polyplexes produced small nanoparticles leading to 
gene expression levels higher than observed for optimized PEI gene vectors in A549 lung 
epithelial cells. CPP polyplexes were stable, maintaining particle size in the absence and 
presence of 10% of FBS over a period of 1 h. The CPPs generally showed negligible 
cytotoxicity up to 5 mg/mL, which may offer an opportunity to increase the dose of 
nucleic acid therapeutics to achieve a desired therapeutic effect. The simplicity of the 
formulation in combination with the efficacy and low cytotoxicity of CPP polyplexes 
makes them highly interesting vectors for future studies in vivo. 
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Chapter 5. 
 
DNA Complexed with TAT and Condensed Using Calcium Possesses Unique 
Structural Features Compared to PEI Polyplexes  
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5.1. Introduction 
While a variety of vectors currently exist for gene translocation, cell penetrating 
peptides (CPPs) have become one of the most popular and efficient agents for 
intracellular delivery of genetic material. CPPs have successfully achieved intracellular 
delivery of proteins 1, nucleic acids 2, small molecule therapeutics 3, quantum dots 4, and 
even MRI contrast agents 5. Highly efficient translocation mediated by CPPs has been 
confirmed in a variety of cell lines with minimal toxicity, overcoming challenges often 
faced with other delivery methods 6. Additionally, CPPs can be covalently or 
noncovalently attached to drugs effectively towing their cargo into cells with no loss of 
biological activity. Once inside the cell, many of these CPPs are also able to localize to 
the nucleus, with or without their cargo 7. A major problem with the use of CPPs as 
nonviral gene vectors, however, is their low level of induction of gene transfection 
compared to viral vectors. The problem is compounded by the lack of structural 
information for these complexes. Previous studies have defined the structure of nonviral 
gene delivery complexes by a combination of methods such as dynamic light scattering 
(DLS), fluorescence, Fourier transform infrared spectroscopy (FTIR), circular dichroism 
(CD) and differential scanning calorimetry (DSC) 8-17. These methods potentially provide 
information-rich data that may be used to describe gene delivery complexes and serve as 
a basis to design next generation gene vectors.     
CPPs possess the physical and chemical characteristics desired of gene delivery 
agents 18. For example, their polycationic, sometimes amphiphilic, nature has been shown 
to overcome one or more of the major biological barriers to transfection (e.g. cell entry, 
endosome escape, and nuclear localization). In addition, many of these peptides can 
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complex pDNA, although somewhat inefficiently. Cationic lipoplex vectors have been 
extensively investigated by various physicochemical methods in previous studies, but 
detailed characterization studies of CPP containing "polyplex" vectors remain scarce.  
TAT complexes containing "soft" calcium cross links have recently shown promise 
by our group as efficient gene delivery agents 19. A method to synthesize small (60-175 
nm) and stable TAT complexes was achieved by the formation of a ‘loose’ complex 
between TAT peptide and pDNA that was then condensed by calcium. The TAT-Ca 
system was shown to display high transfection efficiency even in the presence of serum, 
and negligible toxicity in vitro and in vivo compared to branched PEI polyplexes. The 
transfection efficiency of TAT complexes depends on several factors including the 
nitrogen/phosphate (N/P) ratio and the concentration of CaCl2.  
Despite extensive previous efforts investigating the potential of polycations to 
deliver plasmid DNA, correlations between the properties of polyplexes and their ability 
to transfect cells are still poorly understood 20-24. Thus, we have conducted a thorough 
physical characterization of TAT complexes with the objective of establishing a 
relationship between their physical properties by comparison to PEI polyplexes. The 
secondary structure of pDNA upon complexation with TAT was investigated by using 
FTIR, UV second derivative absorption and CD spectroscopies. The thermal stability of 
pDNA complexed to TAT was studied using DSC. In addition, fluorescence spectroscopy 
was used to probe the extent of pDNA condensation in complexes. Finally, light 
scattering studies were performed to assess the particle size of the complexes.  
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5.2. Materials and methods 
5.2.1. Materials  
 Plasmid DNA encoding firefly luciferase (pGL3, 4.8 kbp) was obtained from 
Promega (Madison, WI, USA) and transformed into Escherichia coli DH5ά (Invitrogen, 
Carls-bad, CA). A single transformed colony picked from an agar plate was cultured in 
LB Broth Base (Invitrogen) liquid for plasmid DNA preparation. Plasmid DNA was 
purified with Plasmid Giga Kit 5 (Qiagen, Germantown, MD) following the 
manufacturer's instructions. All pDNA had purity levels of 1.8 or greater as determined 
by UV/Vis inspection (A260/A280). HIV-1 TAT (49-57) peptide (RKKRRQRRR; Mw = 
1338.85 Da) was purchased from Biomatik (Cambridge, Ontario, Canada). Branched 
polyethylenimine (PEI, 25 kDa) was obtained from Aldrich (Milwaukee, WI). Calcium 
chloride (CaCl2. 2H2O) and agarose medium were purchased from Fisher Scientific 
(Pittsburgh, PA). A549 cells were obtained from the American Type Culture Collection 
(ATCC, Rockville, MD). The cell culture medium (Ham’s F-12 Nutrient Mixture, 
Kaighn’s modified with L-glutamine) and BCA™ Protein Assay were purchased through 
Fisher Scientic (Pittsburgh, PA). Fetal bovine serum (FBS) was purchased from Hyclone 
(Logan, UT). Penicillin-streptomycin was purchased from MB Biomedical, LLC (Solon, 
OH) and Trypsin-EDTA from Gibco (Carlsbad, CA). The Luciferase Assay System was 
obtained from Promega (Madison, WI).                                                                                                              
 
5.2.2. Preparation of complexes 
     
Complexes were formed by addition of appropriate volumes of pDNA and TAT or 
PEI solutions calculated to produce the desired molar ratio, followed by a 20 min 
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incubation at 4º C prior to use 25. Complexes were freshly prepared before each 
individual analysis.  
 
5.2.3. Particle Size and Zeta potential measurement  
 
The effective hydrodynamic diameter of the complexes was analyzed using DLS 
employing a Brookhaven Instrument (Holtsville, NY) equipped with a 50 mW HeNe 
laser operating at 532 nm. The complexes were prepared at a constant pDNA 
concentration of 100 µg/mL while the N/P ratios of the complexes were varied. The 
scattered light was monitored at 90º to the incident beam. For each sample the data were 
collected continuously for three 1-min intervals. The mean diameter of the complexes 
was obtained from the diffusion coefficient by the Stokes-Einstein equation using the 
method of cumulants. Zeta potential measurements were obtained by phase analysis light 
scattering using a Brookhaven Zeta PALS instrument. The electrophoretic mobility of the 
samples was determined from the average of 10 cycles of an applied electric field. The 
zeta potential was determined from the electrophoretic mobility from the Smoluchowski 
approximation.      
 
5.2.4. UV Absorption Spectroscopy 
 
UV absorption spectra of pDNA were obtained employing a Hewlett-Packard 8453 
UV-visible diode-array spectrophotometer (Agilent, Palo Alto, CA). A pDNA 
concentration of 0.025 µg/µL was used. Second derivatives of the absorption spectra 
from 240 nm to 300 nm were generated using a 9-point filter and third degree polynomial 
then fit to a spline function with 99 points of interpolation using software supplied with 
the instrument. Peak positions were determined using Origin® software from Microcal™. 
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5.2.5. Transfection Studies 
 
The transfection efficiencies of the complexes were assessed using plasmid DNA 
encoding firefly luciferase (pGL3, 4.8 kbp) in A549 human lung carcinoma epithelial    
cells. Cells were trypsinized, counted and diluted to a concentration of approximately 
80,000 cells/ mL. Then 0.1 mL of that preparation was added to each well of a 96-well 
plate and the cells were incubated in a humidified atmosphere at 5% CO2 and 37°C for 24 
h. Immediately before transfection, the cells were washed once with PBS and 100 µl of 
sample (20% of complex to 80% of serum free cell culture medium) was added to each 
well. Cells were incubated with the complexes for 5 h. The transfection agent was then 
removed by aspiration and 100 µL of fresh serum medium was added followed by 24 h of 
incubation. The Luciferase Assay System from Promega was used to determine gene 
expression following the manufacturer’s recommended protocol. The light units were 
normalized against protein concentration in the cellular extracts, which were measured 
using the BCA™ Protein Assay. The transfection results were expressed as Relative Light 
Units (RLU) per mg of cellular protein.  
 
5.2.6. Fluorescence Spectroscopy 
 
The dye SYBR Green (Invitrogen, Carls-bad, CA) with an excitation wavelength of 
497 nm and emission wavelength of 520 nm was used in fluorescence studies. SYBR 
Green solution (concentration of 1 X dye) was added to the pDNA before complex 
formation. After a 30 min incubation, the complexes were prepared as described above. 
Fluorescence measurements were performed with a QuantaMaster™ spectrofluorometer 
(PTI, Monmouth, NJ). The excitation and emission slits were set at 4 nm and spectra 
from 480 to 590 nm were obtained by scanning at 1 nm intervals using a 1 s integration 
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time. The fluorescence intensity of dye alone in buffer was subtracted from raw sample 
spectra.     
 
5.2.7. Fourier Transform Infrared (FTIR) spectroscopy 
 
FTIR spectra were obtained using a Nicolet Magna-IR 560 spectrometer equipped 
with a mercury cadmium telluride detector (Nicolet, Madison, WI). Samples were 
measured by an attenuated total internal reflectance (ATR) method in which the sample 
in solution was placed directly in a zinc selenide trough. Spectra were obtained under dry 
air purge by accumulation of 256 interferograms at a final resolution of 4 cm-1. For ATR 
experiments, the association band of water near 2200 cm-1 was used as a reference for 
subtraction of water from the spectra. Base-line correction (1804 to 904 cm-1) and seven 
point Satvitsky-Golay smoothing were applied to all spectra. The final pDNA 
concentration of the samples was 0.5 µg/µL while the polycations concentration was 
varied. 
 
5.2.8. Circular Dichroism (CD) 
  
For CD measurements, complexes were formed at a final pDNA concentration of 
50 µg/mL. CD spectra were obtained using a Jasco J-720 spectropolarimeter (Easton, 
MD) in a 0.1 cm pathlength quartz cuvette at 25°C. Spectra were recorded from 350 to 
200 nm at a scan rate of 20 nm/min and were analyzed as an average of three scans. The 
CD signal was converted to molar ellipticity [θ] based on the molar base concentration of 
the pDNA, smoothed with a Jasco Fast Fourier transform method, and then baseline 
adjusted to zero at 345 nm to correct for a small contribution by differential light 
scattering. 
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5.2.9. Differential scanning calorimetry (DSC) 
 
Differential scanning calorimetry thermograms were obtained with a VP-DSC 
(Microcal, Northampton, MA). Measurements consisted of a single scan from 0 to 120°C 
at 1°C/min under 3 atm of pressure. Samples were examined in triplicate and degassed 
before measurement. Baselines were obtained by scanning with buffer in both the sample 
and reference cells. Data were analyzed by subtracting the baseline from the sample 
thermogram, and converting the differential heat to molar heat capacity using the 
molecular weight and concentration of pDNA (0.4 µg/µL).  
 
5.2.10. Statistical Analysis 
 
Statistical evaluation of data was performed using an analysis of variance (one-way 
ANOVA). Newman–Keuls was used as a post-hoc test to assess the significance of 
differences. To compare the significance of the difference between the means of two 
groups, a t-test was performed; in all cases, a value of p < 0.05 was accepted as 
significant. 
 
5.3. Results 
 
5.3.1. Particle Sizes and Zeta potentials of TAT and PEI complexes 
 
The mean hydrodynamic diameter and zeta potential of the complexes were 
determined by DLS and PALS, respectively (Table 1). In general, adding 113 mM CaCl2 
to TAT complexes at N/P ratios between 4 and 33 induced a substantial decrease in the 
particle size (60-175 nm) with relatively narrow polydispersity. In comparison, PEI 
complexes possessed a small particle size (~74 nm) with zeta potential (16 mV) in the 
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absence of calcium. The zeta potential of TAT complexes produced particles with a 
positive surface charge (> 18 mV). 
 
 
 
 
 
Table 1. The diameter of TAT complexes as a function of N/P ratio with 113 mM CaCl2 
concentration. Results are presented as mean ± SD (n = 3).  
  
 
N/P ratio Effective Diameter (nm) Zeta potentials (mV) 
4  171.8±3.9 15.7±0.8 
9  165.1±3.7 18.2±1.9 
13 133.2±4.3 17.5±2.0 
18  121.0±1.9 20.3±0.3 
25  77.3±9.6 19.0±1.4 
33  55.1±7.5 23.6±1.6 
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5.3.2. In vitro transfection of A549 Cells 
 
The transfection efficiencies of TAT and PEI complexes were evaluated in the 
human lung carcinoma cell line A549. Gene expression levels were dependent on the N/P 
ratio of the TAT complex (Figure 1). The gene expression of TAT complexes was 
enhanced by the inclusion of 113 mM CaCl2 for the various N/P ratios. The highest 
transfection efficiency of TAT complexes was seen at N/P 25. Conversely, negligible 
expression was observed for TAT complexes without CaCl2. In comparison, PEI had 
excellent transfection efficiency in the absence of CaCl2.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The transfection efficiency of TAT and PEI (N/P 10) complexes as a function 
of N/P ratio with 113 mM CaCl2 concentration. Results are presented as mean ± SD (n = 
3), *p < 0.001 for the various N/P ratios of TAT complexes as compared with TAT (N/P 
25) complexes.   
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5.3.3. Second Derivative UV Absorption Spectroscopy 
 
The UV spectrum of pDNA displayed an absorption maximum at 260 nm. Plasmid 
DNA second derivative analysis revealed numerous absorption peaks between 240 and 
300 nm arising from the pDNA bases. Five positive peaks at approximately 256, 268, 
277, 287 and 296 nm, and five negative peaks at 253, 259, 271, 282 and 291 nm were 
found (Figure 2A-E). The positions of these peaks are sensitive to the immediate 
environment of the corresponding residues. In general, the second derivative peaks of 
pDNA complexed with polycations display a shift to higher wavelengths when the 
polycations are in molar excess. TAT complexes in the absence and presence of 113 mM 
CaCl2 showed a reduction in the absorbance and an increase in the wavelengths of these 
peaks. Above an N/P of 13, TAT complexes including calcium showed a reduction in the 
second derivative peaks of pDNA. Conversely, PEI complexes produced only small red 
shifts in the position of these peaks. Including calcium in the PEI complexes formulation 
revealed a marked decrease in the absorbance of the peaks. Free TAT, PEI and CaCl2 had 
no significant peaks over the range of wavelengths examined.     
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Figure 2. Second derivative UV spectra of (A) free TAT and PEI and (B and C) TAT and 
PEI complexes as a function of N/P ratio with and without 113 mM CaCl2. The positive 
peak positions (D) and the negative peak positions (E) of the pDNA bases were plotted 
against the N/P ratios.    
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5.3.4. Fluorescence Studies   
 
The condensation of pDNA by the cationic materials in the presence and absence of 
113 mM CaCl2 was studied using SYBR green dye 26. This fluorophore is virtually 
nonfluorescent in solution but forms highly fluorescent complexes when bound to 
double-stranded DNA. As expected, the fluorescence intensity of free pDNA probed with 
SYBR green was significantly higher than when condensed by polycations (Figure 3A 
and B). It has been shown previously that the addition of cationic carriers to dye labeled 
DNA quenched the fluorescence of the dye without displacing it from the DNA 27. The 
addition of TAT or PEI to pDNA showed a substantial decrease in the SYBR green 
fluorescence intensity with PEI complexes superior to TAT complexes in quenching 
SYBR green fluorescence. This implies that the pDNA was more tightly compacted by 
the PEI. Including 113 mM CaCl2 in the formulation of the complexes resulted in a 
negligible reduction in the fluorescence of the complexes.   
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Figure 3. Extrinsic fluorescence spectra of TAT and PEI complexes in (A) the absence 
and (B) presence of 113 mM CaCl2. 
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5.3.5. Infrared Spectral Properties of TAT and PEI complexes 
 
FTIR spectroscopy was employed to investigate the secondary structure of the 
pDNA component of complexes. The FTIR spectra of pDNA and its complexes with 
TAT (N/P 25) including 113 mM CaCl2 and with PEI (N/P 10) showed clear trends 
(Figure 4A and B). In the absence of cationic reagent, pDNA was in the B conformation 
as indicated by the presence of the guanine/thymidine (G/T) carbonyl stretching band at 
1711 cm-1, an asymmetric phosphate stretching vibration at 1217 cm-1 and a sugar-
phosphate coupled vibration at 966  cm-1 8,10,28. Addition of TAT or PEI to pDNA 
induced an increase in the peak frequency of the base carbonyl stretching vibration and a 
decrease in the antisymmetric phosphate stretch (Figure 4C-F). No change in the peak 
position of the sugar-phosphate coupled vibration was observed upon addition of TAT to 
pDNA. In comparison, PEI induced a blue shift in the position of the vibration arising 
from the pDNA backbone. The position of a pDNA ribose sugar vibration in both TAT 
and PEI complexes (1053 cm-1) shifted to lower frequency. Furthermore, no change in 
the peak position was observed for the symmetric phosphate vibration (~ 1087 cm-1), 
which has been found to be independent of pDNA geometry 28.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 170
 
80010001200140016001800
0.01
0.02
0.03
0.04
0.05
0.06
0.07
A
bs
or
ba
nc
e
Wavenumbers (cm-1)
pGL3        A PEI
 PEI N/P 10
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80010001200140016001800
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
A
bs
or
ba
nc
e
Wavenumbers (cm-1)
pGL3        B TAT TAT-Ca N/P 25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 171
 
 
 
C                                                  D 
1710
1711
1712
1713
1714
pGL3 PEI N/P 10 TAT-Ca N/P 25
 
1200
1205
1210
1215
1220
pGL3 PEI N/P 10 TAT-Ca N/P 25
W
av
en
um
be
r (
cm
-1
))
 172
W
av
en
um
be
r (
cm
-1 
 
 
 
 
 
 
 
 
 
 
 
 
962
964
966
968
pGL3 PEI N/P 10 TAT-Ca N/P 25
W
av
en
um
be
r (
cm
-1
)
1080
1084
1088
1092
pGL3 PEI N/P 10 TAT-Ca N/P 25
W
av
en
um
be
r (
cm
-1
)
E                                                          F  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. FTIR absorbance spectra of (A) TAT and (B) PEI complexes in solution with 
and without 113 mM CaCl2. The peak positions of the pDNA base carbonyl (C), pDNA 
antisymmetric phosphate stretch (D), pDNA sugar-phosphate coupled vibration (E) and 
pDNA symmetric phosphate vibration (F) were plotted against the TAT and PEI 
complexes. 
 
 
 
 
 
 
 
 
 
 
5.3.6. CD of TAT and PEI complexes 
 
CD spectroscopy was also used to monitor the secondary structure of pDNA in 
TAT and PEI complexes. The polycations showed no intrinsic CD signal or ordered 
secondary structure within the UV region monitored. Therefore, the observed signals 
arose entirely from the pDNA molecules. The CD spectrum of uncomplexed pDNA 
demonstrated the characteristics of the native B form conformation, a positive peak at 
275 nm and a negative peak at 245 nm (Figure 5). Upon TAT-Ca and PEI complexation, 
both regions of the pDNA CD spectrum were altered. In general, the spectra of TAT-Ca 
and PEI complexes showed a decrease in the value of the molar ellipticity of the positive 
and negative bands, concomitant with a red shift of the peak position of both the 275 nm 
and 245 nm bands although not to the same degree. A decrease in the ellipticity and a 
shift in the position to higher wavelengths of both bands were observed after calcium was 
added to PEI complexes. Exclusion of calcium from the TAT complexes resulted in a 
change in the overall shape of the spectrum, an increase in the 275 nm peak and a 
decrease in the 245 nm band. Shifts in the peak position of each band to higher 
wavelengths were also evident when excluding calcium. 
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Figure 5. Effect of TAT and PEI in the absence and presence of 113 mM CaCl2 on the 
CD spectra of pDNA in the complexes.  
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5.3.7. DSC of TAT and PEI complexes 
 
The thermal stability of pDNA in TAT and PEI complexes was evaluated using 
DSC (Figure 6). Thermograms of pDNA displayed two major melting transitions. The 
first originated from supercoiled pDNA as a broad transition at ~ 90º C whereas the 
second arose from the linear/open circular species as a series of small transitions within 
the 60º-70º C range 14. All forms of pDNA were thermally stabilized when complexed to 
TAT (N/P 25) including113 mM CaCl2 or to PEI (N/P 10). The 25 kDa PEI stabilized 
both the supercoiled (100º C) and the linear/open circular (78º C) pDNA species at an 
N/P ratio of 10. The thermogram of TAT complexes demonstrated stabilization of both 
the supercoiled (~110º C) and linear/open circular form (~95º C) of pDNA with the 
thermal stability of pDNA in TAT complexes superior to that of PEI complexes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Effect of TAT and PEI in the absence and presence of 113 mM CaCl2 on the 
thermal stability of pDNA in the complexes.  
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5.4. Discussion 
 
In our earlier studies, it was established that adding certain concentrations of CaCl2 
(e.g., 113 mM) to CPP complexes produced small nanoparticles (60-175 nm), leading to 
gene expression levels higher than those observed for the more commonly used PEI 
complexes 19,25. The transfection efficiency of TAT complexes depended on the N/P 
molar ratio. Gene expression of TAT complexes formulated with 113 mM CaCl2 was 
sustained for at least 10 days and was not influenced by the presence of serum. Moreover, 
CPPs showed negligible cytotoxicity. The main goal of this study was to measure a wide 
variety of biophysical characteristics of pDNA in TAT complexes to better understand 
the structure of these particles and compare them to pDNA in PEI complexes.  
As observed in previous reports, pDNA remains in the B form when complexed 
with different amounts, molecular weights and forms of PEI 21. The thermal stability of 
the supercoiled and the linear/open circular forms of pDNA, however, was observed to 
increase in the presence of a charge excess of branched PEI (25 kDa). A direct correlation 
between the biophysical properties of PEI complexes and transfection efficiency was not, 
however, observed as had been previously reported 21.  
Six methods were selected for this study to probe various structural aspects of the 
TAT and PEI complexes. DLS provided a direct measurement of the size 17. The 
condensation of pDNA induced by polycations was evaluated by dye-binding 
fluorescence spectroscopy 24. FTIR and CD have proven to be sensitive tools for 
characterizing the secondary structure of pDNA in complexes 8,10,28-30 with additional 
structural changes studied using UV second derivative absorption spectroscopy 29. DSC 
was used to assess the thermal stability of pDNA within complexes 20. 
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A previous study has shown that the UV absorption spectra of pDNA originates 
from the purine and pyrimidine bases since the sugar phosphate backbones of pDNA 
produce very little contribution to its absorbance spectra above 200 nm 29. Nucleotide 
bases have very low symmetry and several unbonded electrons. Due to the many different 
transitions that occur for each base in the spectral region from 200 to 300 nm 31, the 
second derivative spectra of pDNA is complex. The UV second derivative spectra of 
polynucleotides is known to be dependent on the presence of secondary structure 
resulting in an extensively describe hyper-chromic effect. Since the secondary structure 
does not change in this case, however, an interaction between TAT or PEI and pDNA or 
a subtle change in their internal environment is clearly indicated by the changes in the 
position and the value of the absorbance of the pDNA second derivative peaks. Despite 
these changes, the CD and FTIR results lead us to conclude that the pDNA is maintained 
the B form when complexed to various ratios of N/P TAT and PEI. Although the B form 
was maintained, the pDNA is condensed into small complexes based on the DLS data. 
Dye-based fluorescence studies also provide some indication that PEI compacted pDNA 
to a greater extent than TAT. Surprisingly, the SYBR green fluorescence intensities were 
not perturbed upon the addition of 113 mM CaCl2 to the TAT and PEI complexes 
although calcium clearly does cause a significant decrease in the size of TAT complexes. 
The FTIR spectra of TAT and PEI complexes showed that the pDNA remained in 
the B form although there were changes in the position of the pDNA carbonyl and 
asymmetric phosphate vibrations. The increases in frequency of the base carbonyl 
vibrations suggested altered hydrogen bonding occurred within the bases. Also, the 
reduced frequency of the antisymmetric phosphate stretching vibration can be directly 
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attributed to the electrostatic interactions between polycations and pDNA. All these 
results confirm interaction between polycation and pDNA where the pDNA was 
maintained in B form within the complexes but suggest induction of small changes in the 
structure of the pDNA.   
CD spectra of the TAT and PEI complexes also suggested some changes in the 
structure of pDNA upon complexation, as shown by the changes in the pDNA CD peak 
positions and intensities. Previous studies suggested that these CD changes were best 
explained by limited local changes in the base/base interactions (20). Thus, the reduction 
of the value of the molar ellipticity likely indicated a decreased interaction between bases 
in the complexes. Moreover, such local structural perturbations may be due to a direct 
interaction between polycation and pDNA bases as observed in the change seen in the 
carbonyl stretching region with FTIR. The spectrum for TAT complexes including 
calcium supported such explanations, yielding a reduction in the molar ellipticity 
compared to the spectrum for TAT complexes. In addition, a previous study has shown 
that the CD spectra of Ca/pDNA complexes using different concentrations of calcium, 
general, were similar to the spectrum of pDNA alone with a slight decrease in the 
ellipticity at 275 nm 32. Further increase in calcium concentration beyond ~25.9 mM did 
not affect the spectrum. Comparing these results suggested that calcium interacted with 
both amines (TAT) and phosphates (pDNA), which we have described previously 19. The 
spectral changes seen are also consistent with absorption flattening but since they occur 
as the complexes are becoming smaller, this does not seem a probable explanation for the 
results.  
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DSC studies of TAT and PEI complexes confirmed an effect of complexation on 
the thermal stability of the supercoiled and linear/open circular pDNA components. 
Complexation by both polycations increased the melting temperature of all the forms of 
pDNA suggesting stabilization of the various pDNA structures. TAT complexes 
stabilized pDNA more than PEI complexes presumably as a result of the ability of 
calcium to selectively condense the TAT complexes. Thus, all of the analyses suggest 
some discrete differences in pDNA structure within TAT and PEI complexes.  
 
5.5. Conclusion 
 
Complexes of CPPs such as TAT with pDNA were previously established as a 
potent gene delivery vector when condensed into small complexes using calcium. The 
simplicity of the formulation, high levels of transfection efficiency and negligible effect 
on the viability of host cells inspired us to investigate the structure of pDNA within TAT 
complexes. Calcium concentration and N/P molar ratio were previously varied to 
maximize transfection efficiency and an optimized TAT complex was studied here. 
Extrinsic fluorescence studies provided evidence of compaction of pDNA, with PEI 
seemingly inducing ‘tighter’ complexes. FTIR and CD spectroscopies indicated that the 
secondary structure of pDNA was stabilized within the complexes. Nevertheless, DSC 
studies of pDNA components in TAT and PEI complexes demonstrated an enhancement 
in pDNA thermal stability. These data in combination with the transfection efficacy and 
the low cytotoxicity of TAT complexes support further exploration and perhaps new 
design schemes based on this novel nonviral gene delivery vector. Nevertheless, the exact 
relationship between the structure of the complexes and their efficiency as gene delivery 
vehicles remains elusive.  
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Chapter 6. 
 
Calcium Condensed siRNA Complexes with TAT or dTAT Peptides Offers Simple, 
Highly Effective, and Noncytotoxic Gene Silencing 
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6.1. Introduction 
The discovery and development of small interfering RNA (siRNA) has provided an 
elegant strategy for disabling specific genes responsible for pathological disorders 1,2. 
Since its discovery, siRNA has been developed as a screening tool for cancer studies 3-5, 
and has been evaluated as a potential therapeutic agent for variety of nucleic acid based 
diseases such as HIV 6, hepatitis C 7 and cancer 8,9. Double stranded siRNA is able to 
silence genes effectively in a sequence specific manner 10,11. Once in the cytoplasm, 
siRNA is loaded into RNA-induced silencing complex (RISC) 12-14. Within RISC, the 
passenger strand is degraded while the guide strand is loaded into Argonaut 2 (Ago2), the 
active nuclease component of RISC. The guide strand binds the complementary sequence 
of the target mRNA and catalyzes the cleavage of this mRNA, thus silencing the 
translation of the target mRNA into protein. 
The major limitation to clinical application of siRNA, like most nucleic acid based 
therapeutics, is poor cellular uptake due to the low permeability of the cell membrane to 
negatively charged molecules 15,16. Also, enzymatic lability, rapid renal clearance, low 
transfection efficiency and immune stimulation by siRNA have further delayed 
therapeutic applications 17-20. Several siRNA delivery systems have been proposed, 
including chemical modification of siRNA, lipids, cationic polymers, antibody-
protamines, RNA-aptamers and cell penetrating peptides (CPPs) 21-28. In most cases, 
toxicity of the delivery system and the endosomal escape are key challenges 29-32.  
In general, toxicity can be ameliorated by conjugation with biocompatible, 
hydrophilic polymers such as poly(ethylene glycol) (PEG) or hydroxypropyl 
methacrylamide (HPMA), or by removing excess (uncomplexed) cationic polymers 33-36. 
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Biodegradable polymers are attractive candidates for the design of siRNA polyplexes that 
often show low toxicity 37,38. The main hurdle for these vectors is endosomal escape. The 
siRNA vector or at least the siRNA must escape before degradation in the late 
endolysomal compartment. In order to circumvent this problem, many strategies have 
been employed to enhance endosomal escape. pH responsive lipid or lipid-like molecules 
and viral fusogenic proteins and peptides have promoted endosomal escape via 
membrane destabilization through a pH dependent shift in their conformation 39-48. 
Moreover, polymers such as poly(propylacrylic acid) (PPAA) undergo a hydrophilic to 
hydrophobic transition at endosomal pH offering another mechanism to mediate 
membrane disruption 49-54.  
Cell penetrating peptides (CPPs) have the earmarks of promising delivery vehicles 
for intracellular delivery of siRNA 55-60. Two main strategies have been investigated; 
chemical linkage of CPPs with siRNA 58,61,62 and noncovalent complexes with siRNA. 
Complexes using either liposomes or polyelectrolytes, in general, yield significant 
biological responses 24,55,63. Various CPPs, including TAT and 3-methyladenine-DNA 
glycosylase (MPG) proteins from HIV-1 64-67, as well as polyarginine, penetratin and 
TP10 68-70 have been reported to improve siRNA delivery into various cell lines. The 
interaction between the positive charges of CPPs and the negative charges of 
phospholipids and/or proteoglycans on the extracellular membrane surface is crucial for 
CPP-mediated uptake 71. Due to the negative charge of siRNA and the cationic nature of 
CPPs, it is very cumbersome to generate covalent conjugates and the CPPs can be 
effectively neutralized 72. Moreover, both covalent conjugation and electrostatic 
complexes of siRNA with CPPs were found to be trapped in endosomes even after 
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efficiently entering cells 73-76 and required additional molecules to facilitate cytosolic 
release of siRNA 77-80.       
We have previously demonstrated that adding calcium to CPP/pDNA complexes 
can reduce particle size and maximize transfection efficiency 81,82. This nonviral vector 
was found to display high transfection efficiency, even in the presence of serum, and 
negligible toxicity in vitro and in vivo. In this study, our objective was to investigate the 
ability of this system using the CPPs TAT and dTAT (a modified form of TAT) for 
siRNA delivery. The efficacy of siRNA delivery has been studied as a function of 
CPP/siRNA charge ratio and siRNA dose. The size and charge of TAT and dTAT 
complexes were examined by using dynamic light scattering analysis and transmission 
electron microscopy. Finally, the viability of A549 human lung carcinoma cells was 
investigated by using an MTS cytotoxicity assay of free TAT, dTAT or branched PEI.   
 
6.2. Materials and methods 
6.2.1. Materials 
 Anti-luciferase siRNA-1 (MW 13358 g/mol) and siRNA control (non-targeting) 
were supplied by Thermo Scientific Dharmacon® (Chicago, IL).  TAT peptide 
(RKKRRQRRR; Mw = 1338.6 Da) and dTAT (RKKRRQRRRHRRKKR; Mw = 2201.7 
Da) peptide were purchased from Biomatik Corporation (Cambridge, Ontario, Canada). 
Branched polyethyleneimine (PEI, 25 kDa) was obtained from Aldrich (Milwaukee, WI). 
Calcium chloride (CaCl2. 2H2O), Nuclease-free water and BCA™ Protein Assay were 
purchased from Fisher Scientific (Pittsburgh, PA). A549-luc-C8 Bioware® cell line was 
obtained from Caliper LifeSciences (Hopkinton, MA). The cell culture medium (RPMI-
1640) and (Ham’s F-12 Nutrient Mixture, Kaighn’s modified with L-glutamine) were 
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purchased from the American Type Culture Collection (ATCC, Rockville, MD). Heat 
inactivated fetal bovine serum (FBS) was purchased from Atlanta Biologicals 
(Lawrenceville, GA). Penicillin-streptomycin was purchased from MB Biomedical, LLC 
(Solon, OH). Trypsin-EDTA was purchased through Gibco (Carlsbad, CA). MTS reagent 
[tetrazolium compound; 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt] and Luciferase Assay System were purchased 
from Promega (Madison, WI).    
                                                                                                                                
6.2.2. Preparation of complexes 
     
TAT, dTAT and PEI complexes were prepared essentially as described previously 
81,82. Briefly, various amounts of polycations and siRNA were first dissolved in known 
volume of nuclease-free water (NFW). Ten microliters (e.g., 10 nM) of siRNA solution 
was added rapidly to fifteen microliters polycation (TAT, dTAT or PEI) solution while 
pipetting. To this solution, fifteen microliters (e.g., 23.1 mM) CaCl2 (or NFW in the case 
of PEI) was added and mixed by vigorous pipetting. This resulted in different N/P ratios 
of polycation/siRNA complexes. The complexes then were allowed to form during 20 
min incubation at 4º C prior to use. Complexes were freshly prepared before each 
individual analysis.  
 
6.2.3. Size and Zeta potential measurement  
 
The effective hydrodynamic diameter of the complexes was analyzed using a 
dynamic light scattering (DLS) system (Brookhaven Instrument, Holtsville, NY) 
equipped with a 50 mW HeNe laser operating at 532 nm. The complexes were prepared 
at a constant pDNA concentration of 100 µg/mL whereas the N/P ratios of the complexes 
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were varied. The scattered light was monitored at 90º to the incident beam. For each 
sample, the data was collected continuously for three 1-min intervals. The diameter of the 
complexes was obtained from the diffusion coefficient by the Stokes-Einstein equation 
using the method of cumulants. Zeta potential measurements were obtained by phase 
analysis light scattering using a Brookhaven Zeta PALS instrument. The electrophoretic 
mobility of the samples was determined from the average of 10 cycles of an applied 
electric field. The zeta potential was determined from the electrophoretic mobility from 
the Smoluchowski approximation.      
 
6.2.4. Cell culture 
  
Culturing of human epithelial lung cell line A549-luc-C8, stably expressing 
luciferase, was performed according to the protocol provided by Caliper LifeSciences. 
A549-luc-C8 cells were grown in RPMI-1640 supplemented with 10% (v/v) heat 
inactivated FBS and 1% (v/v) Penicillin/streptomycin at 37º C in a humidified air 
atmosphere containing 5% CO2. 
 
6.2.5. In vitro luciferase gene knockdown studies 
 
A549-luc-C8 cells were trypsinized, counted and diluted to a concentration of 
approximately 100,000 cells/ mL. Then, 0.1 mL of that dilution was added to each well 
of a 96-well plate and the cells were incubated in a humidified atmosphere at 5% CO2 
and 37°C. Twenty-four hours before transfection, the cells were washed once with PBS 
and 100 µl of sample at 10, 25 or 50 nM siRNA concentration (20% of complex to 80% 
of serum-free cell culture medium (Ham’s F-12 Nutrient Mixture, Kaighn’s modified 
with L-glutamine)) was added to each well. Cells were incubated with the complexes for 
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5 h. The media was then removed by aspiration and 100 µL of fresh serum medium 
(RPMI-1640) was added followed by further incubation (48 h). In addition to the anti-luc 
siRNA, a non-silencing siRNA sequence was used to ensure that the decrease in 
luciferase expression was due to the anti-luc siRNA and not to cytotoxicity effects of the 
vector. The Luciferase Assay System from Promega was used to determine luciferase 
gene silencing following the manufacturer’s recommended protocol. The light units were 
normalized against protein concentration in the cells extracts, which were measured using 
the BCA™ Protein Assay. The data were expressed as a percentage of the control (non-
specific siRNA control). 
 
6.2.6. Assessment of cytotoxicity (MTS Assay) 
 
The cytotoxicity of polymers was determined by the CellTiter 96® Aqueous Cell 
Proliferation Assay. A549-luc-C8 cells were grown as described in the transfection 
experiments. Cells were treated with the TAT, dTAT or PEI for ~24 h. The media were 
then removed and replaced with a mixture of 100 µL fresh culture media (RPMI-1640) 
and 20 µL MTS reagent solution. The cells were incubated for 3 h at 37°C in the 5% CO2 
incubator. The absorbance of each well was then measured at 490 nm using a microtiter 
plate reader (SpectraMax, M25, Molecular Devices Corp., CA) to determine cell 
viability. 
 
6.3. Results  
6.3.1. Particle Sizes and Zeta potentials of TAT, dTAT and PEI complexes 
 
TAT, dTAT and PEI complexes were prepared by mixing siRNA with each 
polycation at various N/P ratios. These complexes were thoroughly mixed by pipetting 
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and CaCl2 was added (final concentration 23.1-69.2 mM). The particle size and zeta 
potential of the complexes prepared by 25 nM of siRNA were determined by DLS and 
ZetaPALS, respectively (Table 1A and B). In general, the added CaCl2 produced small 
TAT and dTAT complexes at all N/P ratios (58.5-201.3 nm) with polydispersity (< 0.24). 
With increasing N/P ratios and using the higher concentrations of calcium, the size of the 
TAT and dTAT complexes generally decreased. In comparison, PEI complexes showed a 
small particle size (90 nm) with modest high zeta potential (~20 mV) in the absence of 
calcium. The zeta potential of TAT and dTAT complexes produced particles with a 
positive surface charge (> 15 mV) and the charge did not vary much with the N/P ratio. 
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Table 1. The diameter of (A) TAT and (B) dTAT complexes as a function of N/P ratio 
and CaCl2 concentrations. Results are presented as mean ± SD (n = 3).   
 
A 
 
N/P ratio & (CaCl2 mM) Effective Diameter (nm) Polydispersity 
7 (00.0) 1012.0±23.4 0.265 
7 (23.1) 139.7±3.9 0.108 
7 (34.6) 113.7±3.7 0.211 
7 (69.2) 116.6±11.3 0.125 
18 (00.0) 1411.3±54.1 0.195 
18 (23.1) 112.0±6.9 0.230 
18 (34.6) 99.9±10.8 0.134 
18 (69.2) 60.6±7.5 0.139 
25 (00.0) 2105.0±87.9 0.263 
25 (23.1) 144.2±2.1 0.222 
25 (34.6) 117.8±9.7 0.178 
25 (69.2) 59.3±6.4 0.203 
33 (00.0) 2210.0±76.9 0.271 
33 (23.1) 152.9±8.1 0.169 
33 (34.6) 122.8±4.5 0.225 
33 (69.2) 58.5±7.3 0.189 
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B 
 
N/P ratio & (CaCl2 mM) Effective Diameter (nm) Polydispersity 
6 (00.0) 1170.4±90.4 0.199 
6 (23.1) 124.3±9.4 0.143 
6 (34.6) 101.7±15.2 0.179 
6 (69.2) 98.5±6.8 0.201 
17 (00.0) 2256.5±45.1 0.253 
17 (23.1) 189.3±5.1 0.230 
17 (34.6) 203.4±9.4 0.177 
17 (69.2) 152.0±13.6 0.215 
23 (00.0) 1978.2±68.2 0.223 
23 (23.1) 155.7±4.2 0.242 
23 (34.6) 113.4±7.9 0.196 
23 (69.2) 89.7±5.1 0.103 
31 (00.0) 2190.5±39.6 0.247 
31 (23.1) 197.4±8.3 0.122 
31 (34.6) 145.2±1.9 0.108 
31 (69.2) 90.1±3.3 0.127 
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6.3.2. Cytotoxicity of TAT, dTAT and PEI complexes 
 
Efficient delivery together with low cytotoxicity is extremely desirable. To evaluate 
the cytotoxicity of free TAT, dTAT, and PEI, an MTS assay was performed by 
incubating A549-luc-C8 cells with up to 5 mg/mL of TAT, dTAT or PEI for 24 h (Figure 
1). TAT peptide revealed almost no evidence of cytotoxicity and cells maintained high 
viability, while dTAT showed modest cytotoxicity (IC50 ~ 4000 µg/mL). Branched PEI 
induced substantial cytotoxicity (IC50 22 µg/mL) as expected.  
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Figure 1. Cytotoxicity profiles of TAT, dTAT and PEI in A549-luc-C8 cells. Viability is 
expressed as a function of polymer concentration. Results are presented as mean ± SD (n 
= 3).       
 
 
6.3.3. In vitro luciferase gene knockdown by TAT, dTAT and PEI complexes 
 
The silencing efficiency of TAT and dTAT complexes was investigated using the 
human lung carcinoma cell line A549-luc-C8. This cell line stably expresses firefly 
luciferase. Luciferase knockdown was evaluated 48 h after treatment with the TAT, 
dTAT or PEI polyplexes, and the data were shown relative to the luciferase protein levels 
of cells treated with control siRNA complexes. Five different N/P ratios of TAT or dTAT 
complexes were condensed by adding different concentrations of CaCl2 (23.1, 34.6, and 
69.2 mM) after complex formation. Different siRNA doses (10, 25 or 50 nM) were 
studied and compared to PEI polyplexes (N/P 10). In general, TAT and dTAT complexes 
showed a higher level of luciferase knockdown for the various N/P ratios and CaCl2 
concentrations when compared to PEI, which had excellent interference in the absence of 
CaCl2 (Figure 2 and 3). The level of luciferase knockdown of TAT and dTAT complexes 
seemed to depend on N/P ratio and CaCl2 concentration. TAT and dTAT typically 
showed the greatest gene silencing at high calcium concentration (69.2 mM) and 
moderately high N/P ratios (N/P ratios of 25 and 23, respectively). The luciferase 
knockdown of PEI complexes was found to be somewhat independent of the siRNA dose. 
Strikingly, no luciferase knockdown was observed for TAT and dTAT complexes 
without CaCl2. It is important to note that the TAT and dTAT siRNA control complexes 
including 69.2 mM CaCl2 did not affect luciferase expression levels, which further 
indicates that these vectors did not influence the viability of A549-luc-C8 cells.   
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Figure 2. The luciferase knockdown of TAT and PEI complexes as a function of N/P 
ratio with different concentrations of added CaCl2 using (A) 10, (B) 25 and (C) 50 nM of 
siRNA. Results are presented as mean ± SD (n = 3).   
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Figure 3. The luciferase knockdown of dTAT and PEI complexes as a function of N/P 
ratio with different concentrations of added CaCl2 using (A) 10, (B) 25 and (C) 50 nM of 
siRNA. Results are presented as mean ± SD (n = 3).   
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6.4. Discussion 
 
Previous studies have shown that liposome mediated delivery may provide efficient 
knockdown in vitro but such systems can be inefficient when applied in vivo 83. Among 
polymeric vectors, derivatives of PEI such as degradable oligo-ethylenimine, PEGylated 
PEI and low molecular weight PEI have been used as siRNA carriers 84-86. It seems, 
however, that these systems may have limited efficiency in siRNA delivery compared to 
pDNA delivery and that toxicity may still be a concern 87,88.  
Highly efficient intracellular delivery mediated by CPPs has been confirmed in a 
variety of cell lines with minimal toxicity, overcoming challenges often faced with other 
delivery methods. We have previously developed CPP polyelectrolyte complexes as a 
more efficient and less toxic means of gene delivery 81,82. The use of calcium to condense 
CPP/pDNA complexes resulted in small particles leading to gene expression levels 
higher than PEI polyplexes. These complexes were stable, maintaining particle size in the 
absence and presence of 10% of FBS. Moreover, the transfection efficiency was not 
significantly affected by the presence of serum. The CPPs also showed negligible 
cytotoxicity compared with PEI, which was very cytotoxic.  
In this study, TAT and dTAT complexes including CaCl2 were investigated to 
determine whether these vectors could effectively deliver siRNA while minimizing 
cytotoxicity. Various N/P ratios of TAT and dTAT with different calcium concentrations 
and different doses of siRNA were used. Calcium was found to form compact TAT and 
dTAT complexes (58.5-201.3 nm) leading to high knockdown efficiencies in A549-luc-
C8 lung epithelial cells. TAT and dTAT showed the smallest particle sizes at high 
calcium concentration (69.2 mM) across various N/P ratios. The size of these complexes 
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did not appear to correlate with enhanced gene silencing. A small siRNA dose of 10 nM 
was enough to knockdown luciferase expression by up to 87%. It is important to note that 
absolutely no gene knockdown was observed for TAT and dTAT complexes without 
CaCl2. 
  
6.5. Conclusion 
 
A myriad of design strategies for siRNA vectors in the last few years has led to a 
broad spectrum of various liposomal and cationic polymer systems. Recently, there have 
been several advances in the use of complexes using CPPs 62,89-92. The low levels of gene 
silencing observed when using these low molecular weight polycations as siRNA 
condensing agents must to be improved 93. Here, we show that calcium addition to TAT 
or dTAT complexed with siRNA induced a substantial decrease in the particle size. As 
compared to the PEI complexes, the gene silencing of these CPP/siRNA complexes was 
significantly higher in A549-luc-C8 lung epithelial cells. Furthermore, the TAT and 
dTAT peptides showed negligible cytotoxicity up to 5 mg/mL. The combined features of 
high gene silencing with low cytotoxicity of TAT and dTAT complexes appear to make 
them attractive candidates for nonviral siRNA delivery vectors in vivo.  
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7.1. Conclusion 
Gene therapy holds the promise of correcting a genetic defect or altering protein 
expression to address disease. Various strategies have been explored including 
replacement of an endogenous gene or inhibition of oncogenes using interference such as 
small interfering RNA (siRNA). Despite advances in the field, the delivery of nucleic 
acids to target cells or tissues is still challenging. There are many obstacles to overcome 
in developing effective nucleic acid therapeutics including tissue and cellular transport 
barriers, enzymatic degradation, endosomal escape, toxicity, immunogenicity, and rapid 
clearance after administration. 
 Successful transfer of nucleic acids into cells usually relies on the use of efficient 
carriers, commonly viral or nonviral vectors. Viral vectors often show highly effective 
gene transfer but are deficient in several areas, including the induction of host immune 
response and challenging, expensive scale-up. Nonviral vectors are potential alternatives 
to viral vectors that may overcome several problems encountered in viral vector-mediated 
therapy 1-3; however, nonviral vectors are often inhibited by poor transfection and suffer 
from toxicity, particularly for in vivo applications 4,5. Cationic lipids and cationic 
polymers are the most commonly employed nonviral carriers6-14.  
The objective of this thesis has been to design less toxic vectors for gene delivery 
that offer high transfection efficiency. Poly(D,L-lactide-co-glycolide) (PLG) nanoparticles 
coated with different surface modifiers were synthesized as a first approach. A variety of 
cationic coating materials and conventional surfactants were explored to enhance the 
ability of PLG nanoparticles to transfect A549 lung epithelial cells. High encapsulation 
efficiencies of pDNA with enhanced cellular uptake of PLG nanoparticles were achieved 
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using cationic coating materials. Low levels of gene expression were sustained for at least 
14 days for several PLG nanoparticle formulations and gene expression levels tended to 
increase over the duration of the study. In vitro cytotoxicity studies showed that cationic 
PLG nanoparticles exhibited very low cytotoxicity compared to PEI. The complexity and 
lack of high gene expression compelled us to explore other potential low toxicity vectors.   
Cell penetrating peptides (CPPs) were considered as potential polycations to 
complex and deliver nucleic acids. Calcium was found to compact CPP complexes (~60 
nm) through "soft" crosslinks that could be competitively disrupted in order to increase 
transfection efficiency. The ability of calcium to condense CPP complexes occurred as a 
result of calcium interactions with both amines (polycations) and phosphates (DNA). 
CPP-Ca complexes were stable, maintaining particle size in the absence and presence of 
10% of FBS. Gene expression of CPP-Ca complexes was higher and more sustained than 
PEI polyplexes in A549 lung epithelial cells. CPP complexes showed the highest level of 
gene expression at 113 mM of added CaCl2 for the various N/P ratios considered. 
Cytotoxicity profiles of most CPPs revealed no evidence of cytotoxicity up to 5 mg/mL, 
which may offer an opportunity to increase the dose of nucleic acid therapeutics to 
achieve a desired therapeutic effect. These results encouraged future exploration of the 
structure of pDNA within complexes. 
Plasmid DNA within TAT complexes condensed using CaCl2 showed slight 
differences in biophysical properties when compared to pDNA within PEI polyplexes. 
FTIR and CD spectroscopies indicated that the secondary structure of pDNA was 
stabilized within complexes. DSC studies demonstrated that TAT complexes stabilized 
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pDNA more than PEI complexes as a result of the ability of calcium to condense TAT 
complexes. 
Finally, TAT or dTAT peptides complexed with anti-luc siRNA and condensed 
using calcium achieved significantly higher luciferase knockdown in A549-luc-C8 lung 
epithelial cells. Only a small siRNA dose of 10 nM was necessary to achieve luciferase 
knockdown as high as 87%. Thus, these data suggest that CPP complexes including 
calcium are a novel and effective candidate for delivering different types of nucleic acid 
therapeutics. 
  
7.2. Colloidal stability and calcium condensed complexes 
Colloidal particles in a dispersion medium undergo Brownian motion, continuous 
random movement or diffusion and hence collide with each other frequently. The 
stability of colloids is thus determined by the interaction between the particles during 
such a collision. The balance of the repulsive and attractive forces that exist between 
particles will result in controlling the stability of colloidal system. When attraction 
dominates, the particles will adhere to each other causing aggregation or precipitation. If 
repulsion dominates (e.g. electrostatic or steric), the system will be stable and remain in a 
dispersed state 15. Therefore, a colloidal dispersion is stable only when a sufficiently 
strong repulsive force counteracts the attraction. 
A very useful tool for understanding the stability of colloids is the theory by 
Derjaguin, Landua, Verway and Overbeek (DLVO) 16. The theory is based on a balance 
of forces between electric double layers, which are repulsive for similarly charged 
particles, and van der Waals forces, which are usually attractive. In this theory, the 
potential energy of particles is the sum of these two primary contributions. It is possible 
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to assess the stability of colloidal system against the aggregation by plotting the potential 
energy as a function of separation between the surfaces of charged colloidal particles. 
The minimum of the potential energy depend on the distance between two particles and 
their corresponding equilibrium state. If an electrolyte is present in a colloidal dispersion 
(e.g. CaCl2), repulsive forces between electric double layers will be screened. In the latter 
case, the system will be unstable and aggregation will occur. 
Various efforts have been made to obtain stability to colloidal particles including 
adsorption or attachment of polymeric molecules or surfactants to the particle surface. 
Galactose 17,18, poly(ethylene glycol) 19,20, poly(vinyl pyrrolidone) 21 and dextran 22 have 
been attached to the chitosan backbone or to the preformed nanoparticles to improve their 
physicochemical properties. Phosphorylcholine-substituted chitosan/DNA polyplexes 
exhibited a higher resistance to aggregation compared to deacetylated chitosan 
polyplexes 23. Moreover, PEGylation has proven to improve the stability of PEI/DNA 
complexes 24. PEGylation of TAT was also effective for the CPP complexes developed 
here. 
A previous study explored the effect of calcium on the colloidal stability of 
phosphatidylcholine liposomes in aqueous media. 100-200 mM of calcium induced a 
slight decrease in the size (from 140 nm to 136 nm) of liposome followed by a slow 
increase of the size until a maximum of 155 nm in the range of 300-900 mM 25. Changes 
in the polydispersity were not observed, suggesting a coalescence mechanism or fusion of 
liposomes but no aggregation. A calculated stability factor suggested that 
aggregation/fusion occurred at a critical concentration of 700 mM of calcium. Calcium 
was found to be highly adsorbed on the liposome surface, which implies an increase in 
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the surface area per lipid molecules (A0) in the monolayer. These data indicated that the 
adsorption of calcium on the liposome improved the colloidal stability by controlling the 
balance of the repulsive and attractive forces between lipid molecules. Calcium was also 
induced as part of an electrostatic double layer on the particle surface, which did not 
adversely affect stability in this case.  
  In our study, CaCl2 was found to provide unique ability to condense CPP 
complexes into small size leading to high transfection efficiency or high gene 
knockdown. It seemed that much of the calcium must have entered the ‘loose’ 
complexes, as evidenced by the steady decrease in complex size up to 150 mM of added 
CaCl2. The hypothesis that calcium interacts with both nucleic acids and polyamines was 
supported by dye binding assays. Upon further addition of calcium, calcium CPP 
complexes retained colloidal stability. As with the liposome study mentioned above, 
calcium likely participated in an electrostatic double layer as the concentration increased. 
DLS measurements also confirmed stabilization in the size of the CPP complexes in the 
absence and presence of 10% FBS over a period of time (up to 8 days for TAT 
complexes). Calcium may interact with CPP complexes via surface association or 
adsorption as well as some other forces such water polarization as a resulted of their 
correlated fluctuation on the surface of the complexes. Further studies with other ions 
may support or refute this hypothesis.  
 
7.3. Future directions 
Future work with CPP gene delivery systems should further explore the potential of 
modified CPPs by engineering features to mediate endosomal escape as a means to 
optimize transfection. This would include the addition of histidine residues, myristic and 
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stearic acids to the CPP sequences. For example, TAT peptide contains no acidic residues 
that can be protonated as pH decreases during endolysosomal trafficking. This strategy 
has been implicated in endosomal membrane destabilization 26. For example, attaching 
histidine residues to the TAT peptide showed much higher levels of transfection 
efficiency. The imidazole groups of histidine (pKa ~6) likely absorbed protons in the 
acidic environment (pH 5-6.5) of the endosome, leading to osmotic swelling, membrane 
disruption and gene escape 27. 
The mechanism of a positive effect of calcium on the gene delivery when 
incorporated in the nonviral vectors should also be determined. It is well known that 
calcium phosphate forms complexes with nucleic acids, thereby imparting small, stable 
nanoparticles 28. Reports also suggest that calcium phosphate may help transport 
complexes across the cell membrane by enhancing endocytosis or by enhancing plasma 
membrane permeability 29. Also, the addition of CaCl2 increased transfection efficiency 
when added to the cell culture medium during transfection and post-transfection. In the 
absence of calcium, the complexes were taken up by the cells but remained entrapped at 
an unknown cellular site. Further emphasis on immunohistochemical and imaging studies 
of CPP-Ca complexes would provide more information on the exact mechanism of 
enhanced transfection. The internalization and trafficking should be investigated since it 
can not be excluded from the effect of calcium on gene transfer when using CPP 
complexes.   
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